A transcriptomic and molecular approach uncovering ASCL2 as a novel tumourigenic gene in breast cancer by Faramarzi, N. & Faramarzi, N.
WestminsterResearch
http://www.westminster.ac.uk/westminsterresearch
A transcriptomic and molecular approach uncovering ASCL2 as a 
novel tumourigenic gene in breast cancer
Faramarzi, N.
This is an electronic version of a PhD thesis awarded by the University of Westminster. 
© Miss Nicola Faramarzi, 2019.
The WestminsterResearch online digital archive at the University of Westminster aims to 
make the research output of the University available to a wider audience. Copyright and 
Moral Rights remain with the authors and/or copyright owners.
	
	
	
	
	
	
	
	
	
	
A	transcriptomic	and	molecular	approach	
uncovering	ASCL2	as	a	novel	tumourigenic	gene	
in	breast	cancer	
 
 
Nicola	Faramarzi	
 
 
 
A	thesis	submitted	in	partial	fulfilment	of	the	requirements	of	the		
University	of	Westminster	for	the	degree	of	Doctor	of	Philosophy	
	
	
May	2019	
	
 
i	
	
Abstract	
 
Breast cancer is highly heterogeneous and is considered a collection of 
molecularly distinct tumour subtypes. Substantial efforts have been made to 
explore the gene expression profiles underlying the subtypes, and to elucidate 
possible markers associated with clinical outcomes. However, research in this 
area has been met with significant challenges and despite ongoing 
advancements in diagnostics and targeted therapeutics, incidence and mortality 
continues to rise. Thus, there is a need for greater molecular characterisation of 
breast tumours, to further understand the mechanistic roles of genes within their 
respective signalling pathways. 
 
With the advent of high-throughput technologies in transcriptomics, as well as the 
use of open databases and bioinformatics analysis tools, it is now possible to 
examine thousands of genes in parallel, generating an unprecedented amount of 
information. This provides a means for researchers to identify novel genes and 
targets from large volumes of gene expression data. However, the task of 
extracting clinically relevant results, is a prominent challenge. Therefore, the aim 
of this study was to use a streamlined in silico pipeline, integrated with in vitro 
methods to identify and functionally investigate a novel genetic marker 
demonstrating a key role in breast carcinogenesis. 
 
Gene expression profiles from breast cancer cell lines were obtained from public 
databases (Array Express and Gene Expression Omnibus). Data was filtered and 
subjected to an extreme variation analysis to generate a list of differentially 
expressed genes. Subsequently, multiple pathway analysis tools were used to 
identify a novel candidate gene for further investigation. Achaete-scute complex 
homolog 2 (ASCL2) is a transcription factor and Wnt-target gene, recognised as 
a regulator of stem cell identity and embryogenesis. Gene expression was 
validated in vitro by Reverse Transcription Quantitative Polymerase Chain 
Reaction (RT-qPCR), and to assess the tumourigenic potential of ASCL2, siRNA 
knockdown was performed; assays were employed to measure proliferation, 
wound-healing and apoptosis. Data mining of patient tumours obtained from the 
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METABRIC study was also undertaken to ascertain the potential of ASCL2 as a 
prognostic indicator. 
 
This work utilised a systematic pipeline used by the wider scientific community 
for the identification of candidate genes from transcriptomic data. Differential 
expression of ASCL2 was observed across multiple breast cancer cell lines, with 
largest the expression seen in MCF7 cells. Although evidence did not support the 
usage of ASCL2 as a prognostic indicator in patient tumours, data integrated from 
multiple lines of investigation suggested that this gene may influence the 
migratory capacity of breast tumour cells, whilst exercising its tumourigeneic 
function via the Wnt signalling pathway in breast cancer. Thus, this potential 
novel role of ASCL2 in breast tumourigenesis highlights a prominent area for 
further exploration.  
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Introduction	
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1.1	An	Introduction	to	Breast	Cancer	
1.1.1	Introduction	to	Cancer	
The term cancer refers to a group of widespread diseases caused by the 
uncontrolled growth of abnormal cells that have the potential to spread and 
invade surrounding healthy tissue. In the UK, 1 in 2 people have a risk of being 
diagnosed with cancer during their lifetime (Cancer Research UK, 2019). 
Cancer is a highly complex and multi-step process now considered 
predominantly as a disease entailing genetic changes (Hanahan, & Weinberg, 
2011; Vogelstein, et al., 2013); mutations or alterations in the expression of 
certain genes ultimately sustain the development and growth of tumours. These 
genes can be largely classified as a loss-of-function tumour suppressor gene, 
responsible for preventing uncontrolled growth and encouraging cell cycle 
checkpoints and DNA repair, or a gain-of-function oncogene, which promotes cell 
proliferation and survival (Hanahan, & Weinberg, 2011; Lee, & Muller, 2010).  
Despite its complexity, the development of cancer has been rationally classified 
into a handful of underpinning capabilities that tumours use to govern neoplastic 
growth. These are now universally known as the Hallmarks of Cancer (Figure 
1.1), first described by Hanahan and Weinberg in 2000, and later revised in 2011. 
These key principles cause errors in cellular communication networks (signalling 
pathways), which ultimately affect cell growth, death, motility, metastasis, 
replicative immortality, evasion of the immune system, and instability of the 
genome (Hanahan, & Weinberg, 2011; Hanahan, & Weinberg, 2000). 
Cancer can arise from familial (inherited) or acquired genetic mutations, but may 
also develop as a result of gene expression changes and other epigenetic 
modifications (Rizzolo, et al., 2011). The majority of cancers arise from acquired 
somatic genetic mutations, which can result from factors such as external 
carcinogens, DNA instability or deregulation of gene expression (Greenman, et 
al., 2007). These genetic changes are able to give cells a selective growth 
advantage, which accumulate over time and lead to disruptions in gene activity, 
and subsequently changes in cell behaviour. One could argue therefore, that all 
of the hallmarks affecting cellular behaviour depend on some type of genomic 
alteration in tumour cells, thus the ‘genomic instability and mutation’ hallmark 
3	
	
could be considered to underpin all of the other hallmarks (Figure 1.1) (Hanahan 
and Weinberg, 2011). 
Metastasis is the cause of approximately 90% of cancer related deaths, and 
occurs due to the genetic instability of primary cancer cells which have an 
invasive capacity; these may enter the circulation and eventually adapt to a 
distant tissue microenvironment (Gupta, & Massagué, 2006). Owing to the deaths 
related to invasion, this calls for greater characterisation of the genetic basis and 
markers leading to tumour metastasis (Bos, et al., 2009). 
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Figure 1.1. The 10 Hallmarks of Cancer as described by Hanahan & Weinberg (2011), 
with focus on the ‘Genome Instability’ hallmark, responsible for the genetic variation 
seen in cancer cells.  
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1.1.2	Breast	Cancer	
Breast cancer was classically considered as three predominant subtypes with 
distinct features and behaviours – hormone receptor positive (HR+) (expressing 
oestrogen receptors, ER, and progesterone receptors, PR), human epidermal 
growth factor receptor positive (HER2+) and triple negative breast cancer 
(TNBC). These subtypes represent somewhat clear therapeutic groups. Broadly 
speaking, hormone receptor positive tumours are the most common, typically 
presenting with a good prognosis due to treatment using endocrine therapy. Up 
to approximately 10% of breast cancers are diagnosed as HER2+, and previously 
indicated a poor prognosis. Yet, treatment with anti-HER2 targeted agents has 
since provided a large benefit to patients in this group. Breast tumours that do 
not express any of the aforementioned receptors, are referred to as triple 
negative. These tumours are aggressive in nature, with limited treatment options, 
resulting in a high mortality rate (Karagoz, et al., 2015; Perou, & Børresen-Dale, 
2011; Reis-Filho, & Pusztai, 2011; Yeo, & Guan, 2017).  
However, it has become well-known that breast cancer is highly heterogeneous, 
and the viewpoint that it is a single disease with varying histology is extremely 
outdated. It is now accepted that the term ‘breast cancer’ refers to a collection of 
tumour subtypes with distinctive aetiologies, origins, genetic signatures and 
clinical outcomes; this complex picture encompassing a number of tumour 
entities is considered in further detail in Section 1.1.4 (Karagoz, et al., 2015; 
Perou, & Børresen-Dale, 2011; Reis-Filho, & Pusztai, 2011; Yeo, & Guan, 2017). 
This heterogeneity is mirrored in its complex genomic landscape, and despite 
advancements in subtype-specific therapeutics, many patients are not 
responsive to therapies, or present with unexpected tumour behaviour due to 
underlying genetic mutations that require characterisation.  
In the UK, breast cancer is the most common type of cancer, and incidence is 
projected to rise by 2% by 2035; over 11,500 women died of the disease in 2016 
(Cancer Research UK, 2019). However, due to increasing knowledge of 
underlying molecular aberrations and the development of subsequent 
treatments, survival rates have doubled since the 1970s (Figure 1.2) (Cancer 
Research UK, 2019).  In the western world, breast cancer follows lung cancer as 
the second biggest cause of cancer-related mortality (Fadoukhair, et al., 2015). 
On a global scale, breast cancer is the most frequently diagnosed cancer in 
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women; approximately 1.67 million women were diagnosed with invasive breast 
carcinoma worldwide, with an estimated 522,000 women dying from the disease 
in 2012 (Liu, et al., 2015). This was estimated to reach 627,000 deaths in 2018 
(Bray, et al., 2018). Prominent sites of breast cancer metastasis are the brain, 
bones and lungs (Bos, et al., 2009). These statistics necessitate research 
focussed on further genomic characterisation that nurture the growth of breast 
cancer and that may be beneficial as pharmaceutical targets; this can then be 
translated to patient-tumour-specific molecular diagnosis, partnered with a 
personalised treatment strategy in the near future. 
  
Figure 1.2. Cancer Research UK statistics illustrating that since the 1970s, breast 
cancer survival beyond 10 years has increased by half (statistics taken from Cancer 
Research UK, 2019). 
1970s	
	
	
	
	
Present	
Survival	beyond	10	years	
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1.1.3	Breast	Cancer	Risks	
The risk factors associated with the growth of breast tumours are multifactorial. 
Primarily, inherited genetic variants have been identified as conferring a greater 
susceptibility to breast cancer in patients; these patients have a hereditary 
predisposition, and are considered to be high-risk, thus benefit greatly from 
screening and regular follow-up appointments. Notable genetic loci contributing 
to an increased familial risk are the high-penetrance BRCA1 and BRCA2 
mutations on chromosome 17 and 13 respectively, responsible for disturbances 
in DNA damage and repair mechanisms (Vogelstein, et al., 2013). Other rare, yet 
high-penetrance genes include PTEN, CDH1, STK11, and moderate-penetrance 
genes such as CHEK2, ATM, and PALB2, also screened in medical genetic 
practice (Antoniou, et al., 2014; Michailidou, et al., 2013; Shiovitz, & Korde, 2015; 
van der Groep, et al., 2011). Although mutations in these genes result in a high-
risk of developing breast cancer in the individual, within the general population, 
these only account for a small proportion of cases.  
Yet, genome-wide association studies (GWAS) have now identified a number of 
breast cancer susceptibility variants (single-nucleotide polymorphisms, SNPs) 
that are of small risk individually, but may be grouped together to confer a 
substantial combined effect. These are known as a polygenic risk score (PRS) 
and can be utilised within preventative screening strategies to stratify women 
according to their risk of breast cancer, identifying patients most likely to benefit 
from intervention (Mavaddat et al., 2019; Mina & Arun, 2019). A landmark study 
by Mavaddat et al., (2019) reported the development and validation of subtype-
specific polygenic risk scores for breast cancer, especially for the improved 
prediction of ER-negative breast cancer. The study identified a PRS of 313 SNPs 
significantly more predictive of risk (accounting for subtype, age and family 
history) than previously reported risk scores (Mavaddat et al., 2019).  
There are many hormonal and reproductive risk factors also associated with 
breast cancer, such as early menarche, late menopause, nulliparity and breast 
feeding. Early menarche in women and late menopause is associated with an 
increased breast cancer risk due to greater exposure to associated hormones 
(oestrogen and progesterone). However, earlier full term pregnancy in younger 
women lowers the risk of breast cancer. Women whom have not carried a 
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pregnancy nor given birth are at a slightly increased risk of developing breast 
cancer after 40 years of age, but not at younger ages. 
Other exogenous and lifestyle factors play a large role in the risk of developing 
breast cancer. Over the years, a number of studies have found an association 
between alcohol intake and increased breast cancer risk; compared to women 
who did not drink alcohol, the relative risk of breast cancer increased by 
approximately one third. This risk increased as consumption increased 
(McDonald et al., 2013). Overall, evidence supports that lifetime moderate 
alcohol intake increases the risk of breast cancer (odds ratio [OR] = 2.13) (Terry 
et al., 2006). 
Smoking and alcohol consumption have been shown to be strongly associated 
with DNA methylation in breast tumourigenesis as well as in a range of other 
cancers (Catsburg, et al., 2015; Christensen, et al., 2010; Passarelli, et al., 2016). 
Smoking is well known to cause direct and indirect DNA damage and instability, 
as well as changes in DNA damage responses, and it is estimated that heavy 
smoking for 40 years can cause up to 1,000 DNA aberrations in all cells 
(Alexandrov, et al., 2016; Lord, & Ashworth, 2012). However, in spite of this, most 
prospective cohort studies have found no causal association between both active 
or passive smoking and incidence of breast cancer, highlighting little to no 
relationship between smoking and breast cancer risk (OR = 1.00) (Luo et al., 
2011; Prescott et al., 2007; Lash & Aschengrau, 2002; Ahern et al., 2009). 
Another exogenous lifestyle factor specifically relating to breast cancer risk is the 
prolonged use of oral contraceptives, which have been proven to confer an 
increased risk of developing oestrogen receptor positive (ER+) breast cancer, 
depending on the variable formulation of the pill (Beaber, et al., 2014; Mørch, et 
al., 2017). Obesity and diet can also have an effect on breast cancer risk, as 
dietary changes have been known to prevent approximately one-third of cases 
(Brennan, et al., 2010).  
DNA damaging agents can also increase the risk of breast and other solid 
tumours. These agents can execute damage through occupational exposure, 
chemical warfare, or via genotoxic and mutagenic chemotherapeutic drugs. 
These can affect DNA repair pathways such as base excision and mismatch 
repair. Alkylating agents, such as melphalan, are used in the treatment of solid 
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tumours and have the potential to give rise to secondary cancers. It is for this 
reason that treating patients with ineffective chemotherapy is to be avoided, as 
cytotoxic damage can occur in other tissues. These risks bombard DNA with 
damage over time, causing somatic aberrations that accumulate and eventually 
have the potential to drive carcinogenesis.  
1.1.4	Classification	of	Breast	Cancer	
Over the years, the classification of breast cancer has advanced from being 
focussed on morphological features, to being consolidated with specific 
biomarkers and clinical features. As previously mentioned, breast cancer was 
traditionally categorised into three main subtypes – HR(ER/PR)+, HER2+ and 
TNBC. This classification has now been superseded by the ‘intrinsic subtypes’ 
taxonomy, first classified in 2000, and was developed to better reflect the gene 
expression and molecular patterns of the tumours (Perou, & Børresen-Dale, 
2011). A summary of this is shown in Table 1.1 and Figure 1.3 encompassing the 
five intrinsic subtypes known as Luminal A, Luminal B, HER2-enriched, Claudin-
low and Basal-like (Eroles, et al., 2012). 
Luminal tumours are known to express hormone receptors (ER/PR) and are 
(broadly speaking) divided into types A (ER+, PR+, HER2-) and B (ER+, PR+, 
HER2+). Luminal tumours hold the status of the most common of the breast 
cancer subtypes, with Luminal A representing the majority. Although generally 
prognosis is good for these tumours, Luminal A tumours have a significantly 
better prognosis than Luminal B; these patients can be treated with and respond 
well to endocrine therapy in most cases, such as tamoxifen, as traditional 
chemotherapy can be less effective. Altered gene expression patterns of these 
tumours are commonly associated with ER activating genes (Dai, et al., 2015). 
Tumours within the HER2-enriched subtype over-express the HER2 (ERBB2) 
protein only and are ER and PR negative. Although these tumours are generally 
sensitive to some chemotherapies, they were traditionally known to be associated 
with a poorer prognosis than Luminal tumours due to their high risk of relapse 
(Dai, et al., 2015). However, after the approval of trastuzumab in 2001, advances 
in the therapeutics used to treat these tumours have greatly improved the clinical 
management and survival outcomes of patients diagnosed with HER2+ breast 
cancer (Ortiz et al., 2019).  
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As the name suggests, TNBC lacks the expression of hormone (ER/PR) and 
HER2 receptors, and because of the lack of evident target, is linked with an 
extremely poor prognosis. Its aggressive nature has attracted much research 
interest due to its lack of available molecular treatment targets (Karagoz, et al., 
2015). Lehmann, et al., (2011) has classified TNBC into six further subtypes 
displaying distinctive gene expression patterns – basal-like 1 and 2, 
immunomodulatory, mesenchymal, mesenchymal stem-like, and luminal 
androgen receptor. Further characterising these tumours illustrates the 
complexity of breast cancer, and the notion that each subtype requires its own 
treatment strategy despite similar phenotypes, due to the unique gene expression 
patterns harboured by each individual tumour. 
More recently in 2012, the METABRIC study, integrating genomic and 
transcriptomic sequencing, as well as long-term clinical follow-up, characterised 
2000 primary breast tumours and identified 10 molecularly distinct subtypes, 
known as the ‘integrative clusters’ (Table 1.2) (Curtis, et al., 2012; Dawson, et 
al., 2013a). This ever expanding and scrutinised system of classifying breast 
cancer illustrates the complexity and heterogeneity of the disease, and 
exemplifies the importance of a specific classification system to aid the 
administration of efficient treatments in patients. 
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Table 1.1. A summary of the intrinsic subtype taxonomy and current molecular markers, adapted from Eroles et al. (2012). 
 
Subtype Frequency Receptor Status 
Proliferation 
Genes 
Present 
Origin Associated Genes 
TP53 
Mutation 
Histologic 
Grade Prognosis 
Basal-
like 10-20% 
ER- PR- 
HER2- High 
Myoepithelial 
breast cells 
KRT5, CDH3, 
ID4, FABP7, 
KRT17, 
TRIM29, 
LAMC2 
High High Poor 
HER2-
enriched 10-15% 
ER- PR- 
HER2+ High 
Epithelium of 
breast duct 
ERBB2, 
GR67 High High Poor 
         
Normal-
like 5-10% ER-/+ HER2+ Low 
Adipose 
tissue 
PTN, CD36, 
FABP4, 
AQP7, ITGA7 
Low Low Medium 
Luminal 
A 50-60% 
ER+ PR+ 
HER2- Low 
 
ESR1, 
GATA3, 
KRT8, 
KRT18, XBP1 
Low Low Good 
Luminal 
B 10-20% 
ER+/- PR+/- 
HER2+/- High 
Luminal 
epithelium of 
mammary 
ducts 
FOXA1, TFF3 Medium Medium Medium 
Claudin-
low 12-14% 
ER- PR- 
HER2- High - CD44, SNAI3 High High Poor 
 Table 1. A summary of the intrinsic subtype taxonomy and current molecular markers, adapted from Eroles et al. (2012). 
Figure 1.3. The mRNA expression of ER and HER2 across the breast cancer intrinsic subtypes, Eroles et al. (2012). 
 
Figure 3. The mRNA expression of ER and HER2 across the breast cancer intrinsic subtypes, Eroles et al. (2012). 
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Subtype	 Receptor	Status	 Genomic	Instability	 Associated	Mutations	 Pathobiology	 Prognosis	
IntClust	1	 ER+,	Luminal	B	predominantly	 High	
Amplification	of	17q23	
locus	
High	prevalence	of	GATA3	
mutations	
High	proliferation	 Intermediate	
IntClust	2	 ER+,	Luminal	A	and	B	 High	 Amplification	of	11q13/14	 Aggressive	pathophysiology	
Worst	prognosis	of	all	
ER+	tumours	
IntClust	3	 Mainly	Luminal	A	 Low	 	 Small	low-grade	tumours	 Good,	best	of	all	clusters	
IntClust	4	
ER	+/-	
Can	be	triple	negative.	
Mix	of	the	intrinsic	subtypes	
Low	 	 	 Favourable	outcome	
IntClust	5	
ERBB2	amplified	
HER2+/ER-	
Luminal	ER+	
Intermediate	 	 Presents	at	younger	age	High	grade	tumours	 Poor	
IntClust	6	 ER+,	Luminal	A/B	 High	
Amplification	of	8p12	locus	
Low	levels	of	PIK3CA	
mutations	
	 Intermediate	
IntClust	7	 ER+/PR+,	Luminal	A	 Intermediate	 	 Low	grade	well	differentiated	tumours	 Good	
IntClust	8	 ER+,	mainly	Luminal	A	 	 1q	gain/16q	loss.	High	PIK3CA,	GATA3	mutations	
Low	grade	well	
differentiated	tumours	 Good	
IntClust	9	 Mix	of	intrinsic	subtypes	Mainly	ER+	Luminal	B	 High	 Increased	TP53	mutations	 	 Intermediate	
IntClust	10	 Mostly	triple	negative	Basal-like	tumours	 Intermediate	 High	TP53	mutations	
Presents	at	young	age	
High	grade,	poor	
differentiated	
High	risk	pre-5	years	
Good	post-5	years	
Table 1.2. A summary of the integrative cluster taxonomy as proposed by Dawson, et al., (2013).   
 
	13	
	
1.1.5	Current	Diagnostics	&	Therapeutics		
At present, subtypes are diagnosed on the basis of immunohistochemical 
analysis of a tissue biopsy, and in situ hybridisation to detect a single gene 
amplification if results are equivocal (Hansen, & Bedard, 2013). However, it could 
be argued that this basic diagnosis using a panel of so few histopathological 
markers is not reflective of most tumour types and treatment requirements. 
Hence, there is a requirement for more widely available clinical molecular 
screening programmes and molecular diagnostic testing to shed light on patient 
specific genetic signatures that can be more efficiently targeted.  
Although systemic therapy for the treatment of breast tumours is determined by 
subtype, few approved drugs have emerged in the past few decades in the hope 
of specifically targeting biomarkers of breast cancer. Those demonstrating 
success include endocrine therapies, aromatase inhibitors, or tamoxifen directed 
at treating ER+ breast cancers, and the anti-HER2 class of monoclonal 
antibodies (such as trastuzumab or pertuzumab), and tyrosine kinase inhibitors 
(TKI’s, such as lapatinib), used for treatment of HER2+ tumours. Trastuzumab 
was the first therapy to specifically target HER2+ metastatic tumours, and is 
considered a leading example of using patient genomic profiles to direct 
treatment decisions (Fadoukhair, et al., 2015; Hansen, & Bedard, 2013).  
While targeted treatments such as tamoxifen and trastuzumab arose to improve 
the survival of patients with hormone receptor positive and HER2+ cancers 
respectively, these were initially met with unexpected inefficiency in a large 
number of patients who were thought to possess the corresponding molecular 
markers for these treatments (Rexer, & Arteaga, 2013; Vu, & Claret, 2012). Some 
patients with HER2+ breast cancer fail to respond to trastuzumab and ultimately 
develop progressive disease, likely due to the manifestation of a resistant 
phenotype. However, new strategies have been developed to circumvent the 
different acquired therapeutic resistance mechanisms observed in some HER2+ 
tumours; for example, utilising a combination of PI3K inhibitors and cyclin D1-
cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors alongside anti-HER2 agents, to 
target the alterations that lead to hyperactivation of downstream signalling in the 
PI3K/AKT/mTOR axis, which otherwise instigate and perpetuate resistance to 
	14	
	
HER2 targeting therapies (Goel et al., 2016; Ortiz et al., 2019; Vernieri et al., 
2019).  
TNBC is treated with often ineffective traditional or adjuvant chemotherapy, 
however recent efforts to produce targeted therapies has brought about the 
advent of poly (ADP) ribose polymerase inhibitors (PARP) (for BRCA1 tumours 
and TNBC), epidermal growth factor receptor inhibitors (EGFR) and 
antiangiogenic agents (Karagoz, et al., 2015). Despite this, adjuvant 
chemotherapy is still administered to approximately 60% of all early-stage breast 
cancer patients, with only up to 15% of these patients benefitting (Reis-Filho, & 
Pusztai, 2011). It is important to only treat tumours likely to be responsive to 
genotoxic chemotherapy, as all patients are at risk of the highly toxic side effects 
(Reis-Filho, & Pusztai, 2011).  
1.1.6	The	Problem	with	Current	Therapies	
It is now accepted that breast cancer as a disease requires the interplay of 
multiple signalling pathways that are capable of sustaining proliferative signalling 
and evading apoptosis, among the other hallmarks of cancer (Hanahan, & 
Weinberg, 2011). These cause distinct tumours in each patient likely to benefit 
from a more personalised treatment approach. Factors such as nodal status or 
tumour burden are no longer thought to be the only determinants of treatment 
response, but rather the molecular characteristics of the tumour (Reis-Filho, & 
Pusztai, 2011). However, current therapies are not patient specific and are 
usually targeted at the ‘average’ population rather than smaller, targeted groups 
of patients with certain biomarkers or molecular signatures. Nevertheless, before 
new pharmaceuticals can be designed and administered to patients for a more 
‘personalised’ approach, new and robust molecular markers need to be identified, 
thoroughly examined and validated (Eroles, et al., 2012).  
Ali, et al., (2016) investigated metastatic TNBC, a subtype for which there is no 
effective targeted therapy after conventional platinum-based and anthracycline 
chemotherapies become ineffective. This study used in-depth genomic profiling 
of the patient’s tumour to identify a commonly mutated anti-apoptotic gene, 
MCL1, in TNBC, which then dictated personalised treatment using sorafenib and 
vorinostat (preclinical evidence demonstrated the efficacy of these drugs for 
TNBC with MCL1 amplification) (Ali, et al., 2016). 
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This study highlights that despite the failure of many rounds of differing 
conventional therapies, treatment based on the patient’s tumour genetic profile 
prevailed and extended survival. Therefore, characterising further subtype-
specific genetic markers driving breast cancer tumorigenesis is extremely 
valuable in developing a greater selection of targeted drugs to aid in designing 
tailored treatment regimens for patients. This has the potential to limit the amount 
of toxic chemotherapeutic agents administered to patients who may have 
tumours resistant to conventional therapies.  
However, the differing molecular characteristics per subtype is not the only 
challenge. The dissemination of cancer cells that migrate away from the primary 
tumour via the lymphatic and circulatory system, and metastasise as secondary 
tumours in other regions of the body, is a main cause of death in women (Braune, 
et al., 2018). Another significant hurdle for researchers and clinicians alike is 
multidrug resistance (MDR); in these cases, tumour cells develop the ability to 
acquire resistance and escape the cytotoxic effects of drugs and 
chemotherapeutic agents, leading to increased cell survival and thus resulting in 
ineffective treatment and inevitable relapse (Dewangan, et al., 2017).  
Cancer stem cells (CSCs) also present another prominent challenge to current 
treatment strategies. These cells have multiple characteristics that allow them to 
evade cytotoxic treatment. Firstly, their ability to self-renew, regenerate and 
differentiate permits the accumulation of genetic mutations. Secondly, these cells 
possess a quiescent nature, which is protective against conventional treatments 
that target rapidly diving cells. In addition, their capacity to self-renew gives rise 
to the production of multiple heterogeneous cancer cell lineages that make up a 
tumour (Dewangan, et al., 2017). With these challenges in mind, research efforts 
have taken a shift towards selectively targeting therapy-resistant cells and CSCs, 
by interfering with the mechanisms and signalling pathways that these cells rely 
on.  
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1.2	Breast	Cancer	Signalling	Networks	
It is well known that genetic and epigenetic changes are responsible for driving 
the development of breast cancer. These changes most often correspond to a 
signalling pathway that controls cellular functions and allows cells to 
communicate; hyperactivation or inactivation of these pathways disrupts the 
homeostasis of cells and can alter downstream signalling networks, leading to a 
cascade of disturbances and gives rise to the hallmarks of cancer (Sever, & 
Brugge, 2015).  
Frequent mutations in various parts of the PI3K pathway have been confirmed by 
many studies and represent a very relevant tumourigenic pathway in breast 
cancer (Yang, et al., 2016). Sustained proliferative signalling in breast cancer 
may also be a result of deregulated HER2 signalling in some tumours. The 
human epidermal receptors have tyrosine kinase activity which can activate 
JAK/Stat and Ras/Raf/MAPK pathways, as well as PI3K/Akt/mTOR signalling 
(Eroles, et al., 2012). Studies have also shown that Wnt/β-catenin signalling, a 
regulator of migration, differentiation and proliferation, is implicated in TNBC due 
to upregulated Wnt receptors (FZD7 and LRP6). Salinomycin has been identified 
as an inhibitor of Wnt/β-catenin signalling (primarily expression of LRP6) and a 
specific killer of CSCs in breast cancer, lending itself to be a potential treatment 
option in the future (King, et al., 2012). Notch signalling has also been implicated 
in breast cancer, with Notch1 being shown to promote the epithelial-
mesenchymal transition, thus stimulating proliferation and subsequent 
metastasis (Bolós, et al., 2013). Other less characterised pathways, such as the 
stress-induced JUN-kinase pathway has been suggested to predict 
chemosensitivity of ER+ tumours via mutations in MAP3K1 and MAP2K4 
(Hansen, & Bedard, 2013; Xue, et al., 2018)   
Knowledge of deregulated signalling pathways can aid treatment development or 
selection for breast cancer patients. For example, for patients with HER2+ breast 
cancer that are resistant to trastuzumab, a monoclonal antibody able to 
downregulate HER2 from the surface of the cell, there are multiple known 
mechanisms whereby cancer cells can escape the action of this drug. The PI3K-
Akt pathway is now known to aid in the anti-tumour effect of trastuzumab. Hence 
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in these cases, a PI3K inhibitor may be administered alongside trastuzumab for 
greater treatment efficiency (Rexer, & Arteaga, 2013).  
There are many emerging pharmaceutical agents targeting the numerous 
aberrant signalling pathways in breast cancer (Table 1.3). The quantity of 
dysfunctional pathways is further evidence of the complex heterogeneity in breast 
cancer, and demands greater characterisation of the aberrant genes perturbing 
these transduction pathways. Many large-scale sequencing projects such as The 
Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium 
(ICGC) have been undertaken, revealing the complexity of the full molecular 
profile of breast cancer. The most frequently mutated genes are TP53 and 
PIK3CA (36-37%), but there are many other persisting gene mutations that occur 
at much lower frequencies which may prove to be significant targets for drugs 
(Hansen, & Bedard, 2013).  
 
 
 
   
Pathway	 Targets	 Agents	
PI3K/Akt/mTOR	
mTORC1	
Isoform-selective	PI3K	inhibitors	
Dual	mTOR/PI3K	inhibitiors	
Everolimus,	temsirolimus,	rapamycin	
GDC-0023	
XL765	
ErbB/HER2	 EGFR	inhibitor	HER2	inhibitor	
Erlotinib,	gefitinib,	cetuximab	
Pertuzumab,	trastuzumab-DM1	
MAPK	 MEK1/2	inhibitors	 Binimetinib,	cobimetinib	
FGF	 Multi-targeted	FGFR	inhibitors	 Dovitinib,	lucitanib	
Notch	 Gamma-secretase	inhibitor	 PF-03084014	
PARP	 PARP1/2	 Olaparib,	niraparib	
Wnt	 NOP14,	BKCa	channels,	Emilin2,	WISP,	NRBP1,	TRAF4,	Wntless	 Salinomycin	
 
  
Table 1.3. Current aberrant signalling pathways identified to be involved in breast 
cancer and the agents in development to target them. Adapted from Fadoukhair et al., 
(2015) and Liang, et al., (2016). 
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1.2.1	Wnt	Signalling	in	Breast	Cancer	
Wnt signalling is a highly important network for development, and is renowned 
for its involvement in cancer; this pathway is particularly considered a hallmark 
of colorectal cancer (Basu, et al., 2016; Howe, & Brown, 2004). The pathway is 
divided into the canonical (β-catenin dependent) and non-canonical, (β-catenin 
independent) pathway – for the purpose of this thesis, the canonical Wnt 
signalling pathway will be of focus.   
The main purpose of Wnt signalling in normal cells is to regulate embryonic 
development, adult homeostasis and tissue morphogenesis, chiefly using β-
catenin to transduce Wnt signals from the extracellular membrane, into the 
nucleus from the cytoplasm (Figure 1.4). This pathway must be strictly regulated 
at each stage in the network, from ligand-receptor binding to transcriptional and 
post-transcriptional control, to maintain its finely-tuned normal activity (Zarkou, et 
al., 2018). In synergy with other pathways, such as TGF-β and Notch, Wnt 
signalling maintains cellular homeostasis by regulating migration, differentiation, 
proliferation and apoptosis; it has also been reported that Wnt signalling 
encourages self-renewal in stem cells (Howe, & Brown, 2004; Zarkou, et al., 
2018).    
Therefore, it is expected that abnormal activation of the Wnt pathway is 
responsible for tumour initiation and growth, motility and migration, and invasion, 
as well as playing an integral role in the epithelial-to-mesenchymal-transition 
(EMT) in cancer (Anastas, & Moon, 2013). In the past few decades, activated 
Wnt signalling involving β-catenin has become increasingly studied in breast 
cancer, and elevated β-catenin levels are commonly observed in most clinical 
breast tumour tissue samples (Braune, et al., 2018; Howe, & Brown, 2004; Jang, 
et al., 2015). Additionally, overexpression of many Wnt genes, such as WNT1, 
and abnormal expression of Wnt regulators (e.g. soluble Frizzled-related protein, 
sFRP1) have been seen in mouse model breast cancers in the past (Howe, & 
Brown, 2004). While the primary molecular performers of Wnt signalling have 
been extensively studied and characterised, many aspects of the pathway remain 
elusive (Zarkou, et al., 2018).  
Additionally, when considering the increased attention received by CSCs in 
breast cancer, their regulation by the Wnt pathway is extremely promising as a 
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potential therapeutic target (Kazi, et al., 2016). Aberrant Wnt signalling is 
considered to be important in the regulation of CSC migration and self-renewal. 
1.2.2	Cancer	Stemness		
The epithelial-to-mesenchymal transition (EMT) is a mechanism harnessed in 
embryonic development and tumour progression. This process encourages 
epithelial cells to convert to mesenchymal stem cells by losing cell polarity and 
adhesion, and gaining motility and other invasive characteristics, by which tumour 
cells can migrate from primary sites and spread via blood vessels and the 
lymphathic system. In addition to this, EMT induces tumour cells with an invasive 
capacity to acquire ‘stemness’ traits, much like those seen in normal stem cells; 
these cells are known as CSCs and have the capacity to self-renew and 
differentiate into multiple lineages (previously described in Section 1.1.6) (Basu, 
et al., 2018)  
There is sufficient evidence to suggest that Wnt signalling activity involving β-
catenin increases tumourigenic potential in breast CSCs; it has been 
demonstrated by numerous studies that Wnt signalling upregulation has 
increased breast tumour metastasis, and conversely, inhibiting Wnt signalling 
suppresses breast cancer metastasis in mice models (Jang, et al., 2015; Chen, 
et al., 2011). CSCs have become an attractive research area for potential 
targeting, and the Wnt signalling pathway may be the most fruitful option to 
attempt to improve clinical outcomes.  
However, the mechanisms through which the Wnt pathway contributes to CSC 
function have not fully been elucidated, and it has been suggested that the most 
viable starting point would be Wnt target gene investigation, in genes such as 
ASCL2, LGR5, MYC, CCND1, and CD44 (Kim, et al., 2017). One such target 
gene, and acknowledged CSC marker is cluster of differentiation 44 (CD44); 
CD44 is a cell adhesion molecule induced by EMT and has been directly linked 
with the acquisition of CSC traits. Overexpression of CD44 is associated with 
advanced stages of breast cancer development and has been directly linked to 
enhancing Wnt signalling in tumour cells (Basu, et al., 2018; Kim, et al., 2017). 
Another example of a Wnt target gene is Achaete-scute Complex Like-2 
(ASCL2), a transcription factor implicated in colorectal cancer. This gene has 
been shown to work as a transcriptional switch within the Wnt pathway, activating 
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genes that are crucial for the maintenance of stem cell identity and persistence 
of CSCs (Kim, et al., 2017).   
1.2.3	Achaete-scute	Complex	Like-2	(ASCL2)	in	Cancer 
Achaete-scute Complex Like-2 (ASCL2) (11p15.5) belongs to a conserved family 
of transcription factors containing a basic helix-loop-helix (bHLH) domain, which 
activates transcription by dimerising through this basic domain and binding to the 
E-box of target genes (Jubb, et al., 2006). In the normal state, ASCL2 is involved 
in the development and maintenance of trophoblasts in the placenta, neuronal 
precursor determination in both the central and peripheral nervous system, as 
well as controlling the fate of intestinal crypt stem cells (Hu, et al., 2015; Tian, et 
al., 2014). Expression of ASCL2 has been found in the placenta and at the base 
of small and large intestinal crypts, but is generally low or even undetectable in  
other normal tissues (Tian, et al., 2014; Zhongfeng, et al., 2018). 
ASCL2 is a key intestinal stem cell marker and a known downstream target of 
Wnt signalling (Figure 1.4), activated by WiNTRLINC1 (van der Flier, et al., 2009; 
Giakountis, et al., 2016). The gene is thought to act as a Wnt dependant and 
responsive transcriptional switch, regulated by an autocrine loop, that defines 
stem cell (LGR5+) fate in the intestine by acting in cooperation with β-catenin and 
Tcf (Hu, et al., 2015; Schuijers, et al., 2015). However, recently ASCL2 has been 
seen to be involved in tumour progression; due to the loss of imprinting at the 
11p15.5 locus (where ASCL2 resides) being a common occurrence in colorectal 
cancer (CRC), this prompted the investigation of ASCL2 in CRC, leading to the 
findings that this gene is upregulated in colorectal tumours (Jubb, et al., 2006). 
Since, a number of groups have shown that ASCL2 overexpression is seen in  
colon and intestinal tumours (Giakountis, et al., 2016; Jubb, et al., 2006; 
Schuijers, et al., 2015). Not only has ASCL2 been found to be upregulated in 
these tumours, but its activity within the Wnt pathway appears to be disturbed; 
this disturbance is thought to lead to the overexpression of ASCL2 in CRC. 
As well as expression in primary CRC, Stange, et al., (2010) found that ASCL2 
is a likely signature affecting CRC metastasis to the liver; ASCL2 overexpression 
leads to changes in stem/progenitor cell hierarchy (Kim, et al., 2017). Additionally, 
it is thought that this gene can potentially affect the behaviour of these metastatic 
tumours by altering the potential of stem and progenitor cells, subsequently 
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causing self-renewal as opposed to differentiation (Tian, et al., 2014). ASCL2 
overexpression has previously been found in a number of other cancers such as 
lung squamous cell (Hu, et al., 2015), gastric (by induction of EMT) (Kwon, et al., 
2013; Zuo, et al., 2018) and osteosarcoma (Liu, et al., 2016), conferring a poor 
prognosis. A recent study by Juarez, et al., (2018) found that Ivermectin, an 
antiparasitic agent being explored as an anticancer drug, interacts with the Wnt 
pathway and supresses ASCL2, and has the ability to target CSCs. It was also 
discovered that cells overexpressing ASCL2 show a resistance to 5- fluorouracil 
in gastric cancer, a drug used to treat many solid tumours including breast cancer 
(Kwon, et al., 2013; Kim, et al., 2017).  
In 2014, a study published by Conway, et al., (2014) used DNA methylation 
profiling and clustering analysis to reveal a group of hypermethylated 
developmental genes, including ASCL2, in hormone receptor positive breast 
cancers; ASCL2 was one of many genes showing large differential methylation, 
reduced expression, and a predictor of poor prognosis in patients. This study 
showcased evidence of an association between epigenetic profiles such as DNA 
methylation and breast tumour classification. Other than this, ASCL2 had not 
been investigated specifically or thoroughly in breast cancer when the present 
study began. Since, an in silico meta-analysis of the ASCL gene family was 
published in 2017 (Wang, et al., 2017), revealing that ASCL2 demonstrated 
significantly increased expression in breast, stomach, head and neck, ovarian 
and testicular cancers, as well as exhibiting low expression in melanoma, 
sarcoma, prostate and neurological cancers. In terms of breast cancer 
specifically, a study by Xu, et al., (2017) found that ASCL2 was expressed highly 
in breast cancer cells compared to normal epithelial cells, and expression 
appeared to correlate with tumour size, growth, and metastasis; the study also 
suggested that ASCL2 may be used as a marker to assess the risk of relapse in 
cancers. In 2018, Wang, et al., (2018) used Gene Ontology (GO) functional 
enrichment analysis and identified ASCL2 as one of many differentially 
expressed genes in BT474 breast cancer cells compared to MCF10A cells.  
Despite the study by Xu, et al., (2017) being the first to document the clinical 
relevance of ASCL2 in breast tumours, experimental analysis was extremely 
scarce and relied on immunohistochemical staining alone, with small sample 
sizes; no elucidation of the function of ASCL2 was explored. Although there have 
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been other recent studies hinting at the involvement of ASCL2 in breast cancer, 
none of these have led an in-depth investigation into the role of ASCL2 in breast 
tumourigenesis, or integrated multiple layers of examination.  
From the studies mentioned, it is clear that interest in ASCL2 in breast cancer is 
peaking in the scientific community and research in this area is extremely 
prospective, however, functional investigation or further exploration of this gene 
has not been pursued by any of these studies to date. Still, these studies not only 
provide further rationale for the selection of ASCL2 as a candidate gene in this 
study, but also provide evidence that this area of research is a current field of 
interest requiring knowledge contribution, and has given some new insight that 
can be built upon within this project.  
Therefore, these factors pave the way for investigation into the function of the 
ASCL2 gene in breast cancer, particularly within the Wnt signalling pathway. Wnt 
signalling is considered to be important in the regulation of CSC migration and 
self-renewal, and taking into account what is already known about the role of 
ASCL2 in development and defining stem cell fate, this may be a link that needs 
exploring. 
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Figure 1.4. Proposed signalling mechanism by which ASCL2 works within the Wnt 
signalling pathway to affect the expression of Wnt target genes and advance the 
growth of cancer. Diagram adapted from Schuijers, et al., (2015) & de Sousa, et al., 
(2011). 
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1.3.	Cancer	Genetics,	Biomarkers	&	Gene	Discovery	
There has been great progress in identifying many germ-line mutations, such as 
BRCA1/2, which have given the ability to detect susceptibility, predict prognosis 
and dictate patient stratification. However, the success of these genes is 
dampened by the fact that hereditary mutations are only responsible for 
approximately 5% of breast cancers. Therefore, the remaining 95% are sporadic 
and instigated by an accumulation of somatic mutations (van der Groep, et al., 
2011).  
Somatic mutations occur in all dividing cells due to exogenous (environmental 
factors such as radiation) or endogenous (faults in DNA replication) mutagens. 
These types of mutations are acquired and may be classed as a ‘driver’ or 
‘passenger’. Solid tumours typically can contain up to thousands of genetic 
aberrations and alterations, but only a handful of these are considered driver 
mutations (Tomasetti, et al., 2015). Driver mutations allow cells a selective growth 
advantage and are considered positively selected in cancer cells; these alter 
critical cellular processes leading to the hallmarks of cancer (Gonzalez-Perez, 
2016). In contrast, passenger mutations may arise within the cell, but do not give 
the cell any growth advantage (Greenman, et al., 2007). A driver gene therefore, 
is a gene containing driver mutations (Tomasetti, et al., 2015).  
Vogelstein, et al., (2013) estimated that an average tumour contains two to eight 
driver gene mutations. These driver mutations are thought to only provide a small 
growth advantage to cells, which eventually build up over many years and result 
in billions of additional cells. Hence, it follows that the number of these somatic 
mutations is correlated to age. In this sense, sequential somatic mutations 
occurring during tumourigenesis can be thought of as an ‘evolutionary clock’ 
(Vogelstein, et al., 2013). 
However, despite the exact number of driver gene mutations required for breast 
tumour initiation and progression being unknown, Tomasetti, et al., (2015) have 
shown that for the development of lung and colon adenocarcinomas, only 3 
mutations are needed. This has important implications for driver gene 
identification highlighting that although there is unlikely to be one single gene 
responsible, there may only be a small handful which can be taken advantage of 
for targeting. 
	25	
	
Although, hereditary mutations and mutations in driver genes are not the only 
initiators of cancer development. Epigenetic alterations are also crucial for the 
pathogenesis of breast cancer. Despite all cells holding essentially the same 
genetic information, the variation observed between cell types and cellular 
functions is a result of differences in gene expression. Epigenetics in its broadest 
and simplest form therefore describes the changes in gene expression and 
activity that are not encoded by DNA (Gibney, & Nolan, 2010; Byler, et al., 2014). 
There are a number of ways in which gene expression is controlled via epigenetic 
mechanisms including DNA methylation, histone modification and microRNA 
expression (Gibney, & Nolan, 2010). Epigenetic alterations, such as dysregulated 
microRNAs, can therefore affect the expression of tumour suppressor or 
oncogenes and result in tumourigenic growth (Byler, et al., 2014).  
MicroRNAs are small non-coding RNAs and their involvement in the regulation 
of gene expression has been established in breast cancer, among other cancers, 
for some time. Iorio, et al., (2005) revealed that a number of miRNAs were 
aberrantly expressed in breast cancer compared to normal tissue, namely mir-
125b, mir-145, mir-21, and mir-155, with a number of miRNAs being associated 
with clinical parameters in patients; these include hormone receptor status, stage, 
vascular invasion and proliferation index. Since, it has been recognised that 
microRNAs also play a role in treatment resistance (Rodriguez-Barrueco, et al., 
2017). 
1.3.1	The	Importance	of	Biomarker	&	Gene	Identification	
Identifying key genes in breast cancer, as well as in other cancers, is pivotal in 
revealing crucial information regarding tumour biology, such as which pathways 
are disturbed during tumourigenesis. By identifying the genes responsible for 
driving and altering oncogenic signalling pathways, these can be further explored 
and may be used to gather information on individual tumours during diagnosis in 
order to enhance clinical decisions. Additionally genes within a pathway can be 
potentially targeted, or used to predict and tailor response to therapy (Gatza, et 
al., 2014).  
The important implication that driver genes can be targeted for therapeutic 
development is supported by a study by Rubio-Perez, et al., (2015) highlighting 
that in 4000 tumour samples across 28 tumour types, only 6% were shown to be 
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manageable using currently approved agents. This highlights a need for greater 
in-depth genetic characterisation in cancers, particularly for breast cancer 
patients where current therapies are ineffective; this is the case for many HER2+ 
cancers, where nearly half of patients exhibit resistance to trastuzumab (Esteva, 
et al., 2010). 
1.3.2	The	Current	Genetic	Landscape	of	Breast	Cancer	
It has been established that there are on average approximately 57 somatic 
mutations per breast cancer case, but only a small number of tumours have 
overlap in driver mutations, and no tumour can be considered identical at the 
genome level (Desmedt, et al., 2016; Ng, et al., 2015). It is important to note that 
depending on laboratory methods, sample selection and data analysis, many 
studies identify different sets or signatures of somatic gene mutations (Ng, et al., 
2015). However, there are still a small set of potential driver genes that are 
recurrently identified across breast cancer studies, such as ERBB2, TP53, MYC, 
PIK3CA, GATA3, CCND1, FGFR1 and MAP3KI (Desmedt, et al., 2016). Studies 
have shown that ER-positive tumours have fewer mutations than ER-negative 
tumours, which primarily affect PIK3CA. Of all of the intrinsic subtypes, HER2+ 
has been shown to have the highest mutation rates, with the most frequently 
mutated gene in HER2+ and the basal-like subtype being TP53 (Ng, et al., 2015).  
Presently, it appears that the term ‘driver gene’ can be interpreted in 2 different 
ways in the scientific literature. At its core, a ‘driver gene’ is used to define a 
mutation that gives a cell a selective growth advantage. Thus, a driver gene must 
have a driver mutation. However, some recognised driver genes do not possess 
a mutation and enhance tumourigenicity via changes in expression by epigenetic 
alterations. Although both mutated or over/under expressed genes can still drive 
the neoplastic process and can therefore be regarded as a driver gene, this 
terminology is vague. Vogelstein, et al., (2013) suggest clarifying this by 
categorising driver genes as a ‘mut-driver’ or ‘epi-driver’. Epi-drivers can 
therefore be considered to be aberrantly expressed in tumours but not 
necessarily mutated (Vogelstein, et al., 2013). 
Gatza, et al., (2014) used gene expression microarray data and a panel of gene 
expression signatures to examine patterns of pathway activity to identify specific 
DNA amplifications and genes within these that represent key drivers. This study 
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identified 8 genes (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and 
SLC2A10) amplified only in patients with proliferative luminal breast cancers, a 
subtype with few therapeutic options. Liu, et al., (2015) have also identified 
candidate driver mutations in the luminal subtype, revealing mutations in BRAF, 
GNAS, IDH1 and KRAS, by sequencing hotspot regions from cancer related 
genes. 
A study by Lawrence, et al., (2014) revealed 33 novel candidate genes related to 
the hallmarks of cancer. The authors suggest that a complete catalogue of cancer 
genes, which would be helpful for precision medicine, is still far from achievable, 
with the new number of new candidate genes continuously expanding, especially 
with increasing sample sizes. This would ultimately be useful for clinicians to 
select the optimum combination of therapies based on the disrupted pathways in 
each patients’ specific tumour. Despite this study, and numerous others 
identifying large sets of novel candidate genes in breast cancer, few of these 
candidate genes are functionally investigated to determine their role on tumour 
growth and progression. It is important that for our knowledge of genes to be 
useful, follow up studies must fully validate them and explore their potential 
drugability (Lawrence, et al., 2014). 
A comprehensive genomic, transcriptomic and proteomic analysis integrated with 
clinical data, by Michaut, et al., (2016) has confirmed that PI3K pathway 
mutations and CDH1 inactivating mutations are most frequently altered in 
invasive lobular breast carcinoma. Other mutations in HER2, MAP3K1, and 
MAP2K4 were revealed at low frequency. As can be seen from these studies, 
there is seldom complete agreement or overlap of identified driver genes across 
the different breast cancer subtypes; the variety of subtypes also make it difficult 
to obtain a generalised picture of the genes present in breast cancer. This further 
demonstrates the complexity of breast tumorigenesis and the challenge of 
identifying true driver genes, necessitating further investigation and 
characterisation. 
Other studies have put focus on the immunoglobulin superfamily genes, such as 
ALCAM, CXCR4, MUC18 and L1CAM (Li, et al., 2016). This novel study 
investigated the superfamily by integrating different levels of data (genomic, gene 
expression, protein-protein interactions). Results indicated that the majority of 
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these genes could be considered cancer drivers, or have links to drivers, thus 
show potential as breast cancer biomarkers.  
In 2016, a landmark study used whole genome sequencing and comprehensive 
bioinformatics analyses to analyse 560 breast cancers (Nik-Zainal, et al., 2016). 
Ninety-three potential driver genes (protein coding somatic mutations) were 
identified, along with 12 base substitution and 6 base rearrangement driver gene 
signatures. To date, this research has been the largest study to attempt to 
encompass the majority of somatic mutations in breast cancer, and has made 
efforts to confirm the accepted notion of each breast tumour’s genetic profile 
being individual (Nik-Zainal, et al., 2016). Despite this study gaining a general 
picture of the driving mutations in breast tumourigenesis, it is likely that subtle or 
uncommonly mutated genes still need classification. As well as this, further 
functional analysis and development of this list of 93 genes is needed to improve 
the clinical utility of this research. Smid, et al., (2016) illustrates the importance 
of functional analysis of somatic mutations by undertaking a comprehensive 
genomic and pathway analysis in breast cancer. The group found that the type 
of genetic substitution has greater impact at triggering an immune response 
against a tumour, rather than the number of mutations, as was previously 
thought. Although smaller studies and research groups are often limited on 
resources to perform such large scale and varied analysis, the trend of integrating 
multiple platforms can still be feasible on a smaller scale, for example by using 
only two or three platforms, smaller samples sizes, or by data mining from free 
public databases rather than performing all laboratory analysis in-house.  
The few driver gene mutations present in cancers in comparison to passenger 
mutations means it is difficult to investigate the function of all mutations identified 
by sequencing. In light of this, bioinformatics analysis tools have been developed 
to predict key genes and mutations, which can therefore be preferentially 
selected for functional analyses. There are two main approaches used in this 
instance, which either examine the mutation frequencies or aim to predict the 
functionality of the mutations (Pon, & Marra, 2015). Alternatively, systematic 
approaches can reveal groups of genes that are functionally related, or genes 
that are linked by a functional network or significantly enriched signalling pathway 
(Figure 1.4) (Gonzalez-Perez, 2016). 
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The molecular markers and gene expression signatures (discussed above) used 
to currently classify patients’ breast cancers, and thus predict prognosis and 
treatment course, have been used in the private clinical laboratory for some time, 
for example, OncoType DX by Genomic Health, and the ‘MammaPrint 70-gene 
prognostic signature’ by Agendia (Cronin, et al., 2007; Slodkowska, & Ross, 
2009). Furthering knowledge of the molecular heterogeneity of breast cancer can 
expand these clinical tests for greater predictive and informative power which 
could be crucial in reducing cancer mortality (Vogelstein, et al., 2013) 
 
 
  
	30	
	
1.3.3	The	Challenges	of	Gene	Identification	in	Breast	Cancer	
The ongoing research in this field by academics and industrial laboratories 
worldwide emulates the challenge of gene identification. Despite sequencing and 
array technologies moving at a phenomenal pace, this is not matched by ‘big 
data’ handling techniques or user-friendly bioinformatics analyses. Furthermore, 
the number of bioinformatics algorithms, possible analysis pipelines and 
databases can make it difficult for researchers with little bioinformatics 
experience. This is further discussed in Section 1.5.  
Aside from technical challenges, there are many factors that cause difficulties in 
gene identification. One important thing to consider is that somatic mutations 
rarely occur at greater than 10% prevalence, meaning that most genes have a 
much lower incidence and are mutated infrequently. This is due to the fact that 
there is such an enormous and assorted range of somatic mutations occurring in 
cancer cells, that the frequency of any identified driving mutation can be 
extremely low, even if they provide cells with a significant growth advantage 
(Tomasetti, et al., 2015; Liu, & Hu, 2014). This can be seen across all breast 
cancers where only somatic mutations in TP53, PIK3CA and GATA3 appear at 
>10% incidence (The Cancer Genome Atlas Network, 2012). The overwhelming 
amount of tumour suppressor or oncogenes, and possible epigenetic changes, 
manifests a huge number of possible genotypic outcomes per tumour. An 
additional complication is that driver genes can also contain mutations that are 
not driver mutations (Vogelstein, et al., 2013).  
Despite breast tumours originating from the same mammary tissues, the different 
subtypes can be considered as molecularly different diseases with differing gene 
expression profiles and therapeutic responses. It is now accepted that these 
subtypes do not exhibit identical sets of mutations or gene expression patterns; 
it is unlikely that each subtype can be represented by a single driving gene or 
biomarker, although the pathways affected may be similar. In this sense, it seems 
that no two breast tumours are genetically the same, and thus no two breast 
cancer cell lines are the same.  
There is growing evidence suggesting that many primary breast tumours consist 
of several genetically distinct clones, rather than existing as a single entity. This 
inter and intra-tumour heterogeneity (Figure 1.5) has been demonstrated in 
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approximately two-thirds of triple negative breast cancers, particularly in basal-
like subtypes, and often means that potential driver somatic mutations are 
actually only seen in a minority of tumour cells (Ng, et al., 2015). This can also 
affect secondary tumours, with the majority of metastatic lesions varying 
significantly in their genetic profile compared to primary breast tumours.  
A single tumour consisting of different cell clones is thought to be a result of 
distinct CSC populations and tumour cell plasticity. There is now evidence that 
breast cancer cells have the ability to convert between different subtypes of the 
disease (Yeo, & Guan, 2017); a study by Jordan, et al., (2016) revealed that 
circulating tumour cells demonstrated reversible HER2 expression plasticity.  In 
light of this, it may be advantageous in the future to utilize multiple subtype-
specific therapeutic agents together to lessen the chance of resistant populations 
from remaining (Yeo, & Guan, 2017).  
Regarding inter- and intra-tumoural heterogeneity, there is currently a disconnect 
between scientific research and clinical practice (Yeo, & Guan, 2017). Progress 
within research has led to the identification of 10 distinct integrated clusters 
(discussed previously) to segregate breast tumours, however these, as well as 
PAM50 genomic testing (a 50 gene prognostic subtype classifier) (Parker, et al., 
2009) have not yet been employed in the clinical setting. Owing to intra-tumoural 
heterogeneity, diagnosis at the cellular level instead of the tumour as a single 
entity would be more beneficial (Yeo, & Guan, 2017). This is where single-cell 
technologies would be favoured in diagnosis, rather than an isolated biopsy of a 
section of the tumour which may not be reflective of the entire mass.  
Additionally, the diversity of somatic alterations found in breast tumours can 
change over time as the tumour develops (Desmedt, et al., 2016). This presents 
a challenge to researchers, as driving mutations found in single breast cancer 
samples may not be characteristic of the whole tumour. Although these complex 
factors pose challenges for gene identification in breast cancer, they may be 
useful for more long-term development and implementation of targeted medicine; 
this would ensure that future therapeutics would be based more upon the 
molecular biology of individual tumours (Ng, et al., 2015).  
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Figure 1.5. Inter- and intra- tumour heterogeneity, a prominent challenge in breast 
cancer research.    
	33	
	
1.3.4	Personalised	Medicine	
When taking into account the complexity, variability and unpredictability of 
tumourigenesis, precision medicine has been the goal of cancer research for a 
number of years, and has been used for some time, e.g. ER and HER2 status. 
The aim of precision medicine is to provide a level of care for the patient that will 
yield the best clinical outcome and avoid adverse reactions, based on the 
patients’ influential profile of genetic variants and factors. Each tumour will exhibit 
different genetic and epigenetic variations, which in turn is responsible for 
different manifestations, behaviour, prognosis, and response to therapeutic 
agents. This goal is becoming seemingly more attainable due to the 
advancements in technology and research discussed in this chapter, allowing a 
patient’s particular tumour to be characterised at the clinic and then administered 
more specific and targeted drugs with greater therapeutic impact (Uzilov, et al., 
2016). As these targeted drugs have proved effective at treating patients with 
these biomarkers, efforts continue to find more of these links to be exploited, but, 
identification and drug development can be extremely complex (Uzilov, et al., 
2016). 
There are many targeted drugs for a variety of cancers, including breast cancer, 
which have been FDA approved or are awaiting approval. Some of these rely on 
an increased expression of cell surface receptors (characterised by 
immunohistochemistry) whereas others rely on genetic biomarkers. An example 
is Lapatinib, a tyrosine kinase inhibitor for HER2 overexpression in breast 
tumours, which received full FDA approval in 2010 (Mcveigh, & George, 2017; 
National Cancer Institute, 2011); A more widely used example is Herceptin 
(Mcveigh, & George, 2017). However, it is important to note that the idea of 
precision medicine does not mean individual drugs custom-made for each 
patient. Instead, drugs and treatment options are given based on a patients’ 
genetic profile and predicted response. 
A number of large studies (including those previously mentioned in this chapter) 
have worked towards using Next Generation Sequencing (NGS) for genetic 
testing to build a well-defined landscape of possible mutations in breast cancer 
to increase the capacity of personalised care. Uzilov, et al., (2016) have 
described an integrative genomic approach to aid in the clinical application of 
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precision medicine. The study performed whole exome sequencing (WES), 
targeted sequencing, panel small nucleotide (SNP) microarray genotyping, and 
RNA sequencing on matched tumour and normal samples. The results 
demonstrated that using WES highlighted a greater and more complete 
‘spectrum’ of alterations in comparison to the targeted panel sequencing. Whole 
exome sequencing also allowed investigation of variants involved in drug 
metabolism processes. 
Overall, the integrated approach of this study gave greater clarity and ‘more 
actionable alterations than several commercially available targeted cancer 
panels’, as well as providing a clinically applicable workflow. Using WES and 
RNA sequencing in this clinical study gave a more inclusive genetic profile for 
patient samples, which could be used to make therapeutic decisions, and 
identified more rare somatic mutations in some patients that were initially missed 
by targeted panel sequencing. 
There are many advantages to this type of investigation for patients. Primarily, it 
allows examination at the pathway level, of whether drivers or multiple 
components are altered consistently in the same pathways. Also, cancer panels 
only consist of already well established, characterised and common mutations; 
rarer mutations or those that are functionally documented but not yet considered 
as a driver may be missed, and may have held important clues for treatment 
determination. Additionally, this type of screening allows more accurate 
differentiation of germline and somatic mutations (and also between tumour and 
germline DNA) which can affect the patient and family. Making this distinction is 
important as it can highlight any possible alterations in DNA repair pathways that 
will determine chemotherapy response and thus dictate the dosage and drug 
toxicity administered. These responses cannot be seen with standard panel 
testing (Uzilov, et al., 2016).  
These types of studies show that NGS and integrated omic approaches are 
extremely effective and more reliable at finding ‘actionable’ genetic variants in 
cancer, and should where possible, be incorporated into clinical testing in 
comparison to techniques with much lower resolution and discovery power 
(Garraway, & Baselga, 2012). With these techniques being so readily available, 
it is now more important than ever to strive for continued identification and 
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classification of genes and pathways in breast cancer, so that these can be used 
for diagnostic purposes and to tailor treatment approaches.  
1.4.	High-Throughput	Technologies	
1.4.1	Next-Generation	Sequencing	
The development of DNA sequencing by chain termination and fragmentation 
methods was first established by Sanger and colleagues in 1977 (Sanger, et al., 
1977), and is known today as first generation Sanger sequencing. This technique 
was time consuming and required radioactive material, however was automated 
in 1987 using capillary electrophoresis and fluorochromes (Liu, et al., 2012). This 
became the predominant method of DNA sequencing, but despite being 
considered as the gold standard, still had many limitations. Firstly, the technique 
requires gels or polymers to separate the DNA fragments that are fluorescently 
labelled. The technique has low throughput so only a few samples can be 
analysed in parallel; sample preparation needs to be manual as automation of 
these steps is difficult. Cloning of the DNA fragments into bacteria is needed to 
produce larger sequences, sensitivity is also low for the detection of low-level 
mutations, even those considered to be clinically relevant, and assembly of whole 
genomes de novo is challenging (Fakruddin, & Chowdhury, 2012). 
Finally in 2004, the first draft of the human genome was successfully sequenced 
and published in its entirety (International Human Genome Sequencing 
Consortium, 2004). From this point onwards there was a call for more rapid and 
cheaper technology that addressed the limitations associated with Sanger 
sequencing. In 2005, the pyrosequencing method by 454 Sequencing™ (Life 
Technologies, Roche) was the first next-generation sequencing (NGS) 
technology to be released. By 2010, the founder of the 454 developed and 
released the Ion Torrent Personal Genome Machine (PGM™) (Thermo Fisher, 
Life Technologies) which resulted in faster, cheaper and more user friendly 
sequencing, making the cost of sequencing more accessible to independent 
laboratories; the target of the $1000 genome was reached in 2014 (van Dijk, et 
al., 2014). 
In the past decade, or the ‘omic era’, massively parallel, high-throughput DNA 
sequencing platforms have become a mainstream preference used across 
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academic and industrial laboratories and has transformed genomic and 
transcriptomic research. The advent of bench-top NGS platforms has improved 
time consumption during sequencing, making the technology much more 
translatable to clinical use (Hansen, & Bedard, 2013).  
To utilise this potential offered by such significant shifts in the capability of 
technology, the UK’s landmark 100,000 Genomes Project was initiated in 2013 
by Genomics England. The project aimed to sequence 100,000 whole genomes 
from the UK National Health Service (NHS) patients by 2017. Ultimately, the goal 
of this large-scale and ambitious project was to transform clinical practice using 
genetic information for rare diseases and cancers, and to drive change such that 
WGS is established and adopted as part of routine assessment and care 
(Turnbull et al., 2018).  
1.4.2	Whole	Exome	Sequencing	
Depending on the requirements of sequencing, it may be practical or cost-
effective to carry out whole genome sequencing (WGS). Alternatively, a more 
distinct or targeted region of the genome may be required. In this instance, and 
is the case in the majority of clinical studies, it may be beneficial to use whole 
exome sequencing (WES) which only sequences the protein coding region (1-
2%) of the genome, but is still able to identify a wealth of single nucleotide 
polymorphisms (SNPs) and small insertions and deletions (INDELS). Moreover, 
almost 85% of potential disease causing aberrations are incorporated into this 
minority (van Dijk, et al., 2014).  
One disadvantage of WES is that it doesn’t investigate the impact that non-coding 
alleles might have on diseases. WES is sometimes criticised as sequences other 
than exons can also be very important in disease, e.g. non-coding RNA such as 
microRNA, and the controversially termed ‘junk-DNA’. A particular challenge 
facing WES is defining the exome and which sequences are rightly protein coding 
in the human genome, as our knowledge of protein coding exons is currently 
unfinished. Although currently, WES is a very economic and prolific option for 
gaining a vast amount of information at a reasonable cost (Bamshad, et al., 
2011).  
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1.4.3	Microarrays		
Prior to NGS for cancer genomics was the production and utilisation of DNA 
microarrays, which continue to be used for gene expression (mRNA) analyses, 
especially in cancer research to gather information on potential transcriptomic 
targets and markers. Gene expression microarrays offer a broad view of the 
entire transcriptional activity in a sample (Slonim, & Yanai, 2009). Other 
applications include assessment of gain or loss of genetic material, DNA 
aberration profiling to identify cancer causing genes, SNP arrays for germline 
mutation identification, the study of protein expression, and DNA methylation and 
microRNA expression analysis (Malone, & Oliver, 2011). 
A microarray is the hybridisation (singularly or multiplex) of labelled samples of 
interest, alongside a complementary nucleic acid probe bound to a miniaturised 
silicon thin-film chip or glass slide (Figure 1.6). A microarray chip is made up of 
thousands of individual nucleic acid probes (these can be complementary DNA 
or known oligonucleotides) which match to a short piece of nucleic acid sequence 
from a human (or other known organism). Ultimately, all of the probes combined 
provide a genome-wide view of all coding regions (Malone, & Oliver, 2011). One 
such commercial array platform is manufactured by Affymetrix 
(www.affymetrix.com). Affymetrix GeneChips are the most commonly used 
microarray platforms for expression profiling, able to interrogate the whole 
genome for transcription activity (Auer, et al., 2009). 
This technology can be performed relatively cheaply (in comparison to NGS) in 
a massively parallel manner, yielding results for thousands of genes in one 
experiment. The Minimum Information About a Microarray Experiment (MIAME) 
standards have also been introduced ensuring consistent and reliable results 
across laboratories. However, microarrays are limited in that they tend to focus 
on more common variants and require knowledge of the sequence prior to 
analysis for primers to be designed, as opposed to RNA sequencing, that 
requires no a priori knowledge (Brazma, et al., 2001; Buermans, & den Dunnen, 
2014; Christie, 2005).  
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Figure 1.6. An Affymetrix gene chip, a popular commercial microarray, showing the 
process of hybridisation of labelled RNA probes to a gene chip expression array in 
order to quantitate RNA expression of selected targets (Figure adapted from 
Bumgarner, 2013, and Macgregor, & Squire, 2002). 
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1.4.4	Data	Mining	
There is an unprecedented amount of genomic and transcriptomic data being 
generated worldwide that is freely available for researchers to use; the act of 
extracting novel information from large datasets is known as data mining. There 
are many purposes of biological data mining, such as association analysis (to 
evaluate relationships in data), pathway and network analysis, gene prioritisation, 
function prediction, pharmacological predictions and toxicology, all of which 
provides researchers with great prospects for discovery (Gonzalez, et al., 2016).   
Since the advent of microarrays and NGS, the number and capacity of sequence 
databases have expanded. The Gene Expression Omnibus (GEO, NCBI) is the 
principal and most established public gene expression data repository, including 
microarray, genomic and proteomic experiments for a variety of organisms. The 
goal of GEO was to ‘provide a robust, versatile database in which to efficiently 
store high-throughput functional genomic data’, and currently holds 3848 
separate datasets of nearly 2 million samples (Barrett, et al., 2005). 
Over the years, the explosion in biological data generation has resulted in the 
emergence of many other gene expression databases allowing researchers to 
successfully share genomic data or mine relevant datasets to advance their 
studies and thus, the global knowledge of cancer (Table 1.4). Data from multiple 
cell lines, tissues, clinical samples and matched normal samples are available. 
Although this international data sharing and mining is extremely useful for smaller 
laboratories lacking the resources for WGS or microarray analysis, there are also 
many drawbacks that researchers must be aware of prior to analysis.  
Firstly, variability between sources is the most prominent difficulty with data 
mining – sample collection and processing, raw data processing and data 
conversion or formatting can all result in discrepancies. Regarding microarray 
databases, a variability can be seen between data using different microarray 
platforms, therefore researchers must take this into consideration if using multiple 
different databases. Also as there is likely to be a large number of genes 
corresponding to a relatively small sample size, this kind of data is at risk of being 
prone to false positives, hence there may be issues extracting relevant alterations 
within the data (Piatetsky-Shapiro, & Tamayo, 2003). In general, large data 
collections are intrinsically prone to errors, so this should be kept in mind by the 
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researcher (Werner, et al., 2014). However, despite these pitfalls, data mining is 
an excellent tool for validation purposes, can provide an excellent foundation for 
answering research questions or formulating hypotheses, and is an economical 
way of strengthening research conclusions.  
 
 
 	
Database	 Description	 URL	
CGHub	
	
Sharing	of	42	cancer	types	and	
normal	controls	
www.cghub.ucsc.edu/	
	
COSMIC	
	
Largest	database	of	somatic	
mutations	in	cancer	 http://cancer.sanger.ac.uk	
cBioPortal	
	
Multidimensional	cancer	genomic	
data,	also	supporting	pathway	
exploration	
http://www.cbioportal.org/public-
portal/	
	
Gene	
Expression	
Omnibus	
Genomics	data	repository	for	array	
and	sequenced	based	data	 https://www.ncbi.nlm.nih.gov/geo/	
UCSC	Cancer	
Genomics	
Browser	
Online	analysis	tool	for	cancer	
genomics	and	clinical	data	
	
https://genome-
cancer.soe.ucsc.edu/	
	 	 	
Table 1.4. Examples of prominent cancer related open genomics databases (adapted 
from Yang, et al., (2015b) 
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1.5.	Systems	Biology,	Bioinformatics	&	Data	Integration	
Since high-throughput nucleotide sequencing and microarrays are much more 
accessible to researchers, scientists are now flooded with an unprecedented 
amount of omics data on a daily basis. These advances have put pressure on 
developing more efficient bioinformatics tools to handle the increasing volume of 
biological data, and the challenge of extracting relevant information.  
In spite of developments in high-throughput technologies making omics data 
acquisition and generation relatively straightforward, the potential of this data to 
add to our knowledge of breast cancer is limited by the difficulty in interpretation. 
For example, just one run of WES can provide a researcher with a large amount 
(terabytes) of raw data; larger studies with multiple samples can generate a vast 
amount of data that can be extremely time-consuming to analyse. Hence, 
analysing these results and pinpointing the most pertinent information in cancer 
research can be a mammoth task (Pabinger, et al., 2014).  
1.5.1	A	Bioinformatics	Workflow	
In order to obtain meaningful results from raw sequencing or microarray data, 
data management needs to be structured and the correct tools need to be used 
to match the goal of the research. There are a large number of bioinformatics 
analysis tools and programs (aside from commercial tools) now available for 
various purposes, or sections of workflows, with each potentially requiring 
different operating systems and data formats. Therefore, it is imperative to select 
analysis programs compatible with the data formats generated from each 
platform, and that are compatible with the operating systems preferred by the 
user. The appropriate analysis tools for the desired workflows should be carefully 
considered for the selected application, and time should be taken to meticulously 
formulate a suitable workflow prior to beginning analysis (Pabinger, et al., 2014).  
Regarding bioinformatics analytical pipelines and workflows, existing systems 
published in the literature or commercially available can be used by the 
researcher; various individual platforms may be used simultaneously and 
compared, or users can formulate their own algorithms which commonly involve 
building R scripts. Tokheim, et al., (2016) examined various different ‘driver gene 
prediction methods’ and concluded that each method varied a large amount in its 
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predictions; this poses problems for comparisons between tools and deciding 
which tools are most likely to give the a realistic picture. As there is no current 
set mode of analysis, ‘gold standard’ or leading pipeline, scientists can tailor NGS 
and microarray analysis to their own preferences or expertise (Pabinger, et al., 
2014). This is extremely convenient and allows researchers flexibility, but creates 
a huge amount of variation and disparities between similar studies – ultimately, 
this has led to a ‘snowball’ effect where unique lists upon lists of distinct candidate 
genes have been identified by groups around the world, but many genes have 
not been followed up.   
1.5.2	Pathway	Analysis	
A frequently used approach for analysing genomic or transcriptomic data for the 
identification of genes in cancer is pathway analysis, discussed in more detail in 
Section 3.1. This allows an understanding of the functional biology underpinning 
a set of differentially expressed genes. This approach sorts and condenses a 
comprehensive gene list into smaller sets of related genes that fit into similar 
pathways, and reduces thousands of genes into hundreds of components with 
functional consequences. There are many established and user friendly web-
based pathway repositories and resources such as Gene Ontology, Kyoto 
Encyclopaedia of Genes and Genomes (KEGG), Database for Annotation, 
Visualization and Integrated Discovery (DAVID) and PANTHER, which use 
‘knowledge base driven pathway analysis’ (Khatri, et al., 2012). Another popular 
method for understanding gene expression data is Gene Set Enrichment Analysis 
(GSEA). These methods all use similar principles for pathway analysis, by 
analysing gene sets based on their corresponding biological pathways. These 
examples and other popular bioinformatics tools are shown in Table 1.5.  
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Name	 Description	 Interface/	Programming	 Level	 Reference	
Bioconductor	 Open	source,	for	high	throughput	omic	data	
R,	command	line	
interface	 Advanced	
Gentleman	et	al.,	
2004	
CHASM	
Prediction	of	SNV	
contribution	to	tumour	
growth	
C++,	Python	 Advanced	 Wong	et	al.,	2011	
DAVID	 Functional	interpretation	of	lists	of	genes	 Web	interface	 Basic	 Huang	et	al.,	2007	
Gene	Ontology	
(GO)	 Classification	of	genes	 Web	interface	 Basic	
Ashburner	et	al.,	
2000	
GSEA	
Determines	statistically	
significant	groups	of	related	
genes	
Java,	R,	Command	
line	interface	 Advanced	
Subramanian	et	al.,	
2005	
IMPaLA	
Pathway	analysis	of	
transcriptomics	by	
enrichment	analysis	
Web	interface	 Basic	 Kamburov	et	al.,	2011	
MADGiC	
Prioritises	somatic	
mutations	based	on	
frequency	and	functional	
impact	
R,	command	line	
interface	 Advanced	
Korthauer	and	
Kendziorski,	2015	
MutsigCV	
Analyses	mutation	lists	to	
see	which	ones	are	mutated	
more	than	expected	
Command	line	
interface	 Advanced	
Lawrence	et	al.,	
2013	
OncodriveFM	 Driver	gene	identification	by	functional	impact	
Perl,	command	
line	interface	 Advanced	
Gonzalez-Perez	and	
Lopez-Bigas,	2012	
PANTHER	 Protein	functional	classification	 Web	interface	 Basic	 Thomas	et	al.,	2003	
Pathway	
Commons	2	
Pathway	queries	and	
annotation	 Web	portal	 Basic	 Cerami	et	al.,	2011	
Table 1.5. Examples of popular bioinformatics and pathway analysis and enrichment 
tools. Information collated from Omictools (2017). 
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1.5.3	Using	a	Multi-Platform	Approach	for	Gene	Identification	
The advent and progression of sequencing and array technologies over the past 
few decades has revealed a vast amount of information regarding breast cancer, 
and provides researchers with an unmatched ability to continuously identify 
genetic alterations driving the oncogenic process. Gene expression and DNA 
microarrays have steered the way for understanding the heterogeneity of breast 
oncogenesis, suggesting that the behaviour of an individual’s cancer is based on 
the tumour’s genetic profile and pattern of gene expression (Perou, & Børresen-
Dale, 2011). In addition, NGS technology has superseded traditional Sanger 
sequencing, and is evolving rapidly into widespread use across research and 
clinical laboratories for cancer surveillance, allowing researchers to sequence 
whole genomes in parallel.  
  
Figure 1.7. An example of a typical workflow for gene identification using an integrated 
and multi-platform data approach. Bioinformatics analysis can be extremely varied 
between studies and is dependent on available resources and the expertise of the 
researcher. Image based on information from Mo et al., (2013) and Suo et al., (2015). 
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With these technologies being increasingly used for gene investigation, alongside 
the notion that data integration can reveal more information than singular analysis 
alone, a multi-level approach for integrating different types of omic data or 
pathway analysis has risen to the forefront of research, with a large number of 
studies coupling gene expression and genomic data (Suo, et al., 2015) (Figure 
1.7). An extensive and comprehensive example of a multi-level approach is the 
use of five data types by The Cancer Genome Atlas Network (2012). This study 
used genomic DNA copy number arrays, exome sequencing, DNA methylation, 
mRNA arrays, microRNA sequencing and reverse phase protein arrays, and 
integrated data across these platforms to analyse primary breast cancers. This 
integrated analysis provided confirmation of previously known somatic mutations, 
as well as novel subtype associated mutations, GATA3, PIK3CA and MAP3KI in 
the Luminal A subtype (The Cancer Genome Atlas Network, 2012). This type of 
analysis appears to be the most productive in gaining an in-depth view of 
underlying tumour biology.    
1.5.4.	Future	Directions	in	‘Big	Data’	and	‘Omics’	technologies	
Third generation sequencing (TGS) is now emerging with further improvements 
to NGS; the main factors distinguishing TGS from NGS is the lack of PCR steps 
during sample preparation which will decrease time consumption and reduce 
errors arising, and the measurement of signal in real time which can be helpful 
for structural variance predication. These newer technologies, such as Nanopore 
and PacBio, which sequences based on an electric current, aim to increase read 
length and turnover (Liu, et al., 2012).  
This greater turnover will continue to produce large quantities of data, therefore 
systems biology and bioinformatics will play a vital role in the search for cancer 
marker genes. In the past, the ability to interpret, analyse and integrate data has 
greatly fallen behind the ability to generate high quality sequence data. As 
therapeutic resistance and low response rates are prominent causes of therapy 
failure, systems biology approaches can aid in selecting which patients are most 
likely to benefit from specific treatments, thus enhance efficacy and potentially 
reduce emerging resistance, as patients in the future will not be wrongly or over 
treated (Werner, et al., 2014). 
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In the clinical setting, molecular characterisation of solid tumour samples to 
inform clinical decisions is well established (Harbeck, et al., 2014; Russnes, et 
al., 2017). However, accessing samples from patient’s tumours can be extremely 
invasive. More recently, a more easily obtainable source of tumour genetic 
material is via circulating tumour cells (CTCs) which can shed into the vasculature 
and subsequently the bloodstream from many primary tumours, for example 
breast tumours (Yee, et al., 2016). These cells can be collected by a traditional 
blood test, and sequential or multiple samples can be collected over time. 
However, sequencing the genetic material of CTCs in blood using NGS can be 
problematic due to low numbers and impure samples (Yee, et al., 2016).  
To address these problems, whole genome amplification can be used to amplify 
the amount of CTC generic material prior to sequencing from just a few or single 
cells. Studies are continuing to improve purification of CTCs from blood for use 
of NGS in the clinical setting (Yee, et al., 2016). Other alternatives investigate the 
circulation of free nucleic acids and exosomes (Friel, et al., 2010). In order for the 
exceptional capacity and potential for these novel technologies to be utilised in 
the clinic, genes need to be established and characterised to aid diagnosis, 
prognosis prediction, and eventually direct targeted and personalised breast 
cancer treatment. 
  
	47	
	
1.6.	Gene	Investigation	in	the	Laboratory:	Harnessing	
Bioinformatics	for	In	Vitro	Investigation	
Although bioinformatics investigation, systems biology methods, and ‘big data’ 
analysis have soared in popularity over the last few years, these methods are far 
from superseding traditional wet lab investigation. In fact, now it is imperative to 
incorporate in silico investigation with laboratory experiments to gain a clearer 
and more accurate picture of biological processes; researchers must question 
whether conclusions drawn from computational investigation can be replicated in 
cell lines, tissues or even patients.  
For gene investigation in cancer, many studies rely on computational biology to 
generate lists of candidate genes from cell line or tissue data, that may be 
mutated, differentially expressed, or function within specific biological pathways. 
From here, researchers may pursue a number of avenues, however arguably the 
most valuable would be to functionally validate and investigate these genes using 
conventional and reliable in vitro and in vivo laboratory techniques. Thus, the 
knowledge of said candidate genes would be more successful in being developed 
in the future as diagnostic, prognostic, or therapeutic markers. In this study, in 
vitro validation has taken place using cell lines, and gene investigation was 
carried out using RNA interference, therefore these methods will be the focus of 
this section.  
1.6.1	Cell	Lines	as	Models	
Research based on immortalised cell lines has been established since the 1950s, 
when HeLa cervical cancer cells were first cloned (Puck, & Marcus, 1955). Now, 
gene exploration using cancer cell lines is still common practice. In fact, an 
extensive amount of foundational and novel knowledge on cancer is the result of 
biological research using cell lines.  
Despite this, cancer cell lines are continuously being scrutinised about whether 
they are representative of the tumours from which they were propagated, and the 
translatability of such research findings to the clinic. Regarding breast cancer 
cells, it’s important to be aware that cell lines may not always mirror the inter- and 
intra-tumour heterogeneity seen in patient tumours, lack the complexity of the 
tumour microenvironment, and the stability of gene expression in cell lines can 
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be unpredictable (Choi, et al., 2014); studies have demonstrated transcriptomic 
drift with prolonged cell culture (Gillet, et al., 2013; Ross, & Perou, 2001). Other 
issues such as cross-contamination and misidentification of cells should also be 
kept in mind, and therefore, to maintain good practice laboratories should perform 
regular cell line authentication (Gillet, et al., 2013). 
Nevertheless, cancer cell lines are considered to be an acceptable experimental 
model for tumours and a basis for screening the efficacy and testing of new 
therapeutics, as well as testing new hypotheses and novel research. If handled 
correctly, chosen with consideration, and good practice is maintained, overall, 
cell lines do well to reflect the behaviour of tumours for initial studies, if their 
limitations are kept in mind (Katt, et al., 2016). 
In relation to gene investigation, cell lines are a prime model for examining novel 
genes as they require little ethical permission for gene manipulation (for example, 
gene knockdown or knockout studies). They are relatively diverse, cheap and 
easy to acquire (multiple cell lines can be compared at low cost), and experiments 
can be performed flexibly and in high-throughput if needs be (Katt, et al., 2016).  
1.6.2	RNA	Interference		
RNA interference (RNAi) is an innate regulatory biological process in cells that 
results in sequence-specific gene silencing (Gavrilov, & Saltzman, 2012). The 
silencing of target genes is mediated by non-coding small interfering RNAs 
(siRNAs) and is shown in Figure 1.8.  
In summary, long double-stranded RNA (dsRNA) molecules are cut and 
separated into 21-25 nucleotide siRNAs by the ribonuclease enzyme Dicer. RNA-
binding protein TRBP together with Dicer, loads this siRNA duplex onto the 
Argonaute protein (AGO2), to create the RNA-induced silencing complex (RISC). 
Argonaute selects the siRNA guide strand, cleaves and removes the passenger 
strand. The guide strand remains tethered to AGO2 and couples with 
complementary mRNA targets which are long enough to be divided, sliced and 
released. Once this process is complete, the RISC is recycled and uses the same 
guide strand to repeat this cycle multiple times (Gavrilov, & Saltzman, 2012)  
Since the discovery of RNAi was published in 1998, its research potential for 
gene suppression, manipulation and regulation has been extremely valuable, 
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especially in the field of oncology research (Fire, et al., 1998; Gavrilov, & 
Saltzman, 2012). Now, using synthetic siRNAs and hijacking this innate RNAi 
pathway for artificial gene knockdown is almost common practice in research 
laboratories (Gavrilov, & Saltzman, 2012). This allows researchers to study the 
effects of genes on cancer growth once expression is switched off, using a 
number of assays or methods that focus on factors such as proliferation, 
apoptosis and migration.  
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Figure 1.8. The mechanism of gene silencing by RNA interference 
(Gavrilov, & Saltzman, 2012). Reproduced under CC BY-NC terms.  
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1.7.	Overall	Conclusions	&	Aims	of	this	Study	
There is an increasing need for greater characterisation of genes across the 
distinct breast cancer subtypes to understand their mechanistic role in 
tumourigenesis within their respective pathways. These may be used in the future 
to aid in the implementation of precision medicine, such as for therapeutic 
exploration or biomarker discovery, or to develop an extensive catalogue of 
genes for which tailored treatment can be built around, addressing the current 
inefficacy of existing breast cancer therapies.  
A multi-method approach for gene identification is a highly strategic, prolific and 
lucrative method for enhancing our knowledge of the molecular foundation 
underpinning breast carcinogenesis, whilst identifying attractive potential targets. 
However, in order to exploit the information generated from sequencing studies, 
the future must focus on addressing the challenges associated with gene 
identification and large-scale omic data, to develop more robust and user-friendly 
bioinformatics pipelines for processing.  
The candidate gene of interest in this study, ASCL2, is a transcription factor 
known to be involved in precursor determination during embryonic and nervous 
system development. This gene has been previously associated with tumour 
progression in colon cancers, proposed as a target of Wnt signalling influencing 
the fate of intestinal stem cells; in a number of other cancers, ASCL2 has also 
been related to poor prognosis. However, despite considerable research into the 
role of ASCL2 in colon cancer, as well as other cancers, its role in breast cancer 
is yet to be defined. 
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The work presented in this thesis aimed to: 
1. Integrate multiple bioinformatics pathway analysis tools to select a novel 
oncogenic candidate gene (ASCL2) from transcriptomic data, for further 
investigation in breast cancer.  
2. Showcase and implement a simple yet integrated in silico analysis 
pipeline, to aid both expert and non-expert researchers with gene 
identification from transcriptomic data. 
3. Investigate the role of the ASCL2 candidate gene in breast cancer cell 
lines, using RNAi and multiple functional assays, to improve 
understanding of its function and shed light on its role in breast cancer 
tumourigenesis.  
4. Investigate the relationship between ASCL2 gene expression and 
clinicopathologic features in patient breast tumours, evaluating the 
suitability of ASCL2 as a possible prognostic indicator in breast cancer. 
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Chapter	II	
	
Methods	
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2.1	Transcriptomics	&	Bioinformatics	
2.1.1	Gene	Prioritisation	Using	‘Extreme	Variation’	Analysis	
Publically available Affymetrix microarray (U133 Plus 2.0 Chip) data (mRNA gene 
expression profiles) for the human breast cancer cell lines, MCF7, T47D, BT474, 
MDA-MB-231, and the non-tumourigenic epithelial cell line, MCF10A, were 
downloaded as raw .CEL files from the online repositories Array Express 
(www.ebi.ac.uk/arrayexpress) and Gene Expression Omnibus (GEO) 
(www.ncbi.nlm.nih.gov/geo). All information relating to raw data were recorded, 
such as dates, publication and experimental design; Array Express and GEO 
accession numbers for datasets, publication ID, citations and replicates can be 
found in Tables 2.1 and 2.2. 
An extreme variation filtering analysis (a gene prioritisation algorithm written in R 
by Dr Rifat Hamoudi) (Hamoudi et al., manuscript in preparation) was performed 
across the five cell lines. Briefly, raw data was subjected to normalisation using 
the GCRMA and MAS5 algorithms, based on the noise in the data. For MAS5, 
the gene would pass filtering if its value was more than 200 across 3 or more cell 
lines. For GCRMA, the gene would pass the filtering if its coefficient of variation 
was more than 50%. The extreme variation filtering analysis was applied to the 
normalised cell line data, identifying 915 differentially expressed gene probes.  
The work in this Section (2.1.1) was carried out by Dr Rifat Hamoudi and Dr 
Nadège Presneau, (with James Whitehead), and formed the basis for candidate 
gene selection and pathway analysis in this study. 
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Subtype	 Cell	Line	Replica	
GEO	Accession	Number	
Array	Express	Number	 PubMed	ID	 Citation/Company	
No
n-
tu
m
ou
rig
en
ic	
MCF10A	 GSE34211	E-GEOD-34211	
PMID:	22222631	
PMID:	24107449	
Pfizer	
Hook,	et	al.,	2012	
Pavlicek,	et	al.,	2013	
MCF10A	 GSE12790	 PMID:	19567590	PMID:	21673316	 Hoeflich,	et	al.,	2009	
MCF10A	 GSE29327	E-GEOD-10890	
PMID:	21673316	
	 Stinson,	et	al.,	2011	
Lu
m
in
al
	A
	 MCF-7	 GSE18912	 PMID:	21220496	 Hou,	et	al.,	2011	
MCF-7	 GSE41445	 PMID:	23894636	 Bayer	Pharma	AG	Bayer,	et	al.,	2013	
MCF-7	 GSE40057	GSE40059	 PMID:	23497265	 Luo,	et	al.,	2013	
Lu
m
in
al
	A
	
T47D	 GSE41445	 PMID:	23894636	 Bayer	Pharma	AG	Bayer,	et	al.,	2013	
T47D	 GSE40057	GSE40059	 PMID:	23497265	 Luo,	et	al.,	2013	
T47D	 GSE34211	E-GEOD-34211	
PMID:	22222631	
PMID:	24107449	
Pfizer	
Hook,	et	al.,	2012	
Pavlicek,	et	al.,	2013	
Lu
m
in
al
	B
	 BT474	 GSE12790	 PMID:	19567590	PMID:	21673316	 Hoeflich,	et	al.,	2009	
BT474	 GSE57083	E-GEOD-57083	 Citation	missing	 Astra	Zeneca,	2014	
BT474	 E-MTAB-37	 PMID:26107615	 Li,	et	al.,	2015	
Tr
ip
le
	
Ne
ga
tiv
e	 MDA-MB231	 GSE41445	 PMID:	23894636	 Bayer	Pharma	AG	Bayer,	et	al.,	2013	
MDA-MB231	 GSE40057	GSE40059	 PMID:	23497265	 Luo,	et	al.,	2013	
Table 2.1. Details of the gene expression datasets for the breast cancer cell lines 
downloaded from online repositories.  
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Cell	Line	 Files	Used	for	Extreme	Variation	Analysis	
MCF10A	
n=10	
MCF10A_221004-4.CEL	
MCF10A_GSM320243.CEL	
MCF10A_GSM320244.CEL	
MCF10A_GSM320245.CEL	
MCF10A_GSM320246.CEL	
MCF10A_GSM320247.CEL	
MCF10A_GSM724633.CEL	
MCF10A_GSM724634.CEL	
MCF10A_GSM724635.CEL	
MCF10A_GSM844584_1_PFIZER.CEL	
MCF-7	
n=9	
MCF-7_GSM1017487_mRNA_12a_081206.CEL	
MCF-7_GSM1017488_mRNA_12b_081206.CEL	
MCF-7_GSM1017489_mRNA_12c_111206.CEL	
MCF-7_GSM468593.cel	
MCF-7_GSM468594.cel	
MCF-7_GSM468595.cel	
MCF-7_GSM468596.cel	
MCF-7_GSM468597.cel	
MCF-7_GSM984498_MCF7_HG-U133_Plus_2_.CEL	
T47D	
n=7	
T47D_GSM1017511_mRNA_20a_200907.CEL	
T47D_GSM1017512_mRNA_20b_200907.CEL	
T47D_GSM1017513_mRNA_20c_210907.CEL	
T47D_GSM844714_1_Good_NCI50_WYETH.CEL	
T47D_GSM844715_2_Good_BREAST_WYETH.CEL	
T47D_GSM844716_2_Good_NCI50_WYETH.CEL	
T47D_GSM984496_T47D_HG-U133_Plus_2_.CEL	
BT474	
n=7	
BT474_brst_SS117188_HG-U133_Plus_2_HCHP-85191_.CEL	
BT474_brst_SS117189_HG-U133_Plus_2_HCHP-85192_.CEL	
BT474_brst_SS117190_HG-U133_Plus_2_HCHP-85193_.CEL	
BT474_GSM1374408_Bx051b_035_HG2.CEL	
BT474_GSM1374409_ap071105.CEL	
BT474_GSM1374410_EA08079_80494.CEL	
BT474_GSM320596.CEL	
MDA-
MB231	
n=4	
MDA_MB_231_GSM1017490_mRNA_13a_111206.CEL	
MDA_MB_231_GSM1017491_mRNA_13b_111206.CEL	
MDA_MB_231_GSM1017492_mRNA_13c_111206.CEL	
MDA_MB_231_GSM984500_MDA-MB-231_HG-
U133_Plus_2_.CEL	
Table 2.2. Details of the gene expression files downloaded from online 
repositories for breast cancer cell lines. These were used for the extreme 
variation analysis.  
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2.1.2	Pathway	Enrichment	Analysis		
Extreme variation data was subjected to pathway and ontology enrichment 
analysis using multiple tools (discussed below). Extensive literature reviews were 
undertaken to determine the most suitable methods for this. The purpose of this 
was to identify in terms of gene expression which pathways and processes were 
most active within breast cancer cell lines, to identify candidate genes for further 
functional analysis, as well as to cross-compare the results of the various 
pathway tools.  
2.1.2.1	DAVID,	GO	&	PANTHER	
Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
functional annotation and gene functional classification (Huang et al., 2007), 
Gene Ontology (GO) enrichment analysis (Ashburner et al., 2000), and 
PANTHER gene list analysis (Thomas et al., 2003), were used in succession for 
analysis of extreme variation genes across breast cell lines. For all analyses, a 
threshold of p<0.05 was used to represent statistically significant data, and for 
consistency, the ‘GO terms biological process’ annotation set was used in each 
analysis.  
DAVID (Version 6.8) functional annotation clustering was selected and a high 
classification stringency was used. Genes were identified against 
‘Affymetrix_3Prime_IVT_ID’. Of the extreme variation list, 650 gene IDs were 
recognised. The ‘GOTERM_BP_ALL’ annotation category was selected.  
Statistically significant clustered enrichment scores were ranked.  
For GO (release 2019-02-01) and PANTHER (version 14.0, 2018-12-03) 
analysis, Affymetrix IDs from the extreme variation list were converted to 
Ensembl IDs (www.ensembl.org), of these, 634 genes were mapped. Two 
overrepresentation tests were carried out and combined. The ‘GO biological 
process complete’ overrepresentation test, was assessed using Fisher’s exact 
test, and the Bonferroni correction for multiple testing. The ‘PANTHER GO-slim 
biological process’ overrepresentation test was also used with Fisher’s exact test, 
and corrected using the false discovery rate. For both of these tests, statistically 
significant GO sets were ranked based on their fold enrichment scores.  
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2.1.2.2	Gene	Set	Enrichment	Analysis	(GSEA)	
Gene Set Enrichment Analysis (GSEA) by the Broad Institute was used to 
determine the classes of genes and biological pathways over-represented within 
the list of extreme variation genes (Subramanian, et al., 2005). This represented 
a more in-depth and cell line specific level of pathway enrichment analysis, 
highlighting the differences in gene expression between breast cancer subtypes.  
The GSEA software (Release 2.0) was downloaded via the Broad Institute from 
the Massachusetts Institute of Technology (Subramanian et al., 2005). GSEA 
was performed comparing tumour vs non-tumourigenic (MCF10A) cell lines 
against the MSigDB C5 Gene Ontology (GO) gene set collection (c5.all.v6.1). 
This collection consisted of 5,917 gene sets divided into three categories - 
‘Biological Process’, ‘Cellular Component’ and ‘Molecular Function’. The 
normalised enrichment score (NES) was used as a means to quantify the scale 
of enrichment, and the false discovery rate (FDR) was used to measure statistical 
significance.  
2.1.3	Candidate	Gene	Selection	
For DAVID and combined GO and PANTHER analysis, the genes present in the 
top 20 enriched annotation clusters and the genes present in the top 20 GO 
annotations were extracted respectively. For GSEA analysis, the genes from the 
top 5 significant annotation terms were taken for each cell line. Hence, gene lists 
were created for each analysis tool (Appendix 1). The gene lists were compared 
and candidate genes were selected based on their commonality between 
enriched pathway lists for each analysis. This identified 10 candidate genes. To 
further condense this list for the selection of a single gene, a literature review was 
conducted for each gene; criteria was relevance to other cancers, potential 
oncogenic (favoured above tumour suppressor) function, and possible miRNA 
regulation. Genes previously well characterised in breast cancer were excluded.  
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2.2	Validation	of	ASCL2	in	Patient	Tumours	via	the	METABRIC	
Study 
Microarray data obtained from the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) study (Pereira, et al., 2016) was accessed 
through the cBioPortal online web application (Cerami, et al., 2012; Gao et al., 
2013). Primary fresh-frozen breast cancer specimens were clinically annotated 
(samples assigned to the PAM50 intrinsic subtypes) and obtained from tumour 
banks in the United Kingdom and Canada. For transcriptional profiling, RNA was 
isolated from samples and hybridised to the Illumina HT-12 (v3) platform (Curtis, 
et al., 2012). Normalised expression level Z-score data of ±2 was used as a 
threshold to classify clinical breast cancer cases into 3 groups according to the 
expression of ASCL2: upregulated (>+2), downregulated (<-2) and unaltered (-2 
to +2).  
For the METABRIC study, 2509 patient samples were downloaded and analysed. 
The parameters measured were ER status, HER2 status, PR status, PAM50 
subtype, age, overall survival, stage, grade and integrative cluster (proposed by 
Dawson et al., 2013). Owing to missing clinical information or expression level 
data, the total number of valid samples varied for each parameter - e.g. out of 
2509 patient samples, ASCL2 expression was measured in 1904 samples. 
Data was downloaded and patient samples were matched with clinical data using 
Microsoft Excel. In some cases, RStudio, version 3.4.3 (RStudio, Inc., Boston, 
USA) was used during the formatting process. Using SPSS for Windows, version 
24 (SPSS, Inc., Chicago, USA), data was then categorised, numbered, and 
missing values were defined. The differences between molecular parameters 
were compared between ASCL2 expression groups using SPSS generating 
descriptive statistics and graphs.  
Statistical differences in the distribution of ASCL2 expression between receptor 
status, subtype, stage, grade, and integrative cluster were analysed using the 
Pearson Chi-Square (χ2) test. Subsequently, to model the impact of ASCL2 
expression on HER2 receptor status, a logistic regression analysis was 
performed. Comparison between means was analysed using a one-way ANOVA 
(with Tukey post hoc multiple comparisons test) for patient age of onset and 
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overall survival. Estimates of overall survival were also generated using Kaplan-
Meier curves, and statistical significance was based on Mantel-Cox log-rank 
tests. To examine the prognostic significance of ASCL2, univariate and 
multivariate analyses were performed using the Cox proportional hazards 
regression models, to estimate Hazard Ratios (HR) and 95% confidence intervals 
(CI) for associations with overall survival. Gene expression was set as a linear 
variable, and adjusted for other known prognostic factors; ER status, HER2 
status and PR status (all positive vs negative), PAM50 subtype (5 levels), age at 
diagnosis (≤60 vs >60 years), stage (4 levels), grade (3 levels) and integrative 
cluster (10 levels) as categorical covariates. Statistical significance was set at 
<0.05. 
 
 
 
 
  
	61	
	
2.3	Cell	Lines	&	Culture	
The breast cancer cell lines (Table 2.3) were obtained from the American Type 
Culture Collection (ATCC), provided by Dr Nadège Presneau, Dr Miriam Dwek 
(University of Westminster) and Professor Marilena Loizidou (University College 
London). Cells had been previously tested for mycoplasma and genotypes had 
been verified by short tandem repeat (STR) profiling.  
  
	 Immunohistochemical	Markers	 	
Cell	Line	 ER	 PR	 HER2	 Complete	Media	
MCF10a	 -	 -	 -	
Mammary	Epithelial	Cell	Grown	Medium	(MEBM)	
2ml	bovine	pituitary	extract	
0.5ml	human	epidermal	growth	factor	
0.5ml	insulin	
0.5ml	hydrocortisone	
0.5ml	gentamicin-amphotericin	
10%	FBS	
1%	L-glutamine	
1%	Pen/Strep	
MCF7	 +	 +	 -	
Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	
10%	FBS	
1%	L-glutamine	
1%	Pen/Strep	
T47D	 +	 +	 -	
Roswell	Park	Memorial	Institute	(RPMI)	1640	
10%	FBS	
1%	L-glutamine	
1%	Pen/Strep	
SKBR3	 -	 -	 +	
Roswell	Park	Memorial	Institute	(RPMI)	1640	
10%	FBS	
1%	L-glutamine	
1%	Pen/Strep	
BT474	 +	 +	 +	
Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	
10%	FBS	
1%	L-glutamine	
1%	Pen/Strep	
MDA-MB-
231	 -	 -	 -	
Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	
10%	FBS	
1%	L-glutamine	
1%	Pen/Strep	
Table 2.3. Details of the breast cancer cell lines used for molecular investigation in this 
study, including details of the complete growth medium used as recommended by the 
literature.  
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Cell lines were maintained in complete media (Table 2.3) as recommended by 
the American Type Culture Collection (ATCC) or as recommended in the 
literature, supplemented with 10% v/v fetal bovine serum (FBS), 1% v/v l-
glutamine and 1% v/v penicillin streptomycin (unless otherwise stated in the 
following methods) (all purchased from Lonza BioWhittaker, Switzerland). 
2.3.1	Routine	Cell	Maintenance	
Cells were maintained as an adherent monolayer in the appropriate medium, at 
37ºC in 5% CO2 to control for changes in pH. Media and other reagents were 
warmed to 37ºC prior to use. Cells were subcultured (passaged) at 70-80% 
confluence. Medium was removed from flasks, and cells were washed with 5 mL 
phosphate buffered saline (PBS) to remove any residual media. To detach cells, 
1 mL 2.5% Trypsin 10X (Gibco, Thermo Fisher Scientific, United Kingdom) was 
added to the flask, and incubated for 5 minutes at 37ºC. To ensure cells had 
detached, cells were observed under a light microscope. To prevent cells from 
further toxicity, Trypsin was deactivated by adding 5mL of complete media, and 
this mix was added to a 15 mL conical tube. Cell suspensions were centrifuged 
at 189 x g for 3 minutes, and the supernatant was discarded. Cell pellets were 
resuspended in media depending on the split ratio and added to 75 cm2 flasks 
(usually at a density of ~2.1 x 106). Flasks were topped up to a total of 10 mL 
media and incubated.  
All cells were passaged 2-3 times prior to experimental use, allowing cells to 
recover from thawing; passaging was carried out as required. Cells were checked 
multiple times weekly to ensure media pH was kept consistent (as indicated by a 
colour change in the media), and cells were ‘healthy’. Where possible, 
experiments were conducted with cells that had been passaged up to a maximum 
of 10 times to minimise genetic drift or genotypic changes that may have affected 
experimental results.  
2.3.2	Cell	Storage	&	Seeding	from	Frozen	
Frozen stocks at low passages were regularly collected and stored in liquid 
nitrogen until needed.  
	63	
	
To freeze a stock of cells, cells were prepared as in Section 2.3.1, however, cell 
pellets were instead resuspended in 1 mL freezing media (maintained cold), 
made up of 10% v/v dimethyl sulfoxide (DMSO) (Sigma-Aldrich, United Kingdom) 
plus 90% v/v FBS, and added to a 1.5 mL cryovial. These were placed in a 
freezing container containing 100% isopropyl alcohol and stored in a -80ºC 
freezer for 2 days. Cryovials were moved to liquid nitrogen for long term storage.  
To seed cells from frozen, cell stocks were removed from liquid nitrogen and 
thawed in a water bath at 37ºC. This was transferred to a 15 mL conical tube and 
topped up with 10 mL media. To remove the freezing solution containing DMSO 
(which is toxic to cells), cell suspensions were centrifuged at 189 x g for 3 
minutes, and the supernatant discarded. The cell pellet was then resuspended in 
10 mL media and transferred to a 75 cm2 flask. Cells were observed daily, and 
media was changed accordingly.  
2.3.3	Cell	Counting	
Where a defined seeding density was required, a haemocytometer was used to 
count cells. In this case, cells were prepared as in Section 2.3.1, however, cell 
pellets were resuspended in 1 mL media and mixed thoroughly. To count, 40 µl 
of cells was mixed with 40 µl Trypan blue (Lonza BioWhittaker, Switzerland) (1:1 
dilution) – as only dead cells take up the blue dye, these were excluded to ensure 
that only viable cells are counted. Cells were counted using a haemocytometer 
to determine the volume of cells needed for a set concentration. The number of 
cells seeded were dependant on the size of the flask or well used.   
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2.4	Primer	Design	
Once a gene was selected for analysis, primer sequences were designed and 
the corresponding Affymetric ID probeset was used to find the target sequence. 
Primer 3 (Untergasser, et al., 2012) was then used with specified parameters – 
product size=100-150 bp, primer size optimum=22 bp, primer GC% optimum = 
50%. Once primers had been selected, Blat and In-Silico PCR 
(genome.ucsc.edu), as well as NCBI BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi) 
were used to check specificity. Finally, SNP checker 
(secure.ngrl.org.uk/SNPCheck/snpcheck.htm) was used to check if any validated 
SNPs lay in the regions of either primer.  
Other primer sequences were identified in the literature, and were checked for 
the above parameters using the aforementioned tools prior to use. 
Oligonucleotide primers were purchased from Eurofins Genomics and 
resuspended at 100 pmol/µl in accordance with manufacturer instructions. Primer 
sequences used in this study are shown in Table 2.4.  
 
		 	
Gene	
Symbol	 Forward	(5’	–	3’)	 Reverse	(5’	–	3’)		 Reference	
ASCL2	 CGT	GAA	GCT	GGT	GAA	CTT	GG	 GGA	TGT	ACT	CCA	CGG	CTG	AG	 Tian,	et	al.,	2014	
BIRC5	 CTG	GCA	GCC	CTT	TCT	CAA	GGA	CC	 CCA	AGT	CTG	GCT	CGT	TCT	CA	 	
CD44	 CCA	TCC	CAG	ACG	AAG	ACA	GT	 CCA	GAG	GTT	GTG	TTT	GCT	CC	 	
CMYC	 GTC	TCC	ACA	CAT	CAG	CAC	AAC	T	
GTT	CGC	CTC	TTG	ACA	TTC	TCC	
T	 Zhu,	et	al.,	2012	
CTNNB1	 AAA	ATG	GCA	GTG	CGT	TTA	G	 TTT	GAA	GGC	AGT	CTG	TCG	TA	 	
HPRT	 GCT	ATA	AAT	TCT	TTG	CTG	ACC	TGC	TG	
AAT	TAC	TTT	TAT	GTC	CCC	TGT	
TGA	CTG	G	 	
LGR5	
	
GAG	GAT	CTG	GTG	AGC	CTG	
AGA	A	
CAT	AAG	TGA	TGC	TGG	AGC	
TGG	TAA	 Zhu,	et	al.,	2012	
RPII	 GCA	CCA	CGT	CCA	ATG	ACA	T	 GTG	CGG	CTG	CTT	CCA	TAA	 Radonić,	et	al.,	2004	
Table 2.4. Primer sequences for PCR and RT-qPCR.  
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2.5	RNA	Extraction	&	Quality	Assessment	
2.5.1	miRNAeasy	Mini	Kit,	Qiagen	
Total RNA was extracted from cell lines grown in 75cm2 flasks using the 
miRNAeasy Mini Kit (Qiagen, United Kingdom) following manufacturer’s 
instructions. Working under a Class 2 cabinet, cells were washed with PBS, 
QIAzol lysis reagent was added to flask, and cells were scraped from the surface 
of the flask. The cell suspension was collected, 140 µl chloroform was added, 
and cells were incubated at room temperature for 2 minutes. The sample was 
centrifuged for 15 minutes at 12,754 x g, 4ºC. The upper aqueous phase was 
carefully added to a new collection tube, and 525 µl of 100% ethanol was added. 
This was added to a mini column and centrifuged at 12,281 x g for 15 seconds at 
room temperature. DNA digest was completed by washing the column membrane 
with buffer, and adding a DNase solution to incubate for 15 minutes (room 
temperature). Buffers were added and the sample was centrifuged as per the 
manufacturer’s protocol. The membrane was dried by centrifuging a final time at 
12,281 x g for 1 minute. Nuclease-free water was added to the column and the 
RNA was eluted from the column during the final centrifugation step. RNA was 
stored at -20ºC.  
2.5.2	Microprep	Kit,	Zymo	
To isolate RNA from 6-well plates after siRNA transfection, the Microprep kit 
(Zymo, Cambridge Bioscience, United Kingdom) was used following 
manufacturer’s instructions. Working under a Class 2 cabinet, media was 
removed from wells and cells were washed with PBS. Qiazol lysis reagent, 100 
µl, was added, and cells were scraped from the surface of the flask using a P200 
tip. The cell suspension was collected, vortexed, and 100 µl 100% ethanol was 
added and mixed. This mix was transferred to a column and centrifuged for 30 
seconds at 12,281 x g (all centrifugation steps using this kit was carried out at 
room temperature). To perform a DNase digest, the column was washed and 
centrifuged with 400 µl wash buffer. The DNase mix consisted of 5 µl DNase and 
35 µl digest buffer, which was added to the column and incubated at room 
temperature for 15 minutes. Buffers were added and the column was centrifuged 
in accordance with manufacturer’s protocols – 400 µl Directzol and 700 µl RNA 
	66	
	
wash buffer respectively. The column was transferred to an RNAse free tube and 
RNA was eluted by centrifuging the column with 15 µl nuclease-free water. 
RNA concentration (ng/µl) was quantified using the NanoDrop 
Spectrophotometer (software ND-2000). For quality control purposes, the 
absorbance ratios of 260/280 nm (~1.8-2.0) and 260/230 nm (~1.8-2.0) were 
used to assess purity. 
2.6	cDNA	Synthesis	
Single-stranded cDNA was synthesised from RNA using the High-Capacity RNA-
to-cDNA™ Kit (Applied Biosystems, Thermo Fisher, USA). The reverse 
transcription (RT) reaction mix was prepared using 2X RT Buffer, 20X RT 
Enzyme mix, nuclease-free H2O and 500 ng of RNA, to a total of 20 µl. A RT 
negative control sample was also made containing all components except the 
20X RT Enzyme. Samples were incubated at 37ºC for 60 minutes, and 95ºC for 
5 minutes, then stored at -20ºC.  
2.7	Polymerase	Chain	Reaction	(PCR)	&	Agarose	Gel	
Electrophoresis	
PCR experiments were performed using the AmpliTaq Gold PCR Mastermix kit 
according to manufacturer’s protocols (Applied Biosystems, Thermo Fisher, 
USA). PCR was used for the purposes of checking primer specificity, qualitatively 
assessing cDNA sample integrity, and checking reference genes. For each 
candidate gene, a mastermix was prepared including 10x Buffer II, 10 mM 
dNTPs, MgCl2, 10 µM Forward and Reverse primer, AmpliTaq Gold, nuclease 
free H2O, and diluted cDNA. Samples were loaded onto a thermo cycler (Techne 
Prime). The following cycles were run: initial denaturation of 95ºC for 5 minutes, 
denaturation, annealing and extension at 95ºC for 10 seconds, 56ºC for 20 
seconds, 72ºC for 30 seconds respectively (35 cycles of each), and a final 
extension of 72ºC for 5 minutes.  
Upon completion, PCR products were separated on an agarose (Fisher Scientific, 
United Kingdom) gel (1.4%) via electrophoresis (100V, 400mA, 45 minutes), and 
visualised using SYBR green dye (Lonza BioWhittaker, Switzerland). These 
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steps were carried out on cDNA, to test all primers, prior to RT-qPCR to ensure 
cDNA was of sufficient quality.  
2.8	PCR	Purification	&	Sanger	Sequencing	
To validate the specificity of the amplified PCR product and primers for ASCL2, 
PCR purification was carried out using the QIAquick PCR Purification Kit (Qiagen, 
United Kingdom), following manufacturer’s protocols. In brief, Buffer PB was 
added to the PCR sample (in a ratio of 5:1). The sample was added to a QIAquick 
spin column and centrifuged at 12,281 x g for 1 minute. 0.75 mL Buffer PE was 
added, and the column was centrifuged. Any flow through was discarded. The 
column was then transferred to a 1.5 mL Eppendorf tube. Finally, to elute the 
DNA sample, 50 µl elution buffer was added directly to the QIAquick membrane 
and this was left to stand for 1 minute before being centrifuged. Purified PCR 
fragments were packaged and sent to GATC Biotech for confirmative LightRun 
Sanger sequencing.  
Upon receipt of results, GATC viewer (www.gatc-biotech.com) and FinchTV 
chromatogram software (digitalworldbiology.com/FinchTV) were used to analyse 
the chromatogram and sequence of ASCL2, and thus confirm the identity of the 
amplified gene.  
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2.9	Quantitative	Reverse	Transcription-PCR	(RT-qPCR)	
Quantitative reverse transcription-PCR (RT-qPCR) was used to check gene 
expression of candidate genes across tumour and normal cell lines. Reactions 
were carried out in a Rotor-Gene cycler using the Rotor-Gene SYBR Green PCR 
kit (Qiagen, United Kingdom) following manufacturer’s instructions. The cycling 
conditions were an initial single hold cycle of 95ºC for 10 minutes (denaturation), 
40 cycles of 95ºC for 10 seconds (primer annealing) and 60ºC for 45 seconds 
(primer extension). A final melt stage was performed at the end of the run to 
generate a melt curve and check reaction specificity (Figure 2.1), heating from 
55ºC to 95ºC at a rate of 1ºC every 5 seconds.  
Each cDNA reaction was performed in duplicate, alongside a negative cDNA 
sample, and a negative non-template control for each pair of primers. All samples 
were also repeated with the reference gene, RNA polymerase II (RPII), chosen 
due to its stable and equal expression across tissues (Radonić, et al., 2004). Melt 
curves (Figure 2.1) were inspected to ensure reliability of data, and Ct values 
were generated from amplification curves (Figure 2.1). Relative quantification of 
gene expression in cell lines was performed using the calculations below. For 
statistical analysis, a one-way non-parametric ANOVA was used to test for 
differences between experimental samples (GraphPad Prism 7 software). 
 
∆CT = mean gene Ct - mean housekeeper Ct 
∆∆CT = ∆CT sample of interest - ∆CT control sample 
Fold change (log) difference = 2^(-∆∆CT) 
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Figure 2.1. RT-qPCR amplification curves and melt curves. A. The typical shape of 
an amplification curve. The threshold level was set manually at the point where the 
curve trends upwards, which was the point at which Ct values were calculated. The 
middle portion of the curve, from cycle 20-25 represents the exponential phase in the 
reaction. Around cycle 30, the lines begin to plateau, indicating a slowing of the 
reaction limited by reagents. B. The typical shape of amplicon peaks seen in a melt 
curve, exemplifying specific gene products, rather than primer dimers or non-specific 
binding i.e. primers are amplifying specific gene products – in this diagram, 2 peaks 
are seen representing the gene of interest and a reference gene.  
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
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2.10	Short	interfering	RNA	(Dicer	siRNA)	Knockdown	of	ASCL2	
siRNAs were obtained from IDT using the TriFECTa Dicer-Substrate RNAi kit 
(Integrated DNA Technologies, Belgium), containing a positive control gene 
duplex Hypoxanthine-guanine phosphoribosyltransferase (HPRT), a non-
targeting negative control duplex (NC), a fluorescently labelled transfection 
control duplex (TYE 563), and three ASCL2 target specific duplexes, which were 
subsequently pooled for experiments (siRNA sequences in Table 2.5). Both 
DharmaFECT (Dharmacon, GE, United Kingdom) and Lipofectamine RNAiMAX 
(Thermo Fisher, United Kingdom) transfection reagents were used to deliver 
siRNA targets.  
 
 
 
 	
siRNA	
Duplex	 Forward	(5’	–	3’)	 Reverse	(5’	–	3’)		
ASCL2	13.1	 GGGUUAUCUAUACAUUUAAAAACCA	 CUCCCAAUAGAUAUGUAAAUUUUUGGU	
ASCL2	13.2	 GCACCAACACUUGGAGAUUUUUCCG	 CCCGUGGUUGUGAACCUCUAAAAAGGC	
ASCL2	13.3	 GAGCGUGAACUUUAUAAAUAAAUCA	 CCCUCGCACUUGAAAUAUUUAUUUAGU	
Table 2.5. Three target-specific Dicer-Substrate siRNA (dsiRNA) duplexes, supplied by 
the TriFECTa kit, for siRNA transfection and knockdown of ASCL2. Gene sequence and 
position of targets are shown in Appendix 3. 
	71	
	
2.10.1	Dicer	siRNA	Preparation	
Lyophilised control duplexes (1 nmole) and target specific duplexes (2 nmole) 
were briefly centrifuged and resuspended with RNase-free Duplex Buffer 
(100mM KAc/30 mM HEPES pH 7.5) to a final concentration of 20 µM. DsiRNAs 
were vortexed and mixed thoroughly. These were diluted to create working 
solutions at 2 µM. Cells were treated with a final concentration of 10 nM dsiRNA 
per well.  
2.10.2	Knockdown	of	ASCL2	in	Cells	
Cells were seeded into plates (24-well, 0.05 x 106 cells, or 6-well, 0.3 x 106 cells) 
the day before transfection using antibiotic free media. At approximately 24 hours 
after seeding, growth medium was removed from each well, and Opti-MEM 
reduced serum medium (Gibco, Thermo Fisher Scientific, United Kingdom) was 
added. A transfection mixture was prepared containing Opti-MEM, Lipofectamine 
(or DharmaFECT) and the corresponding siRNA duplex, and incubated for 15 
minutes at room temperature. For each siRNA, a final concentration of 10nM was 
added to cells. At 24 hours post transfection, cell transfected with siRNA-TYE 
563 were visualised under a fluorescence microscope (to check transfection was 
successful before proceeding). Cells were then harvested and RNA was 
extracted as in Section 2.5.2.  
The cell lines, MCF7, T47D and SKBR3 were transfected and used for further 
analysis. 
2.10.3	Measurement	of	Knockdown	Efficiency		
Gene expression and percentage knockdown was assessed by RT-qPCR. 
Percentage knockdown was calculated by normalising samples to the reference 
gene, RPII (ΔCt), and the non-targeting negative control siRNA sample (NC) 
(ΔΔCt), then the (1-2-ΔΔCt)*100 equation was used (Section 2.9) (Haimes, & 
Kelley, 2010). In this study, a knockdown of 70% was preferable, however at least 
60% was deemed successful and appropriate for further analysis, resulting in an 
average of approximately 70% across replicates.  
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2.10.4	Knockdown	Optimisation	
To begin with, optimisation was planned with a positive control gene (HPRT) in 
order to establish the correct conditions for siRNA knockdown. Once successful 
knockdown of HPRT was observed via fluorescence microscopy and RT-qPCR, 
knockdown of the ASCL2 gene could proceed. However, optimisation presented 
many challenges, and numerous different experimental and troubleshooting 
conditions were tested (Appendix 2). An in-depth summary of optimisation and 
troubleshooting conditions are described in Appendix 2. A timeline of steps 
proceeding siRNA transfection can be seen in Table 2.7 (at the end of this 
Chapter). 
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2.11	Immunostaining	of	Cells		
MCF7 cells were cultured and transfected as per Section 2.10.2. Once 
approximately 80% confluence was reached (at 48h post transfection) cells were 
washed with PBS and fixed in 10% v/v formalin in PBS for 30 minutes. Formalin 
was removed, cells were washed twice with PBS, and cells were stored in PBS 
at 4°C before analysis. 
Prior to staining, PBS was removed from cells, and cells were incubated with 
blocking solution (5% w/v BSA in PBS) for 30 minutes gently rocking at room 
temperature. Cells were washed twice in PBS. Primary antibody diluted in 5% 
w/v BSA in PBS (Table 2.6) was added to cells and incubated gently rocking 
overnight at 4°C. Cells were then washed multiple times with PBS prior to being 
incubated with secondary fluorescently labelled antibody (Table 2.6) for 1 hour, 
gently rocking at room temperature (protected from light to prevent quenching). 
Cells were washed multiple times in PBS, and incubated with NucRed™ Live 647 
(Invitrogen, Thermo Fisher Scientific, United Kingdom) for 15 minutes at room 
temperature.  
Cells were imaged using the GFP and RFP fluorescence channels at 40X 
magnification using the EVOS FL Auto 2 Cell Imaging System (Thermo Fisher 
Scientific, funded by The Guy Foundation), and processed using ImageJ 
(imagej.nih.gov/ij/).     
Antibody	 Dilution	 Supplier	
Primary	
Rabbit	Anti-ASCL2,	ab107046	 1:500	 Abcam	
Secondary	
Goat	anti-rabbit	IgG	H&L	(Alexa	Fluor	488),	ab150077	 1:500	 Abcam	
Table 2.6. Antibodies used for western blot experiments.  
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2.12	Functional	Investigation	
Table 2.7 summarises the timeline of steps for validation and functional 
investigation experiments subsequent to siRNA knockdown. 
2.12.1	Alamar	Blue	Cell	Viability	Assay	
AlamarBlue® cell viability reagent (Invitrogen, Thermo Fisher Scientific, United 
Kingdom) was used for the assessment of cell viability and proliferation 
subsequent to siRNA knockdown. Analysis was carried out using untreated cells, 
non-targeting negative control cells (siRNA-NC) and siRNA-ASCL2 cells. A ‘no-
cell’ control containing media only was also included.  
Cells were seeded in 24-well plates and transfected with siRNA. AlamarBlue® 
reagent was added to growth medium 24h post-transfection, at a concentration 
of 10% v/v. Cells were then incubated at 37ºC (5% CO2) for 2 hours, then 50 µl 
of the Alamar Blue-medium mixture was transferred to a 96-well plate. 
Absorbance was measured at 570 nm and 600 nm using the SPECTROstar Nano 
microplate reader (BMG Labtech, United Kingdom).   
To assess proliferation, absorbance values were substituted into the following 
equations (Bio-Rad Laboratories, Inc., 2016):  
 
% difference in reduction of alamarBlue® =                                                  x 100% 
 
% different in reduction compared to untreated =                                          x 100%  
 
Where,   
117216 and 80586 = molar extinction coefficients of oxidised AB at 600nm and 
570nm wavelengths respectively.  
A1 and A2 = absorbance values in experimental samples at 570nm and 600nm 
respectively. 
P1 and P2 = absorbance values of untreated samples at 570nm and 600nm 
respectively. 
117216•A1 – 80586•A2 
117216•P2 – 80586•P1 
117216•A1 – 80586•A2 
117216•P1 – 80586•P2 
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Three biological replicates were carried out for the cell lines MCF7 and T47D, 
each of which included 3 technical replicates. For SKBR3, cells followed the 
same pattern as the previous cell lines, and experiments were concluded after 
n=1 (inclusive of 3 technical replicates). After calculating percentage difference 
of Alamar Blue reduction in Excel, values were transferred to GraphPad Prism. 
2.12.2	Trypan	Blue	Assay	
The Trypan blue viability assay was used as a means to estimate cell 
proliferation; the cells that exclude the blue dye can be considered as viable. 
Cells were seeded in a 24 well plate at a density of 0.05 x 106 per well. After 24 
hours, cells were transfected with siRNA and incubated for a further 24 hours. 
The media was removed, cells were washed with PBS and then trypsinised. 
Trypan blue was added to wells at a 1:1 ratio; the cell suspension was collected 
and counted using a haemocytometer under a microscope (x10 objective). The 
four corner squares of the haemocytometer were counted and % viability was 
calculated. For each cell line, at least three biological replicates (each including 
3 technical replicates) were carried out.  
2.12.3	Caspase-Glo®	3/7	Assay	
The Caspase-Glo® 3/7 Assay (Promega, United Kingdom) was used to assess 
caspase activity in cells, therefore corresponding to apoptosis, after siRNA 
knockdown. Analysis was carried out using untreated cells, siRNA-NC and 
siRNA-ASCL2 cells. A ‘blank’ control containing media only was also included. 
Cells were seeded in opaque white 96-well plates (0.02 x 104 cells per well) and 
transfected with siRNA. Caspase reagent was added to growth medium at a ratio 
of 1:1 and mixed well, 24 hours post transfection. Cells were incubated at room 
temperature, away from light, for 30 minutes. The luminescent signal was 
measured using the SPECTROstar Nano microplate reader (BMG Labtech, 
United Kingdom). For each cell line, three biological replicates were carried out, 
each of which included 2 technical replicates.  
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2.12.4	Wound-Healing	Scratch	Assay	
To assess the effect of ASCL2 gene knockdown on cell migration, a wound-
healing scratch assay was performed. This assay was designed based on Yue, 
et al., (2010). Cells were seeded in 6-well plates to reach a high confluence on 
the day of transfection. Immediately after transfection (0h), a P200 pipette tip was 
used to make a scratch in the cell monolayer, across the width of the well. Wells 
were visualised and imaged manually at 0h, 24h and 48h, using a bright-field 
microscope and a DCM310-A digital microscope camera. ScopePhoto image 
software by ScopeTek Ltd (China) was used to capture images.  
When imaging cells, a cross was marked on a plastic sheet placed over the plate 
lid, to ensure the same area was visualised at each time interval. The previous 
image was also referred to at 24h and 48h to ensure imaging was as precise as 
possible.  
Images were analysed in Image J. Firstly, the scale was set for images, where 
pixels were converted to µm. Using the polygon selection tool, the cells at the 
edges of the scratch were traced using straight lines. The area of the scratch was 
then measured. This was repeated 3 times for each image (3 measurements per 
3 time intervals per 3 well treatments), and an average was calculated. Average 
scratch area was then used to calculate the percentage closure between 0h, 24h 
and 48h for each experimental sample. The difference in percentage closure 
between negative controls and ASCL2 knockdown samples was also calculated.  
Experiments were carried out in multiple biological replicates (MCF7, n=6, T47D, 
n=2, SKBR3=3). Scratch area values, and percentage closure values were 
transferred to GraphPad Prism, where unpaired t-tests were used to analyse the 
difference between experimental groups (siRNA-NC vs siRNA-ASCL2).  
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2.12.5	Effect	of	ASCL2	Knockdown	on	Wnt-target	Gene	Expression 
The effect of ASCL2 knockdown on the Wnt signalling pathway was investigated 
by assessing changes in the gene expression of Wnt-related genes. These genes 
were selected based on their involvement in Wnt signalling, their varying roles in 
cancer development, as well as their relation/interaction with ASCL2.  
Cells were grown in 6-well plates and subjected to transfection (Section 2.10.2), 
RNA was extracted from cells (Section 2.5.2), cDNA was synthesised (Section 
2.6), and gene expression was measured by RT-qPCR (Section 2.9). 
Samples were measured in technical duplicates, and biological triplicates for 
each gene and cell line combination. Samples were normalised to a reference 
gene (RPII) (ΔCt) and then against the non-targetting negative control (siRNA-
NC) transfected sample (ΔΔCt) – the change in the expression of genes after 
ASCL2 knockdown was compared to that of genes after non-targeting siRNA 
knockdown.  
The genes measured were as follows: CD44, CCND1 BIRC5 (SURV), CTNNB1, 
LGR5 and C-MYC. Primer sequences can be found in Table 2.4.  
 
2.12.6	Statistical	Analysis 
Unless otherwise stated, statistical analysis of experimental data was performed 
using the GraphPad Prism 7 software. Experimental data is represented as mean 
± SEM, and statistical significance was determined using unpaired t-tests.  
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2.12.7	Summary	of	siRNA	Knockdown	&	Functional	Investigation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 Day	0	 Day	1	(0h)	 Day	2	(24h)	 Day	3	(48h)	
Knockdown	Validation	
Seed	
Cells	
	
Transfect	
Fluorescence	
Check	
Extract	RNA	and	make	
cDNA	 RT-qPCR	
Alamar	Blue	 Treat	2	hrs	 Measure	fluorescence	 	
Immunostaining	 	 Wash,	Fix,	Stain,	Image	
Trypan	Blue	 Treat	&	count	cells	 	
Caspase	 Treat	30	mins	 Measure	luminescence	 	
Wound	Healing	 	 Image	 Image	 Image	
Table 2.7. Timeline of chronological steps for siRNA knockdown and functional investigation experiments.  
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2.13	Summary	of	Study	Design	&	Methods	 
  
Figure 2.2. Flow chart depicting the in silico and in vitro workflow implemented in this 
study, to select and investigate the role of ASCL2.  
Cell	Line	Gene 
Expression	Data	Downloaded	&	
Processed 
GEO/Array	Express 
List	of	Differentially	Expressed	
Genes	Generated	Using	‘Extreme	
Variation’	Analysis 
R	Script 
Pathway	Enrichment	Analysis 
	
DAVID 
GO	&	Panther 
GSEA 
Literature	Review	of	Overlapping	
Genes	-	Criteria	Including: 
	
Relevance	to	Cancer 
Potential	Oncogenic	Function 
Novelty	in	Breast	Cancer 
Achaete-scute	Complex	Like-2	
(ASCL2) 
Data	Mining	of	Patient	Samples	 
cBioPortal	(METABRIC	data)	
 
Assessment	of	Clinical	Relevance	of	
ASCL2	&	Survival	Analysis 
In	silico	Candidate	Gene	Selection 
Cross	Comparison	 
of	the	Highest-ranked	Genes	
Identified	by	Each	Tool	 
In	vitro	Functional	Investigation 
siRNA	knockdown	(KD)	of	ASCL2	 
Validation	of	gene	KD	by	RT-qPCR 
Validation	of	protein	KD	by	
immunostaining	of	cells 
Cell	Viability	 
Alamar	Blue	&	Trypan	Blue	assays 
Apoptosis	–	Caspase	3/7	Assay 
Migration	–	Wound	Healing	Assay 
Relationship	with	Wnt	genes 
RT-qPCR 
RT-qPCR	validation	in	Cell	Lines 
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Chapter	III	
	
Identification	of	ASCL2	as	a	candidate	gene	in	breast	
cancer,	using	pathway	enrichment	analysis	
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3.1	Introduction	
The clinical heterogeneity observed in breast cancer is mirrored in its complex 
genetic landscape. The search for novel genetic markers and greater molecular 
characterisation is necessary to understand breast carcinogenesis and the 
signalling pathways that are at the core of tumour development. However, 
research potential for the development of novel markers and therapeutic agents 
has been limited in the past, for example, due to the lack of specificity of some 
genes, the low incidence of some genetic changes, or the lack of in-depth 
knowledge of gene function (discussed in Section 1.3.3). The pursuit of 
oncogenes is of prominent research interest now more than ever in the era of 
precision medicine, to better understand the intricacies of each breast cancer 
subtype and in the hope of developing more targeted therapeutics in the future. 
With the emergence of high-throughput techniques within transcriptomics, 
researchers are now able to rank and group large volumes of genetic data. 
Pathway analysis has become a prolific and powerful means of efficiently 
handling gene expression data to advance hypothesis generation and gene 
discovery (Mathur, et al., 2018). Though the phrase ‘pathway analysis’ is 
somewhat broad, in the context of this study it refers to enrichment-based 
analysis, involving the condensing and aggregation of large transcriptomic 
datasets into functional groups of related genes termed gene sets; gene sets 
share a common biological function or property, defined by a reference 
knowledge base. Knowledge bases, such as Gene Ontology (GO) or MSigDB, 
are databases comprising  molecular information relating to regulation, 
interaction and phenotypic associations (Khatri, et al., 2012; Mathur, et al., 2018). 
Large gene lists can be systematically mapped to related GO terms, emphasising 
the most statistically over-represented terms and highlighting the most relevant 
biological factors underpinning the samples of interest. In this way, large gene 
lists are sorted and reduced so biologically meaningful information can be 
extracted (Huang, et al., 2007).  
However, as noted in Section 1.5, selecting the optimal tools from the growing 
number available, and extracting biologically meaningful results has become 
increasingly demanding, especially for the evaluation of interconnecting cancer 
pathways. This process is very complex, involving many steps, and represents 
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an area of cancer research that resides between traditional wet-lab biology and 
systems biology. To bridge this gap, many web-based tools have emerged to 
provide sophisticated in silico analysis with greater accessibility (Zhang, et al., 
2018). 
The pathway tools selected in this study, DAVID, GO and PANTHER, and GSEA, 
(described in Section 1.5.2, Table 1.5) are well established and have been cited 
in numerous publications (DAVID alone has been cited over 33,000 times 
according to PubMed). These tools cover two types of pathway analysis methods. 
Overrepresentation analysis (ORA) (DAVID, GO, PANTHER) results in a list of 
relevant pathways based on the hypothesis that the proportion of differentially 
expressed genes, is greater than expected. Functional class scoring (FCS) 
(GSEA) works on the premise that small yet coordinated expression changes 
may have significant effects on a pathway, in the same way that large expression 
changes do (García-Compos, et al., 2015).  
The objective of this chapter was to formulate a user-friendly pathway analysis 
pipeline, utilising popular and convenient in silico methods, to identify a novel 
candidate gene that may play a role in breast tumourigenesis. To execute this, 
gene expression profiles for multiple breast cancer cell lines were obtained from 
public databases and were subjected to an extreme variation analysis (a gene 
prioritisation and filtering algorithm) to identify a list of differentially expressed 
genes across cell lines (as described in Section 2.1.1) (Hamoudi et al., 
manuscript in preparation). The pathway analysis tools, DAVID, GO and 
PANTHER, and GSEA were used to biologically group the most significantly 
enriched genes in cell lines, to sort and reduce gene expression data into gene 
sets related to biological processes. Subsequently, the tools were cross-
compared, and an in-depth literature review was undertaken, to identify a novel 
candidate gene for further investigation. Finally, the expression of this gene was 
validated in breast cancer cell lines using RT-qPCR.   
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3.2	Results	
3.2.1	Pathway	Enrichment	Analysis	Using	DAVID,	GO	&	PANTHER	
Gene expression data from five breast cancer cell lines (BT474, MCF7, MDA-
MB-231, T47D, and MCF10A, representing the non-tumourigenic subtype) were 
downloaded (described in Section 2.1.1). This data underwent extreme variation 
analysis to condense expression data to 915 gene probes, with varying 
expression (log2) across cell lines (Section 2.1.1) (Hamoudi et al., manuscript in 
preparation).   
Extreme variation data was subjected to multiple pathway enrichment analyses, 
using the tools DAVID, GO and PANTHER, and GSEA. The purpose of this was 
to efficiently sort gene expression data into biologically meaningful over-
represented terms and classify genes into functions to ultimately guide and select 
a candidate gene for further investigation. From the extreme variation gene list, 
650 Affymetrix IDs and 634 Ensembl IDs were mapped in DAVID and 
GO/PANTHER analysis respectively. This pipeline is illustrated in Figure 3.1.  
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Figure 3.1. Pathway enrichment analysis pipeline for transcriptomic data: workflow 
of pathway/ontology enrichment analyses and tools used to identify a candidate 
gene(s) for further analysis. Enriched ontologies were selected based on 
commonality between analyses. Data mining of patient samples and in vitro 
investigation will be followed up in subsequent chapters of this thesis.  
Cell	Line	Gene 
Expression	Data	Downloaded	&	
Processed 
GEO/Array	Express 
‘Extreme	Variation’	Analysis	of	
Differentially	Expressed	Genes 
R	Script 
Pathway	Enrichment	Analysis 
	 
DAVID 
GO	&	Panther 
GSEA 
Literature	Review	of	
Overlapping	Genes	 
Criteria: 
Relevance	to	Cancer 
Potential	Oncogenic	Function 
Novelty	in	Breast	Cancer 
Candidate	Gene	Selection 
Data	Mining	of	Patient	Samples	
to	Assess	Clinical	Relevance	of	
Candidate	Gene 
cBioPortal 
In	vitro	Investigation 
Cross	Comparison	 
of	the	Highest-ranked	Genes	
for	Each	Tool	 
RT-qPCR	Validation	in	Cell	Lines 
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Figure 3.2 shows the top 20 (of 348) pathway clusters from DAVID analysis 
exhibiting significant enrichment in breast cancer; among these, regulation of 
peptidases, developmental processes and cell migration/motility had the largest 
enrichment scores. Terms relating to migration and motility, including EMT, 
reoccurred numerous times in this top 20 list, as well as developmental ontologies 
such as reproductive development processes, and ontologies relating to 
apoptosis were also recurrently enriched.   
 
 
 
  
Figure 3.2. DAVID functional annotation clustering analysis using a high 
classification stringency, highlighting the top 20 (of 348) enriched annotated GO and 
pathway clusters, ranked by enrichment score. All top 20 clusters were considered 
statistically significant, P<0.001. Of 915 extreme variation gene IDs, 650 gene IDs 
were mapped.   
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For GO and PANTHER analysis, two overrepresentation tests were carried out 
(GO biological process complete and PANTHER GO-slim biological process 
analyses) shown respectively in Table 3.1 and 3.2. The latter test uses a smaller 
set of GO terms representing those that have been specifically curated and 
decided to be most informative of function and evolutionarily conserved (Mi, et 
al., 2019).  
The Top 20 significantly enriched GO pathways highlighted in Table 3.1, showed 
that enriched biological process ontologies were mainly relating to gland 
(prostate) development and morphogenesis (sitting at the top of the analysis on 
the basis of fold enrichment) EMT, hemostasis, wound healing and embryonic 
skeletal development. PANTHER analysis, shown in Table 3.2, displays 
significant enrichment in ontology terms associated with nervous system 
development and neurogenesis, cell development, cell death and cell adhesion.  
Although different pathway analysis tools were used, built upon differing 
algorithms, they were all configured to use the same GO biological process 
annotation set for consistency. Overall, at a superficial level, the three tools 
discussed so far exhibited a good agreement and identified similar patterns of 
enriched ontology terms in the dataset; terms relating to cell development, 
migration/motility, EMT, cell death/apoptosis, and metabolism were consistently 
enriched in cell line data. It is also of note that the enriched ontologies apparent 
in the cell line expression data aligned well with many cancer hallmarks such as 
sustained angiogenesis, evasion of apoptosis, abnormal metabolic pathways and 
invasion and metastasis (Hanahan, & Weinberg, 2011). In light of this, although 
650 Affymetrix IDs and 634 Ensembl IDs mapped to DAVID and GO/PANTHER 
respectively (compared to the full list of 915 IDs), a broad spectrum of GO terms 
were highlighted in correspondence with oncogenic features, representing that 
this analysis was sufficiently inclusive and wide-ranging, encompassing 
important pathways with biological significance.   
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GO	biological	process	complete	 #	Human	
Reference	
#	Ext	
Var	
Expected	 +/-	 Fold	
Enrichment	
P	value	
hemidesmosome	assembly	
(GO:0031581)	
12	 7	 0.36	 +	 19.47	 5.54E-03	
prostate	gland	morphogenesis	
(GO:0060512)	
24	 10	 0.72	 +	 13.91	 2.47E-04	
prostate	gland	epithelium	
morphogenesis	(GO:0060740)	
22	 8	 0.66	 +	 12.14	 1.42E-02	
prostate	gland	development	
(GO:0030850)	
40	 11	 1.2	 +	 9.18	 1.67E-03	
regulation	of	collagen	metabolic	
process	(GO:0010712)	
42	 10	 1.26	 +	 7.95	 1.86E-02	
gland	morphogenesis	(GO:0022612)	 99	 22	 2.97	 +	 7.42	 5.05E-08	
positive	regulation	of	epithelial	to	
mesenchymal	transition	(GO:0010718)	
46	 10	 1.38	 +	 7.26	 3.76E-02	
cornification	(GO:0070268)	 112	 22	 3.36	 +	 6.56	 4.13E-07	
regulation	of	blood	coagulation	
(GO:0030193)	
77	 14	 2.31	 +	 6.07	 3.19E-03	
regulation	of	hemostasis	
(GO:1900046)	
78	 14	 2.34	 +	 5.99	 3.66E-03	
regulation	of	coagulation	
(GO:0050818)	
81	 14	 2.43	 +	 5.77	 5.48E-03	
regulation	of	epithelial	to	
mesenchymal	transition	(GO:0010717)	
82	 14	 2.46	 +	 5.7	 6.25E-03	
positive	regulation	of	ossification	
(GO:0045778)	
83	 13	 2.49	 +	 5.23	 3.64E-02	
regulation	of	wound	healing	
(GO:0061041)	
130	 20	 3.89	 +	 5.14	 1.30E-04	
negative	regulation	of	epithelial	cell	
proliferation	(GO:0050680)	
124	 18	 3.71	 +	 4.85	 1.49E-03	
digestive	system	development	
(GO:0055123)	
140	 19	 4.19	 +	 4.53	 1.75E-03	
regulation	of	response	to	wounding	
(GO:1903034)	
155	 21	 4.64	 +	 4.52	 4.12E-04	
digestive	tract	development	
(GO:0048565)	
128	 17	 3.83	 +	 4.43	 9.98E-03	
extracellular	matrix	organization	
(GO:0030198)	
333	 42	 9.98	 +	 4.21	 6.91E-10	
embryonic	skeletal	system	
development	(GO:0048706)	
127	 16	 3.8	 +	 4.21	 3.80E-02	
Table 3.1. Gene ontology analysis of extreme variation genes showing the top 20 (of 248) 
enriched biological process ontologies. Of 915 gene IDs, 634 were mapped to the human 
reference list. Results classified as significant using Fisher’s Exact statistical test and 
corrected using the Bonferroni correction for multiple testing (p<0.05) were ranked on the 
basis of fold enrichment score.  
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PANTHER	GO-Slim	Biological	
Process	
#	Human	
Reference	
#	Ext	
Var	
Expected	 Fold	
Enrichment	
P	value	 FDR	
smooth	muscle	contraction	
(GO:0006939)	
9	 4	 0.27	 14.84	 4.11E-04	 4.59E-02	
collagen	fibril	organization	
(GO:0030199)	
13	 5	 0.39	 12.84	 1.28E-04	 2.29E-02	
regulation	of	neurogenesis	
(GO:0050767)	
33	 7	 0.99	 7.08	 1.38E-04	 2.24E-02	
regulation	of	nervous	system	
development	(GO:0051960)	
40	 7	 1.2	 5.84	 3.90E-04	 4.64E-02	
cell	development	(GO:0048468)	 92	 14	 2.76	 5.08	 2.42E-06	 7.20E-04	
cellular	protein	metabolic	process	
(GO:0044267)	
110	 16	 3.3	 4.86	 8.00E-07	 3.58E-04	
multi-organism	process	
(GO:0051704)	
70	 9	 2.1	 4.29	 4.73E-04	 4.02E-02	
regulation	of	multicellular	
organismal	development	
(GO:2000026)	
71	 9	 2.13	 4.23	 5.19E-04	 4.03E-02	
cell	proliferation	(GO:0008283)	 88	 11	 2.64	 4.17	 1.43E-04	 2.14E-02	
cell	differentiation	(GO:0030154)	 350	 35	 10.49	 3.34	 2.97E-09	 5.30E-06	
cell	death	(GO:0008219)	 174	 16	 5.21	 3.07	 1.46E-04	 2.00E-02	
regulation	of	cell	death	
(GO:0010941)	
214	 17	 6.41	 2.65	 4.53E-04	 4.05E-02	
protein	metabolic	process	
(GO:0019538)	
441	 34	 13.21	 2.57	 2.21E-06	 7.88E-04	
cellular	developmental	process	
(GO:0048869)	
506	 39	 15.16	 2.57	 3.41E-07	 2.03E-04	
anatomical	structure	
development	(GO:0048856)	
389	 27	 11.65	 2.32	 1.53E-04	 1.95E-02	
cell	projection	organization	
(GO:0030030)	
354	 24	 10.61	 2.26	 4.82E-04	 3.91E-02	
cell	adhesion	(GO:0007155)	 380	 25	 11.38	 2.2	 4.46E-04	 4.43E-02	
biological	adhesion	(GO:0022610)	 380	 25	 11.38	 2.2	 4.46E-04	 4.19E-02	
developmental	process	
(GO:0032502)	
1035	 68	 31.01	 2.19	 5.58E-09	 4.99E-06	
system	process	(GO:0003008)	 493	 32	 14.77	 2.17	 9.71E-05	 1.93E-02	
Table 3.2. PANTHER analysis of extreme variation genes, showing the top 20 list of 
biological process ontologies. Of 915 gene IDs, 634 were mapped to the human reference 
list. Results classified as significant using Fisher’s Exact statistical test and corrected 
using the false discovery rate (p<0.05) were ranked on the basis of fold enrichment score. 
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3.2.2	Pathway	Enrichment	Analysis	Using	GSEA	
GSEA was performed to examine subtype-cell line specific differences in gene 
expression and to shed further light on pathway functions prior to selection of an 
oncogenic candidate gene. Analysis was completed to compare gene set 
enrichment in the extreme variation data of tumour cell lines vs non-tumourigenic 
cells (MCF10A). The normalised enrichment score (NES) and false discovery 
rate (FDR) were used to assess enrichment.  
GSEA (Table 3.3) revealed that MCF7 Luminal A tumours exhibited significant 
upregulation of genes associated with nervous system development; it is now 
recognised that the nervous system has a large role in cancer development, and 
metastasis, with a primary site of breast cancer metastasis being the brain (Kuol, 
et al., 2018). The top GO gene set enriched in MCF7 cells compared to MCF10A 
cells, ‘Regulation of Nervous System Development’ (Table 3.3), was highlighted 
as 1 of 7 gene sets significant at FDR <25% out of 476 upregulated gene sets. 
Figure 3.3 illustrates the corresponding enrichment plot, exhibiting the highest 
normalised enrichment score in MCF7 cells. The enriched gene probes within 
this gene set are shown in Table 3.3; a number of these are already established 
as oncogenic genes in breast cancer, such as FOXA1, SOX2, BMP5 and BMP7, 
and ID4. In concordance with GSEA analysis, regulation of nervous system 
development was also ranked highly in PANTHER analysis, Table 3.2.  
TNBC tumours (MDA-MB-231) displayed gene sets significantly enriched in 
GTPase mediated signal transduction, while T47D-Luminal A and BT474-
Luminal B showed no significantly enriched gene sets according to the false 
discovery rate values (Table 3.3).  
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Cell	Line/Subtype	 Gene	set	 Gene	Probes	 NES	 Nominal	p-value	
FDR	q-
value	
MCF7	/	Luminal	A		 GO_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT	
GO_REGULATION_OF_NEURON_DIFFERENTIATION	
GO_REGULATION_OF_NEURON_PROJECTION_DEVELOPMENT	
GO_REGULATION_OF_CELL_PROJECTION_ORGANIZATION	
GO_ENSHEATHMENT_OF_NEURONS	
ASCL1,	CXCL12,	SOX3,	BMP5,	SYT1,	
DSCAM,	OLFM1,	FOXA1,	SOX2,	
PCP4,	ASCL2***,	ID4,	KLK6,	BMP7,	
COL3A1,	PREX1,	EPHA7,	NRCAM,	
PACSIN1,	RET,	DLX1,	TBC1D30,	SBF2	
2.28	
2.24	
2.21	
2.17	
2.14	
<0.001	
<0.001	
<0.001	
<0.001	
<0.001	
0.099**	
0.070**	
0.063**	
0.078**	
0.089**	
T47D	/	Luminal	A	 GO_NEURON_FATE_COMMITMENT	
GO_ORGANIC_ACID_CATABOLIC_PROCESS	
GO_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION	
GO_REGULATION_OF_RAS_PROTEIN_SIGNAL_TRANSDUCTION	
GO_MHC_PROTEIN_COMPLEX	
HOXC10,	FOXA1,	DLX1,	PON3,	
ACOX2,	RASGEF1A,	PREX1,	APOE,	
PLCE1,	LPAR1,	PLEKHG4B,	HLA-
DMA,	CD74,	AZGP1	
1.87	
1.85	
1.85	
1.84	
1.71	
<0.05	
<0.05	
<0.05	
<0.05	
<0.05	
1.00	
1.00	
1.00	
1.00	
1.00	
BT474	/	Luminal	B	 GO_SIGNAL_RELEASE	
GO_ORGANIC_ACID_CATABOLIC_PROCESS	
GO_RAS_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY	
GO_CILIARY_PART	
GO_TRANSPORT_VESICLE_MEMBRANE	
FAM3B,	LIN7A,	NRXN3,	TBX3,	
SYTL5,	SYTL2,	GAL,	SYNRG,	CLTA,	
SYT1,	HNMT,	HGD,	PON3,	BCAT1,	
ACOX2,	PREX1,	PLEKHG4B,	MCF2L.	
ERBB2,	RET,	SBF2,	GFRA1,	
RASGEF1A,	GSTM3,	TBC1D30,	
SHANK2,	MARCKS	
2.09	
1.92	
1.92	
1.84	
1.81	
<0.001	
<0.05	
<0.05	
<0.05	
<0.05	
	
0.704	
1.00	
1.00	
1.00	
1.00	
MDA-MB-231	/	
TNBC	
GO_REGULATION_OF_RAS_PROTEIN_SIGNAL_TRANSDUCTION	
GO_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION	
GO_POSITIVE_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION	
GO_REGULATION_OF_RHO_PROTEIN_SIGNAL_TRANSDUCTION	
GO_ENDOSOME	
NRG1,	LPAR1,	ABCA1,	TGFB2,	PLCE1	 1.99	
1.96	
1.88	
1.88	
1.74	
<0.001	
<0.001	
<0.001	
<0.001	
<0.001	
0.116**	
0.085**	
0.194**	
0.153**	
0.703	
Table 3.3. GSEA investigation showing the top 5 GO gene set results for each cell line ranked normalised enrichment score (NES). Gene probes are 
shown corresponding to their rank. Only gene probes from gene sets with false discovery rate (FDR) <25% were considered significant **Indicates 
significance at FDR <25% *** ASCL2, candidate gene selected in this study, significantly enriched within the regulation of nervous system ontology. 
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Figure 3.3. GSEA enrichment analysis showing an enrichment plot for the ‘regulation 
of nervous system development’ ontology. Panel A represents the enrichment score 
of genes (hits) ordered by a spectrum of correlation from MCF7 cells (tumour, red) to 
MCF10A cells (normal, blue). Panel B shows the ranked list of genes between tumour 
and normal phenotypes. The ‘regulation of nervous system’ development was the top 
most significantly enriched GO gene set in the MCF7 cell line. 
A 
 
 
 
 
 
 
B 
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3.2.3	Cross-comparison	of	Tools	and	Selection	of	ASCL2	
As the GO biological processes most active within transcriptomic cell line data 
had been highlighted, the results of this analysis was further interrogated. The 
gene probes present within each of the top enriched GO terms highlighted by the 
distinct analysis tools (presented in Figure 3.2, Table 3.1, 3.2 and 3.3) were 
extracted and collated.  
The Venn diagram in Figure 3.4 illustrates the number of gene probes identified 
by pathway analysis for each tool, as well as the number of genes commonly 
identified by each tool. Despite the gene sets and enriched ontology terms ranked 
by each tool exhibiting a good agreement overall, there appeared to be 
discrepancies between the tools at the gene probe level. As a result, direct 
comparison indicated there was no identical crossover of gene probes (other than 
the fact that all GSEA gene probes were also present in the high number of 
DAVID gene probes).  
In spite of this, the large number of gene probes identified by DAVID analysis 
compared to the intermediate and small number of genes highlighted by 
combined GO and PANTHER analysis, and GSEA respectively, allowed a large 
number of gene probes (915) to be reduced to a group of 10 genes (Figure 3.4). 
Thus, candidate genes were chosen on the basis of their appearance in enriched 
lists and clusters common to all pathway tools used in this study.  
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Figure 3.4. Venn diagram depicting the number of candidate genes identified by each 
pathway analysis tool, and the number of genes overlapping between tools. Overall, the 
genes present in the cross-section of all analyses (shown in the grey box) were 
considered as the final list of candidate genes. 
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An extensive literature review was subsequently undertaken as described in 
Section 2.1.3 and Figure 3.1. Genes with an already established link to breast 
cancer were omitted leaving ASCL2, which was yet to be defined in breast 
cancer. Previous reports highlighted the role of ASCL2 in colon cancer, more 
specifically as a Wnt-target gene, affirming that this gene had oncogenic potential 
(Giakountis, et al., 2016; Jubb, et al., 2006; Schuijers, et al., 2015). According to 
pathway analysis and in line with the literature, this gene was identified to be 
enriched within developmental processes and nervous system development 
(Table 3.4). Interestingly, ASCL1, a member of achaete-scute complex-like 
family, was also identified in pathway analysis (Figure 3.4); this gene similarly 
controls the development of the nervous system in early embryonic stages and 
has been previously identified as a potential oncogene in lung cancer (Augustyn 
et al., 2014; Borromeo et al., 2016; Wang et al., 2017). These results, alongside 
a systematic review by Wang et al., (2017), suggest that the ASCL family may be 
an interesting family of genes to focus on in future studies. However, for the 
purposes of this study, ASCL2 will be of central focus; a detailed literature review 
and evidence supporting the rationale behind the selection of ASCL2 can be 
found in Section 1.2.3. 
With regards to the GSEA data previously presented (Section 3.2.2), Figure 3.3 
illustrates an enrichment plot for the ‘regulation of nervous system development’ 
ontology. A strong enrichment for the nervous system gene signature was 
observed whereby ASCL2 (0.27 enrichment score) was positively correlated with 
the MCF7 cell line. Within this ranked gene list, ASCL2 was ranked 11 of 20 
genes that were positively correlated with the MCF7 tumour phenotype, and of 
52 genes overall. Of the entire ranked gene list of all gene sets identified in MCF7 
cells, ASCL2 ranked 49 of 692 genes with an enrichment score of 2.79.   
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Tool	 GO	Number	&	Name	
DAVID	 GO:0048856	anatomical	structure	development	
GO:0032502	developmental	process	
GO:0048731	system	development	
GO:0007275	multicellular	organism	development	
GO:0044767	single-organism	developmental	process	
GO/PANTHER	 GO:0050767	regulation	of	neurogenesis		
GO:0051960	regulation	of	nervous	system	development		
GO:0048468	cell	development		
GO:2000026	regulation	of	multicellular	organismal	development	
GO:0030154	cell	differentiation	
GSEA	 GO:0051960	regulation	of	nervous	system	development	
Table 3.4. A summary of the gene ontology terms associated with ASCL2, identified 
in pathway analysis. This information highlights that ASCL2 is a developmental 
gene, involved in the regulation of the nervous system and cell development.   
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3.2.4	Extreme	Variation	Analysis	of	ASCL2	
After cross-comparison between multiple pathway enrichment analyses, process 
of elimination and consideration of novelty, the gene most prominently lacking 
investigation in breast cancer was ASCL2 (Table 3.4). For an indication of the 
differential expression of ASCL2 across breast cancer cell lines, the initial 
extreme variation analysis was referred back to.  
As can be seen from the extreme variation analysis in Figure 3.5, ASCL2 was 
significantly expressed most highly in the luminal subtypes, BT474 and MCF7 
(9.16 and 8.84 respectively). A lower expression was seen in T47D, with lowest 
expression observed in MDA-MB-231 and MCF10A. Here, the expression in 
MCF10A (2.51) was regarded as ‘normal’ or baseline. The lowest expression 
seen in the cancer cell lines was in the triple negative subtype. This data is 
consistent with that of the GSEA analysis whereby ASCL2 was seen to be 
significantly enriched in the MCF7 cell line, thus these findings suggest that 
ASCL2 expression may be associated with the characteristics of MCF7 cells.  
 
  
Figure 3.5. Extreme variation analysis of ASCL2, n<4 per cell line, represented as a 
bar chart and scatter plot. Transcriptomic data highlights statistically significant 
differential expression of breast tumour cell lines compared to a normal-like control, 
MCF10A (mean ± SEM, **p<0.0001). ASCL2 is expressed most in BT474 and MCF7 
respectively, and highly overexpressed compared to non-tumourigenic breast cells.  
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3.2.5	RT-qPCR	Validation	of	ASCL2	Expression	in	Breast	Cancer	Cell	Lines	
The extreme variation analysis highlighted that ASCL2 was expressed most 
highly in BT474, MCF7 and T47D cells respectively, with pathway enrichment 
analysis specifying the involvement of ASCL2 in MCF7 cells. The next step was 
to validate these findings in breast cancer cell lines, ensuring that in silico data 
was concordant with cell lines models prior to continuation of the project.  
Prior to quantitative measurement of gene expression in cell lines, a standard 
PCR was carried out in MCF10A, MCF7, T47D, BT474, SKBR3 and MDA-MB-
231 cells, and samples were run on an agarose gel by standard electrophoresis. 
This was for quality control purposes to improve reliability of data, optimise 
experimental conditions, ensure sample integrity prior to proceeding and to 
ensure PCR products and primers were entirely specific for the ASCL2 gene 
(Appendix 3). The PCR products were visualised and sequenced; Sanger 
sequencing (Appendix 3) validated the gene sequence and the identity of the 
ASCL2 gene was confirmed. Results from PCR analysis indicated that ASCL2 
was expressed only in MCF7 cells (Appendix 3), mostly consistent with in silico 
data; though, no band was visualised in BT474 or T47D cells indicating no 
expression. However, due to the lack of sensitivity and qualitative nature of this 
technique, RT-qPCR was also carried out.  
For quantitative evaluation of ASCL2 gene expression across the cell lines, RT-
qPCR, was undertaken. Figure 3.6 shows the gene expression across cell lines 
relative to the reference gene, RNA polymerase II (RPII), and the non-
tumourigenic cell line, MCF10A; ASCL2 was expressed most highly in MCF7 
cells, concordant with in silico and previous data from PCR analysis. In 
experimental data, T47D and SKBR3 cell lines also showed expression of 
ASCL2, whereas MDA-MB-231 was seen to show little to no ASCL2 expression; 
with the exception of SKBR3, which was not analysed in the previous chapter, 
T47D and MDA-MB-231 cells also matched transcriptomic data in Chapter 3. 
Although, contrary to RT-qPCR data, the expression of BT474 appeared 
inconsistent between in silico and in vitro data, as extreme variation data 
highlighted the greatest gene expression in this cell line. Descriptive data is 
presented in Appendix 4.  
 
	98	
	
Due to unforeseen circumstances towards the end of this project, replacement 
MCF7 cell line stocks were obtained from a collaborator (Prof Marilena Loizidou); 
ASCL2 expression matched previous MCF7 cells further validating the 
expression of ASCL2 in MCF7 Luminal A breast cancer cells (data not 
presented). 
 	
Figure 3.6. RT-qPCR analysis: Quantification of relative gene expression highlights 
varied expression of ASCL2 across breast cancer cell lines, particularly in MCF7, 
T47D and SKBR3 cell lines, compared to ‘normal-like’ MCF10A cell line (mean ± 
SEM, n=2, p<0.05). MCF7 exhibited the highest gene expression. The variance in 
error bar size was likely due to biological variation between cell passages.    
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3.3	Discussion 
The work presented in this chapter used multiple computational methods, to 
highlight the most over-represented functional groups of genes from the 
expression profiles of breast cancer cell lines. As a result, ASCL2, a novel 
candidate gene was identified for further investigation in breast cancer, and an 
original pathway analysis pipeline was developed (Figure 3.1). Pathway analysis 
was completed at the beginning of the study, and later reviewed at the end of the 
project.  
A strength of using gene prioritisation (the extreme variation algorithm, by 
Hamoudi et al., manuscript in preparation) combined with a layered pathway 
analysis approach, is that it captures critical aspects of tumour biology, which 
analysing mutation or gene expression data alone lacks. Such comparative 
analysis harnessing the power of multiple methods have been demonstrated to 
outperform the use of single tools, providing more biologically meaningful results 
(Alhamdoosh, et al., 2017). At its core, cancer is a disease of dysfunctional 
pathways, therefore it is imperative that the growing amount of omics data is used 
to understand how genetic disturbances cooperatively impact normal pathway 
function (Frost, & Amos, 2018). This type of investigation not only raises 
awareness of likely genetic candidates in breast cancer, but also provides clues 
as to how these genes function to direct research hypotheses and allow efficient 
research execution. In this case, the gene ASCL2 was selected for further 
investigation, and, extreme variation and GSEA data directed the use of the 
MCF7 cell line for primary laboratory investigation, which is useful as a starting 
point for experimental design and analysis.  
For consistency, analysis tools were selected to use the GO classification and 
annotation database under the ‘biological process’ domain, therefore comparison 
between tools was as reliable as possible. It was also ensured that the tools 
selected in this study encompassed both ORA and FCS methods. These were 
deliberately used in combination to ensure the analysis pipeline was robust, and 
as an attempt to circumvent prominent pitfalls. Although these conventional tools 
have been well recognised in the literature, they were not without their limitations 
(Khatri, et al., 2012).  
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Firstly, ORA treats each gene as an equal, overlooking any expression values 
and concentrating on the quantity of genes only. In doing this, ORA assumes the 
independence of genes and ignores any interactions, co-expression, or 
downstream effects; this results in the reduction of highly complex biological 
interactions in cancer, to a simplistic configuration. Therefore, these methods do 
not account for the dependence among pathways (Khatri, et al., 2012). This type 
of analysis also disregards any genes deemed insignificant based on arbitrary 
thresholds, meaning that false negatives may arise and some information may 
be neglected. In this sense, the stringency of statistical analysis can be seen as 
a challenging equilibrium (Khatri, et al., 2012).  
Secondly, though FCS analysis can be considered as an improvement on ORA, 
FCS still considers pathways independently of one another, therefore omitting the 
biological crosstalk of pathways, and the fact that genes can function in multiple 
pathways - these only consider pathways as overly simplified and independent 
groups. This is challenging to bypass as defining gene sets based on GO terms 
is hierarchical by nature (Khatri, et al., 2012). For example, GSEA assessment 
presented no significant gene sets in T47D and BT474 cell lines; however, this 
may not be completely reflective of the true biological situation – the lack of 
significant gene sets may be a result of more subtle expression. Ultimately, 
cancer is tremendously complex and the development of certain tumour subtypes 
may be the result of multiple gene sets working at lower levels but in synergy, 
rather than one overarching process. Although valuable, these types of analyses 
also ignore important biological information such as the positions of genes in 
pathways, the direction of interaction, and type of interactions with other genes, 
not to mention crosstalk with other pathways. Therefore, multiple stages of 
pathway analysis have been used as a foundation for in vitro work in this study, 
which intends to further investigate the ASCL2 candidate gene in a laboratory 
environment (using cell lines) to shed light on its role in breast tumourigenesis. 
Additionally, large variation in the candidate gene lists produced by each analysis 
tool was observed (Figure 3.4, Appendix 1); of 915 differentially expressed gene 
probes, only 10 genes were found to intersect between tools. These 
discrepancies may be because of innate differences in the tools themselves. 
Each tool uses unique mathematical methods and relies on different 
mathematical assumptions, meaning that results often lack concordance due to 
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intrinsic complexities, and therefore small differences in approaches can lead to 
large discrepancies between outputs. This is exacerbated by the fact that there 
is no ubiquitous algorithmic method for ontology enrichment (Piccolo, & 
Frampton, 2016). Additionally, many knowledge-based computational biology 
tools rely on frequent updates; in this study, the tools used were regularly updated 
to align with constantly growing and newly published data, however, individual 
tools may be updated at different times. For example, the latest DAVID update 
was of 2016, in contrast to the current release of GSEA in 2018, and GO and 
PANTHER in 2019. As carried out in this work, Piccolo, & Frampton, (2016) 
suggest combining approaches to enhance reproducibility. In many reports, a 
single tool may be used for pathway analysis, whereas this study gained added 
value by comparing multiple tools (Alhamdoosh, et al., 2017). 
Although the ranking of genes could be considered as rudimentary in DAVID, GO 
and PANTHER analyses, GSEA was more intricate. In this work, the extreme 
variation gene list was input into DAVID, GO and PANTHER analysis tools as a 
whole, in contrast to the GSEA method which compared the gene expression of 
the gene list of each breast cancer cell line vs MCF10A cells individually. Similarly 
to DAVID, GO and PANTHER, GSEA was designed as a means of identifying 
groups of genes that are over-represented. However, GSEA takes into 
consideration the association of gene expression with a particular phenotype (in 
this case, a tumour); this has allowed researchers to better understand biological 
processes by observing the functional portraits of gene sets in tumours compared 
to normal controls (Subramanian, et al., 2005).  
For DAVID, PANTHER and GSEA analysis tools, the false discovery rate (FDR) 
was used for the assessment of significance rather than the nominal p value (the 
exception to this was GO analysis, where the Bonferroni test for multiple testing 
was used to ensure significance <0.05). This is because the nominal p value 
estimates statistical significance based on the enrichment scores of each gene 
set in isolation. In contrast, the FDR takes into account the size of the gene set 
and multiple hypothesis testing, and adjusts for these. 
However, unlike the generally accepted 0.05 value of significance used in DAVID, 
GO and PANTHER tools, the FDR in GSEA uses 0.25 instead. The FDR is an 
estimation of validity – the probability that an enriched gene set is a false positive. 
Using a generous significance cut off of 0.25 has been designed to account for 
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typical inconsistencies seen in expression datasets, and to avoid potentially 
noteworthy results from being disregarded. The Broad Institute GSEA user 
guidelines suggest this is practical for exploratory gene discovery as a basis for 
the further validation of candidate genes, and that these results (FDR<25%) are 
expected to be the most interesting for further research (Broad Institute, 2019; 
Mootha, et al., 2003; Subramanian, et al., 2005). However, in spite of this more 
lenient cut off, the GSEA method still produced the smallest number of candidate 
genes. 
Aside from analytical limitations, the technical limitation of incomplete gene probe 
mapping and recognition is also a general and common issue associated with the 
use of pathway analysis tools (Khatri, et al., 2012). The gene identifiers input into 
each pathway tool were not entirely recognised or mapped to a reference list, or 
the gene identifiers valid for each tool differed, for example, in DAVID analysis 
650 Affymetrix IDs were mapped to the human reference list. This meant that the 
full list of 915 Affymetrix IDs generated from the extreme variation analysis were 
not analysed. However, this was due to the fact that some genes were mapped 
to multiple Affymetrix IDs, representing multiple transcript isoforms or different 
regions of the same gene (for example, ASCL1 mapped to 209987_s_at and 
209988_s_at probe identifiers). As well as this, some probe IDs could not be 
mapped to a HUGO gene symbol, nevertheless, it could be argued that the 
inability to map these genes to a reference list limits the genes’ experimental 
possibilities; hence, those IDs that weren’t captured within GO terms were 
unlikely to compromise the biological insight of this study, and it was decided that 
no genes of interest were lost of masked in this process. Despite this drawback 
of pathway analysis tools, a large sample of genes were recognised and 
analysed, and consistent patterns between the analyses could be demonstrated. 
Also, most candidate genes identified in Figure 3.4 do show heavy involvement 
in tumourigenesis when browsing the literature, so this issue was not thought to 
affect the integrity of the study. 
Overall, the limitations discussed in this chapter were outweighed by the 
advantages held by these widely used pathway analysis tools. These tools were 
an excellent starting point as they are freely available, and therefore accessible 
to all researchers regardless of their financial means. These tools are relatively 
user-friendly (they don’t require software installation, advanced coding or 
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bioinformatics experience which could limit application), and due to their 
mainstream use and web-application, they can be used on any operating system 
with lots of resources (such as user-guidelines and tutorials) present to ensure 
correct usage. They also do well to reduce the complexity of large volumes of 
data whilst preserving explanatory power (Khatri, et al., 2012), and their usage 
has also lead to the recognition of novel research possibilities due to unexpected 
associations between biological functions (Mathur, et al., 2018). Therefore, these 
tools provide an informative framework from which to build an analysis model for 
the pursuit of candidate genes in breast cancer.  
As well as the identification of a novel candidate gene for further exploration, an 
efficient, strategic and comprehensive pathway analysis pipeline was utilised 
(Figure 3.1). Many methods have been designed for the analysis of large 
transcriptomic datasets, but researching and choosing the correct tool or 
combination of tools can be time-consuming. This model for candidate gene 
selection utilised multiple tools to gain a thorough and consistent picture of the 
pathways and biological processes responsible for driving breast tumourigenesis, 
and therefore hopes to have generated a representative list of candidate genes 
(Figure 3.4). Despite the shortfalls discussed surrounding this type of analysis, 
these have been addressed by using multiple analyses to ‘correct’ for any intrinsic 
biases or inaccuracies in tools; hence genes seen in the cross-over between tools 
were considered to be most likely involved in the breast cancer cell lines 
examined. In light of this, the pipeline used in this study is considered to be 
advantageous as it combines numerous tools in parallel whilst maintaining 
simplicity to bridge the gap between computational scientists and biological 
scientists. As systems biology approaches for pathway analysis is an active and 
continuously growing area of research, this pipeline could be utilised as a 
foundation by researchers of any level of expertise, which could be adapted by 
the user to evolve with the field.  
From a biological standpoint, findings from DAVID, GO and PANTHER analysis 
indicate enrichment in ontologies involving cell development, migration and 
motility, regulation of apoptosis and the EMT; which are considered to be 
trademarks of the Wnt signalling pathway. Adding weight to this was the GSEA 
results, exhibiting the association of MCF7 cells with genes relating to nervous 
system development; Wnt signalling, a highly conserved morphogenic signalling 
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pathway, has also been recognised as crucial for nervous system formation, 
development and maintenance, as well as neural plasticity (Freese, et al., 2010; 
Ille, & Sommer, 2005). This corresponds with the selection of ASCL2, as this 
gene has known involvement in the central nervous system (Liu, et al., 2016), 
development of the neuroectoderm (Simionato, et al., 2008) and has been 
recognised as a target of the Wnt pathway in colon and gastric cancer studies 
(Schuijers, et al., 2015; Zhu, et al., 2012; Tian, et al., 2014; Basu, et al., 2018). 
However, its role has not yet been established in breast cancer. Although this is 
only considered to be foundational evidence, the data presented in this chapter 
substantiates the hypothesis that via Wnt signalling, ASCL2 may be a prominent 
force influencing Luminal A tumours with a similar molecular profile to MCF7 cells. 
It may also be hypothesised from this analysis that tumour cell migration may be 
heavily involved.  
Overall, this chapter demonstrates that a thorough investigation of transcriptomic 
data for candidate gene selection need not be overly complicated, and therefore 
the pipeline (Figure 3.1) used in this study may be utilised by other researchers 
in the future. Given knowledge from the literature regarding ASCL2 in cancer 
discussed in Section 1.2.3, and the ontologies and functions alluded to in pathway 
analysis, it is reasonable to suggest that ASCL2 is likely to exercise its effect 
within the Wnt signalling pathway in breast cancer. The dysfunction of the Wnt 
pathway has a renowned effect on invasion and metastasis in cancer, a primary 
cause of cancer related deaths, therefore, novel targets of the Wnt/β-catenin 
pathway are igniting interest in breast cancer specifically, to benefit from newly 
emerging anti-metastatic drugs (Liang et al., 2016).  
To develop the in silico work presented in this chapter it was important to validate 
these findings in vitro in well-established cell lines. Currently, the use of RT-qPCR 
is the gold standard for confirming microarray data, to ensure that the same 
results can be observed using multiple techniques; this biological replication in a 
different set of samples provides greater power and confidence of conclusions. 
Therefore, to validate the microarray gene expression changes seen in ASCL2, 
RT-qPCR was employed (Ding, et al., 2007; Horgan, & Kenny, 2011; Morey, et 
al., 2006). Results demonstrated that the differential gene expression patterns of 
ASCL2 in breast cancer cell lines mostly mirrored the transcriptomic data; in 
accordance with microarray data, the expression of this gene was significantly 
	105	
	
different between tumour and non-tumourigenic cells. ASCL2 was differentially 
expressed across the breast cancer cell lines that were chosen to reflect the 
different breast cancer subtypes. ASCL2 was overexpressed most highly in the 
MCF7 Luminal A cell line, as well as T47D (Luminal A) and SKBR3 (HER2+) cell 
lines; as analysis in the previous chapter lacked representation of the HER2 
subtype, the SKBR3 cell line was added to RT-qPCR investigation here. To 
further validate this data, the RNA expression of ASCL2 was checked using the 
Human Protein Atlas (Pontén, et al., 2008);  of 65 cell lines present in the 
database, T47D, MCF7 and SKBR3 cells ranked fifth, seventh and thirteenth 
respectively in terms of ASCL2 gene expression, behind colorectal, placenta and 
myeloid cell lines, as expected from the literature. 
In the next Chapter, the role of ASCL2 will be investigated to improve 
understanding of its function and role in breast tumourigenesis. This will be 
actioned using MCF7 cells primarily (other cell lines may be used for comparison) 
with conventional methods to assess gene function.  
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Chapter	IV	
 
Investigating	the	potential	role	of	ASCL2	in	breast	
cancer	
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4.1.	Introduction	
The identification of molecular markers over the years has directed detection and 
treatment development, to combat the heterogeneity of breast cancer and thus 
improve mortality rates (Braune, et al., 2018). Therefore, establishing robust and 
specific markers, or key genetic features, is crucial for the development of 
therapeutics or strategic management of the disease.  
The Wnt signalling pathway has emerged as a major driver of breast tumour 
development, and its connection to cancer stem cells (CSCs) has received much 
attention. This is largely because the main challenges associated with cancer, 
such as metastasis, relapse, and therapy resistance, can be attributed to CSCs 
(Kazi, et al., 2016). The deregulation of the Wnt pathway and overexpression of 
the genes present in this cascade, plays a key role in these factors, therefore 
therapeutic blockade of this pathway could be exploited in the future (Kazi, et al., 
2016). Although there are a large number of components and target genes 
present within the Wnt pathway expected to play a role in breast tumour 
development, there has been a lack of exploration in the past.  
Evidence has demonstrated that levels of Wnt signalling varies between breast 
cancer subtypes and that the pathway is highly expressed in breast populations 
enriched with CSCs (Lamb, et al., 2013). Additionally, deliberately activating the 
Wnt pathway in breast cell lines increases cell motility and migratory potential 
(Jang, et al., 2015). Despite this, abnormal activation of this pathway in breast 
cancer is not completely understood, and the exact molecular biology remains 
unclear. 
In Section 1.2.3, Achaete-scute Complex Like-2 (ASCL2) was broadly reviewed, 
and it was noted that this gene, a determinant of neuroblast fate, has been 
established as a Wnt target gene implicated in colorectal cancer (Zhu, et al., 
2012). Published studies in colon cancer have revealed that ASCL2 functions as 
a transcriptional switch in the Wnt pathway, and accumulating evidence points to 
ASCL2 as an interesting gene requiring further exploration. 
Although ASCL2 has been investigated in tumourigenesis (lung squamous cell, 
gastric, osteosarcoma), the majority of work has focused on colon cancer (Zhu, 
et al., 2012; Zuo, et al., 2018; Kwon, et al., 2013; Basu, et al., 2018). Though 
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some studies have emerged more recently suggesting the expression of ASCL2 
in breast cancer (Conway, et al., 2014; Wang, et al., 2017; Xu, et al., 2017), these 
studies have been rather incomprehensive, and within the scope of literature 
searches carried out for this thesis, have not been ongoing. Despite what is 
known about this gene in colon cancer, further research in this area is highly 
prospective and may yield lucrative results.  
Thus, ASCL2, essential for the maintenance of intestinal stem cells and linked 
with the CSC-phenotype in other cancers, is a prime candidate for further 
investigation (van der Flier, et al., 2009). Furthermore, as this gene is a 
transcription factor and known to be an important developmental gene (for 
example, in embryogenesis), this suggests that its biological function may have 
been underrated in the past (Guillemot, et al., 1994; Schuijers, et al., 2015); 
transcription factors account for approximately 20% of all oncogenes currently 
known, they can be attractive ‘drugable’ targets in cancer, and may be 
responsible for aberrant activation of other key regulatory genes (Lambert, et al., 
2018).  
Given that poor survival of breast cancer patients is predominantly due 
metastasis and relapse, investigating genes, such as ASCL2, which could 
potentially be fundamental to these processes in tumorigenesis, are of significant 
interest. As discussed throughout this thesis, ASCL2 is a target of the Wnt-
signalling pathway, and linked with an oncogenic CSC-phenotype typically 
associated with metastasis, relapse, and therapy resistance in cancer. Thus, by 
this reasoning, it could be considered that expression levels of ASCL2 may be 
increased in aggressive breast cancers or those enriched with CSCs, such as 
HER2+ or TNBC tumours. However, Xu et al., (2017) found that high levels of 
ASCL2 were related to high tumour reoccurrence rate, yet found no correlation 
of ASCL2 expression between the subtypes of breast cancer, implying that the 
gene may play a central role in breast tumour development and progression, as 
opposed to a specific role, thereby affecting all or most subtypes. On a cellular 
level, it was hypothesised that overexpression of ASCL2 may contribute to 
increased cellular migration and an aggressive phenotype in breast cancer cells.  
As it stands, there is a scarcity of research conducted on this gene specifically 
relating to the function and clinical implications of this gene in breast cancer, so 
thus far, general assumptions have been drawn and applied from work on other 
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cancers and biological processes, and built upon to form the infrastructure of this 
study. Given what is known about this gene (discussed in Section 1.2.3), current 
evidence suggests that exploring the role of ASCL2 in breast tumourigenesis may 
yield interesting findings. 
In light of this, the aim of this chapter was to investigate the expression and role 
of ASCL2 in breast cancer cells. To assess the relationship between ASCL2 
expression and breast tumourigenesis in vitro, cells were subjected to siRNA 
transfection to knockdown expression of the gene; cellular processes commonly 
disrupted in cancer, such as proliferation, apoptosis, migration and possible 
association with stemness were then investigated.  
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4.2	Results	
4.2.1	Selection	of	Breast	Cancer	Cell	Lines	for	Functional	Analysis	
In Chapter 3, extreme variation analysis highlighted that ASCL2 was expressed 
most highly in BT474, MCF7 and T47D cells respectively, with pathway 
enrichment analysis specifying the involvement of ASCL2 in MCF7 cells. To 
validate this, ASCL2 expression was quantified in six cell lines, demonstrating 
that ASCL2 was expressed most highly in MCF7 cells, and also T47D and SKBR3 
cell lines.  
The combination of in silico and in vitro data was considered and thus the MCF7 
(Luminal A) cell line was the focus of further experiments; as T47D demonstrated 
expression of ASCL2, this cell line was also chosen for further investigation and 
comparison as another Luminal A cell line. Considering all of the evidence, as 
well as the lack of HER2+ representation in the extreme variation datasets, 
SKBR3 cells were chosen for further investigation in additional to Luminal A cell 
lines.  
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4.2.2	Transfection	Validation	and	Knockdown	of	ASCL2	in	Breast	Cancer	Cell	
Lines	
In order to investigate the possible impact of ASCL2 overexpression seen in 
tumour cells (MCF7, T47D, SKBR3) compared to non-tumourigenic cells 
(MCF10A), as well as the involvement of ASCL2 in the Wnt signalling pathway, 
the ASCL2 gene was temporarily silenced using siRNA. It was hypothesised that 
temporarily silencing the gene expression of ASCL2 may result in slowed tumour 
growth or function.  
To validate genetic knockdown prior to data collection, control cells were 
transfected with TYE 563-labelled siRNA. These were visualised under a 
fluorescence microscope 24h post-transfection. The presence of a fluorescent 
signal in approximately 70% of nuclei was observed qualitatively, allowing 
quantitative measurement of knockdown efficiency to continue (Figure 4.1). 
Knockdown of ASCL2 was confirmed and quantified compared to non-targeting 
control siRNA (NC) samples using RT-qPCR. The relative mRNA expression of 
ASCL2 in cell lines are shown in Figure 4.2. Detailed descriptive statistics are 
presented in Appendix 4. All cell lines achieved an average of approximately 70% 
knockdown of ASCL2 (MCF7, 67%, T47D, 70%, SKBR3, 78%), which was used 
as a threshold to represent any true changes in tumour biology via functional 
laboratory investigation (Yang, et al., 2011). However, transfection efficiency was 
seen to vary between biological replicates.  
Functional exploration of ASCL2 in breast cancer proceeded, and evaluated 
several parameters subsequent to gene silencing - cell viability, apoptosis, 
migration, and Wnt-target gene relationships. 
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Figure 4.1. Cell lines transfected with TYE 563-labelled siRNA and visualised 24 
hours post-transfection to qualitatively validate transfection success, with bright-field 
(light) and fluorescence, 4X objective. Once uptake and sufficient gene silencing was 
confirmed, RT-qPCR was completed. MCF7 cells pictured as a representative image. 
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Figure 4.2.  Validation of knockdown efficiency after 24h: mean expression (±SEM) 
of ASCL2 in experimental samples relative to expression in negative control samples 
(relative fold change is shown), as measured by RT-qPCR after knockdown (MCF7, 
n=5, T47D, n=4, SKBR3, n=3, *p<0.0005, **p<0.0001). 
	114	
	
4.2.3	The	Effect	of	ASCL2	on	Cell	Viability		
Cell viability was measured using two common methods – the Alamar Blue assay 
and the Trypan Blue Exclusion Test. The Alamar Blue assay (a fluorometric 
method) was used as an indicator of cell health and metabolic activity by 
analysing the percentage difference in reduction of Alamar Blue in experimental 
samples compared to untreated controls. However, by nature of estimating cell 
viability based on metabolic activity, results may appear equivocal due to 
potential metabolic reprogramming in cancer cells (discussed further in Section 
4.3). Thus, to validate these findings, the Trypan Blue assay, a dye exclusion 
method, was also used based on the principle that viable cells had intact 
membranes. Incubation times were optimised for these experiments. 
Overall, there was no change in percentage reduction of Alamar Blue after 
ASCL2 knockdown in all 3 cell lines, and to validate this, no change was observed 
in the percentage viability after Trypan Blue staining in MCF7 and SKBR3 cells 
(Figure 4.3 and 4.4). Unpaired t-tests showed no statistically significant 
differences in cell viability between ASCL2-silenced cells and negative controls 
for either method.  
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Figure 4.3. Alamar blue assay: percentage difference in reduction of Alamar Blue 
compared to untreated controls (mean ± SEM), across MCF7 (n=3), T47D (n=3) and 
SKBR3 (n=1) respectively. No changes were observed.  
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Figure 4.4. Trypan blue cell viability assay: percent viability of cells (mean ± 
SEM). No change in viability was observed. (MCF7, n=4, SKBR3, n=3). 
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4.2.4	The	Effect	of	ASCL2	on	Apoptosis	
The Caspase-Glo 3/7 assay was used to determine apoptosis activity in cells. 
Apoptosis activity was judged based on caspase 3 and 7 activities in cells, as 
these are crucial in cell death induction and the promotion of apoptosis (Chen, et 
al., 2016).  In both MCF7 and SKBR3 cells, apoptosis was marginally elevated in 
siRNA-ASCL2 treated cells compared to untreated and siRNA-NC treated cells 
(Figure 4.5). However, since the role of ASCL2 could not be definitively measured 
or statistically established between ASCL2 silenced and negative control 
samples, there was insufficient evidence to confirm a role of ASCL2 in apoptosis.    
Figure 4.5. Caspase 3/7 assay: Measurement of caspase 3/7 activity representative 
of apoptosis shows a minor increase in cells with ASCL2 knockdown (mean ± SEM, 
MCF7 n=4, SKBR3 n=3, *p<0.05). The large error bar size and variation between 
replicates is likely due to variable transfection efficiency.    
T47D cells were omitted due to technical issues 
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4.2.5	The	Effect	of	ASCL2	on	Wound	Healing	&	Migration	
Previous reports in colon and gastric cancers have shown that downregulation of 
ASCL2 has reduced cellular invasion and migration in vitro, therefore suggesting 
that ASCL2 plays a role in promoting the migration of tumour cells (Jubb, et al., 
2006; Tian, et al., 2014; Zhu, et al., 2012; Zuo, et al., 2018). However, this link 
has not been explored in breast cancer.  
Wound closure was measured over 48h in experimental (siRNA-ASCL2) and 
negative control (siRNA-NC) samples. The area of the wound (µm) was 
measured at 0h, 24h and 48h, and percentage closure was calculated between 
time points for each sample. Measurements and descriptive statistics are 
summarised in Appendix 4.   
As can be seen from the microphotographs in Figure 4.6 and the data in Figure 
4.7, there was a clear visual and numerical trend between the rates of wound 
closure in MCF7 cells where ASCL2 expression had been silenced, compared to 
non-targeting siRNA control (NC) cells. Figure 4.6, highlights the observable 
differences in wound closure between MCF7 samples; it can be seen that cells 
migrated closed together, and the wound gap decreased more in control cells 
(untreated and siRNA-NC transfected) compared to siRNA-ASCL2 cells. To 
better observe complete closure of wounds, analysis would have benefited from 
data collection at a time point of 72 hours, however, this was limited by the 
transient nature of siRNA transfection. Figure 4.7 depicts the trend that wound 
closure was slowed in MCF7 cells after ASCL2 silencing with a mean difference 
of 14.9% after 24h and 13.8% after 48h between experimental conditions (Figure 
4.7 C). Figure 4.7 A and B both illustrate that the area of the scratch decreases 
more steadily in MCF7 cells after ASCL2 silencing.    
After 48 hours, no statistical significance was observed when comparing scratch 
area or percentage closure between ASCL2 and NC transfected samples (Figure 
4.7). These findings may be because, despite consistent trends, there was a large 
variation between biological replicates in this assay, which in turn had an effect 
on the determination of statistical significance. This was due to the semi-
quantitative nature of manual measurements, and will be discussed further in 
Section 4.3. Nevertheless, this data was still sufficient for further inquiry that 
ASCL2 may play a role in migration in MCF7/Luminal A breast cancer.  
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Figure 4.6. Microphotographs of scratches made in untreated cells, ASCL2 
transfected cells and NC transfected cells, at 0h and 48h, under a bright-field 
light microscope, x4 objective.  
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Figure 4.7. A & B. Rate of wound closure in MCF7 cells (n=6) over 24 h and 48h in 
ASCL2 and NC transfected samples, as measured by the area of the scratch. Area of 
wound measured at each time point across replicates is presented as mean ± SEM. C. 
Percentage closure of scratches measured at 24h and 48h. 
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The same pattern was observed in Luminal A T47D cells in Figure 4.8 and 4.9. 
Although this appeared less apparent from the microphotographs in Figure 4.8 
compared with MCF7 cells in Figure 4.6, this was seen in the quantitative data in 
Figure 4.9. The graphs in Figure 4.9 highlight that wound closure is slowed in 
T47D cells after ASCL2 silencing with a mean difference between siRNA-ASCL2 
and siRNA-NC transfected samples of 10.22% after 48h. This difference was 
statistically significant (p=0.03), signifying that ASCL2 may contribute to 
enhanced cellular movement and migration.  
Contrary to the trend observed in MCF7 and T47D cells, ASCL2 did not appear 
to be associated with wound healing and migration in SKBR3 cells. Figure 4.10 
and 4.11 highlights that there was no change in the rate of wound closure (area 
of scratch) or percentage closure over 48h.  
A challenge faced using SKBR3 and T47D cell lines was achieving the correct 
cell density for analysis; these cells would have benefitted from being grown to a 
greater confluence to gain a better picture of the growth and movement of cells. 
However, although this was attempted, this resulted in greater cell death and thus 
obstruction of the wound area with detached cells. T47D data collection was also 
problematic due to high volumes of cell death post transfection, hence only two 
replicates were able to be analysed for data collected at 48h. Therefore, further 
optimisation is required for the future.   
  
	122	
	
 
  
Figure 4.8. Microphotographs of scratches made in untreated cells, ASCL2 
transfected cells and NC transfected cells, at 0h and 48h, under a bright-field 
light microscope, x4 objective. 
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Figure 4.9. A & B. Rate of wound closure in T47D cells over 24h (n=3) and 48h (n=2) 
in ASCL2 and NC transfected samples, as measured by the area of the scratch. Area 
of wound measured at each time point across replicates is presented as mean ± SEM. 
C. Percentage closure of scratches measured at 24h and 48h, *p<0.05. 
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Figure 4.10. Microphotographs of scratches made in untreated cells, ASCL2 
transfected cells and NC transfected cells, at 0h and 48h, under a bright-field 
light microscope, x4 objective.  
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Figure 4.11. A & B. Rate of wound closure in SKBR3 cells (n=3) over 24h and 48h in 
ASCL2 and NC transfected samples, as measured by the area of the scratch. Area of 
wound measured at each time point across replicates is presented as mean ± SEM. C. 
Percentage closure of scratches measured at 24h and 48h, *p<0.05. 
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4.2.6	The	Effect	on	Wnt-target	Genes	and	‘Stemness’	Markers	Following	
ASCL2	Silencing		
To further shed light on the relationship between ASCL2 and the Wnt signalling 
pathway in breast cancer, and to confirm if ASCL2 interference in breast cancer 
cells inhibited stem-like properties of cancer cells, 6 genes were selected for 
investigation. The genes C-MYC, CCND1, CD44, CTNNB1, LGR5 and SURV 
(BIRC5) were selected based on their relation/role in Wnt signalling and their 
roles regarding their cellular behaviour (Chen, et al., 2016; Kim, et al., 2017; Wei, 
et al., 2017; Zhu, et al., 2012), intending to mirror the functional investigations in 
this study.  
The differential expression of genes involved in Wnt signalling was measured by 
RT-qPCR. Figure 4.12 A shows a significant reduction in the gene expression of 
the markers CD44, CTNNB1, LGR5 and SURV upon silencing of ASCL2 in MCF7 
cells; conversely, expression of the genes C-MYC and CCND1 were not reduced 
after ASCL2 silencing, but were instead significantly increased compared to the 
expression in negative control cells (siRNA-NC). Expression of the gene SURV 
also showed a marked decrease after ASCL2 knockdown which may back the 
trend from the Caspase-Glo 3/7 assay, suggesting that ASCL2 may play a role in 
the evasion of apoptosis in breast cancer.  
Likewise, Figure 4.12 B illustrates a significant reduction in expression of all Wnt 
markers in T47D cells, following ASCL2 silencing, however little change was 
observed in SKBR3 cells other than in LGR5 in which an increased expression 
was observed, in contrast to Luminal A cells.   
The greatest reduction of mRNA expression after ASCL2 knockdown was seen 
in the genes CD44 and LGR5, in MCF7 and T47D cells. These genes are widely 
known members of Wnt signalling and cancer stem cell markers, therefore this 
data, in line with the literature, suggests that the knockdown of ASCL2 may inhibit 
the action of CSCs or may reduce breast cancer ‘stemness’.   
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Figure 4.12. Changes in relative mRNA expression (fold change, mean ± SEM) of Wnt 
pathway markers and ‘stemness’ genes after silencing ASCL2 compared to NC 
(*p<0.05,**p<0.01). A. MCF7 cells (n=3), the genes CD44, CTNNB1, LGR5, and SURV 
exhibited significantly decreased gene expression when ASCL2 was silenced. 
Conversely, C-MYC and CCND1 showed significantly increased expression. B. T47D 
cells (n=2), the expression of all genes was reduced after ASCL2 knockdown. C. 
SKBR3 cells (n=2), the expression of most genes appeared unchanged after ASCL2 
silencing; although LGR5 showed overexpression, no significant difference was 
observed. Data for CD44 was inconclusive. 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
C 
	128	
	
4.2.7	Validation	of	ASCL2	Protein	Knockdown	in	MCF7	Cells	
To ensure the completeness and rigour of the study, the protein expression of 
ASCL2 was examined to confirm that siRNA knockdown had been translated 
through to the protein level. Immunostaining of MCF7 cells was performed, and 
it was observed that ASCL2 was located within the cytoplasm upon fixation 
(Figure 4.13); however, protein knockdown could not be definitively confirmed. 
Possible reasons for this outcome are discussed in greater detail in Section 4.3 
Although these results were not as anticipated, and functional changes are not 
usually to be expected without an observed change in protein levels after gene 
silencing, the previous experiments maintain validity, as a number of processes 
or feedback pathways may be affected that are currently unknown. The 
significance of these experiments, and this Chapter as a whole, in assessing the 
outcome of ASCL2 knockdown in breast cancer cells is therefore justified by the 
scarcity of information currently available within the literature. 
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Figure 4.13.  Immunofluorescence displaying no change in protein expression after ASCL2 gene knockdown using siRNA in MCF7 cells 
(48h post transfection). It was observed that at the time of fixation, ASCL2 protein was predominantly located in the cytoplasm.   
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4.3	Discussion	
Regarding siRNA experimental data collection in this study, untreated and non-
targeting negative control (NC) duplex transfected cells were used as controls. 
For gene expression analysis and to assess statistical significance in functional 
assays, siRNA-NC treated cells were used for comparison. The siRNA-NC 
treated cells were favoured for experimental comparison over untransfected cells 
as this allowed any non-specific effects to be observed and distinguished from 
sequence-specific effects. 
Prior to beginning functional investigation of ASCL2 it was important to validate 
and optimise the process of gene knockdown. As shown in Appendix 2, a large 
body of time was devoted to optimising this procedure, as this formed the 
foundation of functional investigation. To ensure that the functional effects of 
gene knockdown could be observed, a knockdown of approximately 70% was 
required, and optimisation continued until this could be consistently achieved – 
unfortunately, despite best efforts, knockdown efficiency still varied between 
experiments, and this seems to be reflected in the variation seen between 
biological replicates. Many influencing factors on transfection efficiency were 
scrutinised in the process, including but not limited to cell seeding density, siRNA 
delivery, incubation times, RNA purity and extraction, and cDNA concentration. 
However, transfection efficiency can still vary dramatically from one experiment 
to another due to the inherent and unavoidable cellular toxicity caused by 
transfection methods and reagents; achieving the very fine balance between 
adequate siRNA delivery and toxicity was challenging (Biocompare, 2012). With 
regards to variable transfection efficiency, it is worthwhile mentioning that the 
difficulties faced to maintain knockdown consistency may be exacerbated by the 
intra-tumour heterogeneity of breast cancer cells. To combat this variability, 
multiple replicates were carried out, and this was kept in mind throughout the 
study when analysing data and drawing conclusions.  
One prominent limitation of this analysis was the inability to demonstrate ASCL2 
knockdown at the protein level in MCF7 cells, despite seeing some phenotypic 
effects of the gene silencing. This was attempted using two methods – Western 
Blot (not presented) and immunostaining. Although protein expression of ASCL2 
was observed in MCF7 cells using both techniques, a knockdown of protein 
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expression could not be detected. However, in model disease systems, whereby 
a plethora of factors and circumstances are simultaneously at play at any given 
time, unanticipated results requiring troubleshooting are to be expected.  
With regards to the observed lack of protein knockdown, changes in gene 
expression levels do not always accurately reflect the protein level, and in fact, 
this correlation is often weak (Maier et al., 2009; Vaklavas et al., 2020). this 
inconsistency between mRNA and protein levels has been investigated in 
transcriptomic and proteomic studies, whereby research has found that typically, 
cellular concentrations of proteins to their corresponding mRNAs only correlate 
by approximately 40% (Vogel & Marcotte, 2013). 
A likely explanation may be due to the half-life of ASCL2; very stable proteins 
have a longer half-life, therefore may be highly transcribed or degraded at a 
slower rate, resulting in a longer time required for mRNA reduction to translate to 
the reduction of protein (Boettcher, & McManus, 2015). In this study, protein 
based experiments were measured after 48 hours, but may have benefitted from 
measurement after 72 hours or longer, as protein stability can vary from minutes 
to days. In contrast, the rate of mRNA degradation is restricted to a much tighter 
range, as mRNAs are generally less stable than their protein counterparts (half-
life = 2.6-7 hours versus 46 hours) (Vogel & Marcotte, 2013). This may also be 
attributed to the rate at which mRNA is transcribed in comparison to the rate at 
which protein is translated, which has been estimated to be around 2 copies of 
mRNA versus dozens of the corresponding protein per hour (Vogel & Marcotte, 
2013).  
Overall, levels of cellular protein require the orchestration of a number of 
regulatory processes including the transcription, processing and degradation of 
mRNA, post-transcriptional events, and translation, localisation and modification 
of proteins (Vogel & Marcotte, 2013; Kim et al., 2019). Therefore, a change in 
any one of these events may highly impact the abundance levels of mRNA or 
protein, especially in cancer cells, where the cross-talk of a number of pathways 
is likely to be over activated and highly dynamic in nature.  
From an experimental standpoint, development of the stable expression of 
lentiviral shRNA would be more beneficial to circumvent the issue of transient 
transfection using siRNA, and eventually lead to full protein depletion (Boettcher, 
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& McManus, 2015). Another possible reason was that these experiments could 
have had a poor transfection efficiency prior to protein extraction for western 
blots; to improve certainty of knockdown in samples, the RNA (for RT-qPCR 
validation of efficiency) could have been simultaneously extracted while purifying 
out the corresponding protein for Western Blot analysis. Other reasons may 
include but are not limited to antibody specificity, or the presence of multiple 
different transcripts of the same gene (Bass, et al., 2017). Antibody specificity 
was not validated by testing different antibodies prior to performing western blot 
or immunostaining analyses. Though, this will be done in the future to ensure that 
changes in protein expression can be accurately determined. By correctly 
identifying the most specific antibody, observed expression changes (even no 
expression change) can be more confidently relied upon to reflect the biological 
picture, and rules out the potential of technical or experimental artefacts. In 
addition to this, future work in the continuation of this study will also include the 
MCF10A cell line as comparison control cells in immunofluorescence analysis.  
Previous data from Zhu, et al., (2012) highlighted that ASCL2 knockdown inhibits 
proliferation in colon cancer cells. Although in this study, the results from the 
Alamar Blue cell viability assay showed no change in viability (representing 
proliferation) after knockdown in breast cancer cell lines, the suitability of this 
assay for measurement of proliferation may be scrutinised. The main reason for 
this is that the assay was based on redox changes – this assumes that only live 
cells were metabolically active, where a reduction of Alamar Blue was 
proportional to the amount of ‘viable’ cells (Bio-Rad Laboratories, Inc, 2016). 
Hence, the reliance on metabolic changes in the cells representing changes in 
cell proliferation is problematic for a multitude of reasons.  
Firstly, there are a large number of enzymes present in cells that may be 
responsible for the reduction of Alamar Blue; this makes it difficult to assess 
whether Alamar Blue reduction is due to genetic knockdown altering processes 
like cell death and proliferation, or just a change in cellular metabolism 
(Rampersad, 2012). Secondly, cells use a large amount of energy to push 
invasion and migration in cancer cells; assuming that ASCL2 knockdown results 
in the decrease of migration (based on other findings in this chapter), it follows 
that this could be causing a great demand for energy in cells (Han, et al., 2013). 
To address these shortfalls, the Trypan Blue dye exclusion assay was used to 
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estimate cell viability based on membrane integrity, rather than metabolic activity; 
this confirmed Alamar Blue data and the indication that ASCL2 did not enhance 
cell proliferation. However, using a more direct and sensitive method of 
quantifying cell proliferation may have been more valuable in this case, for 
example, measuring DNA synthesis using an 5-ethynyl-2′-deoxyuridine (EdU) 
staining assay and flow cytometry (Salic, & Mitchison, 2008). Jubb, et al., (2006) 
suggested that ASCL2 promoted cell progression through the G2/M checkpoint 
of the cell cycle in intestinal neoplasia; investigating this using EdU staining would 
be particularly useful for further research into the role of ASCL2 in breast cancer. 
Still, after 48 hours of gene knockdown in this study, no change in protein levels 
could be detected, as well as no effect on cell viability. Therefore, the relationship 
between ASCL2 and cell viability could not be determined. 
Results from the Caspase-Glo 3/7 assay indicated a slight elevation of apoptosis 
in siRNA-ASCL2 treated cells compared to the negative control cells in both 
MCF7 and SKBR3 cell lines. Although this insinuated a possible role of ASCL2 
in apoptosis in breast cancer, evidence was not sufficient to confirm this. As 
previously identified by Wang, et al., (2018) in gastric cancer, it was anticipated 
that ASCL2 silencing would increase apoptosis in breast cancer cells. In contrast 
to this notion, Zhongfeng, et al., (2018) demonstrated that overexpression of 
ASCL2 increased levels of Caspase 3 in neuronal stem cells, thereby promoting 
apoptosis in these cells. Although, it is possible that ASCL2 may act in a context 
dependent manner within different cells. Within this study, there were some 
technical reasons why ASCL2 knockdown did not result in the significant increase 
of apoptosis in breast tumour cells.  
Sundquist, et al., (2006) demonstrated that caspase 3/7 activity was time 
dependent, and increased over the first 7 hours in their study. Therefore, they 
highly recommended that the optimal peak activity was determined consistently 
over a broad time period prior to data collection, as monitoring caspase activity 
prematurely or after its peak could result in a weakened signal leading to false 
conclusions. In this study, apoptosis was measured 24 hours post siRNA 
transfection, which may have been too late to capture peak caspase 3/7 activity; 
measuring caspase 3/7 activity at an earlier time may have shown a more 
pronounced effect of ASCL2 knockdown on apoptosis. Although, collecting 
experimental data too soon post-transfection may result in taking measurements 
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when cell activity is most perturbed by other reagents, for example, apoptotic 
markers may increase as a consequence of transfection-induced toxicity. 
However, this knowledge can be carried forward to improve this study and solidify 
knowledge of ASCL2 in breast cancer. 
It was also noted after experimental analysis that the functional caspase 3 gene 
product is absent in MCF7 cells, which may have been another contributing factor 
in the potential underestimation of apoptosis induced by ASCL2 silencing 
(Jänicke, et al., 1998; Jänicke, 2008; Sundquist, et al., 2006). In light of this 
notion, it could be deliberated that the results seen in this chapter were not 
entirely demonstrative of the real cellular behaviour relating to apoptosis in MCF7 
cells; with further investigation using a different method, such as flow cytometry, 
a greater change in apoptosis after ASCL2 silencing may be observed. However, 
seeing as this is subject to debate, further research is required to confirm this. 
The wound-healing scratch assay was chosen as a core technique to assess cell 
migration in an extremely convenient and economical manner. As discussed by 
Jonkman, et al., (2014), the lack of a standardised method poses a challenge to 
researchers, however the guidelines outlined in this paper were followed within 
the means of resources available. Despite demonstrating clear trends towards 
decreased migration subsequent to ASCL2 silencing in Luminal A cells, the 
difficulties in managing the variability of transfection efficiency between replica 
compromised reproducibility of the assay and posed difficulties for statistical 
analysis in MCF7 cells. Although every effort was made to address these 
reproducibility issues within the assay design, the manual nature of the assay 
meant that there were still a number of limitations.  
For example, a challenge faced was ensuring that scratches made in each well 
for each replicate were the exact same width (the same tip pressure and angle) 
– however, this was combatted by calculating and comparing the percent closure 
of each well (making the scratch at the beginning and end of the assay, relative 
to each well individually). One method to combat this difficulty is the use of silicon 
inserts to ensure gap consistency. As well as this, there was a risk of manually 
imaging a different section of the scratch for each well. Although, every effort was 
made to ensure images were captured precisely for each time point; for example, 
marks were made on plate lids to ensure repeat images were as precise as 
possible, and a 4X objective was used to maximise the field of view of the wound 
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area. However, the reproducibility of the assay could have been improved by 
using an automated live imaging digital camera and more specialised 2D image 
analysis software. Sampling at multiple positions with automated stage control 
would have also been useful to eliminate user-bias. Another complexity of this 
method was that while manually imaging, cells had to be removed from the 
incubator for each time interval, possibly impacting cell growth. Making the 
procedure automated by using an environment-controlled microscope would 
ensure optimal culture conditions were maintained consistently throughout the 
process, eliminating any effects on cell microenvironment and physiology 
(Gough, et al., 2011; Johnston, et al., 2014; Jonkman, et al., 2014).  
Other reproducibility issues could have been attributed to possible variation in 
transfection efficiency for each biological replicate – for example, gene silencing 
of ASCL2 with a transfection efficiency of 65% compared to 80% could have had 
profound differences on the functional effect. This was likely to be causing the 
large variation in scratch migration between biological replicates in MCF7 cells, 
which in turn affected statistical significance in this study (despite the same trends 
across replicates observed, that ASCL2 silencing decreased migration compared 
to negative controls). In spite of best efforts of quality control and experimental 
handling, fluctuating transfection efficiency between biological replicates could 
have given rise to the large variation in the closure of the wound.  
Examining the raw data in Appendix 4, although MCF7 cells closed on average 
a greater percentage between ASCL2 and NC transfected cells compared to the 
same conditions in T47D cells, the variation of data between biological replicates 
was more apparent in MCF7 cells. For example, in MCF7 cells, the mean 
percentage closure after 48h between the two conditions (siRNA-ASCL2 vs 
siRNA-NC) was 13.8%, with a SEM of ±11.53. However, in T47D cells, the 
difference between the mean percentage closures of each condition was 10.22% 
± 3.108. This is reflected in the coefficient of determination (R2) values of 0.1332 
and 0.7299 in MCF7 and T47D cells respectively. Therefore, despite 6 replicates 
in MCF7 cells vs 2 replicates in T47D cells, and a clear graphical trend, the large 
variation has affected the statistical significance in MCF7 cells. It can therefore 
be assumed that repeating this work with more sophisticated technology would 
yield a sounder conclusion and confirm that ASCL2 enhances migration in 
Luminal A breast cancers. 
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With regards to the SKBR3 (HER2+) cell line, ASCL2 silencing did not influence 
cell migration. Untreated cells appeared to close the wound gap much quicker 
than transfected cells, which may have been attributed to the toxicity of the 
transfection process. As there was no change observed in cellular behaviour in 
SKBR3 cells, this may suggest a subtype specific effect of ASCL2. This is 
contrary to work published by Xu, et al., (2017), who claimed to find no differences 
in ASCL2 gene expression between breast cancer subtypes in patient tissue 
samples, but suggest the use of ASCL2 as a prognostic marker in patients. 
Although it could be argued that patient tissue samples are much more 
representative of tumours than cell lines, cell lines are comparatively less 
susceptible to high heterogeneity and provide a relatively stable genetic basis for 
exploration; additionally, the differential expression of ASCL2 has been verified 
at multiple levels in this study (transcriptomic pathway analysis and in vitro 
analysis). Therefore, it is plausible to say that ASCL2 is expressed in breast 
cancer cell lines in a subtype-specific manner. 
Overall, this analysis has presented some evidence that ASCL2 may be involved 
in the collective migration of Luminal A breast cancer cells, however, further 
assessment of migration would improve the reliability of these results. This could 
be done using previously mentioned silicon gap inserts, or using the Boyden 
chamber assay, or Dunn cell chambers, both of which use a chemical 
concentration gradient to follow the movement and migration of cells; however, 
both of these would require time-lapse recording equipment.  
It was summarised in Section 1.2.3 that ASCL2 controls intestinal stem cell fate 
via the downstream effects of Wnt signalling (van der Flier, et al., 2009; Zhu, et 
al., 2012). In colon cancer, ASCL2 regulates cell self-renewal and plasticity 
through EMT, and selective blockade of ASCL2 has been suggested to contribute 
to the reversal of EMT and thus cancer progression (Tian, et al., 2014). With this 
in mind, its role in the ‘stemness’ of colon cancer has received much attention 
within the literature, yet has been neglected in breast cancer. In order to highlight 
this link between ASCL2 and stemness in breast cancer, and its activity within 
the Wnt pathway, genes with Wnt involvement were examined after ASCL2 
silencing.  
Multiple genes were selected in the hope to broadly represent various cancer 
hallmarks and functional parameters relating to cancer within the Wnt signalling 
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pathway. The genes CD44, LGR5, CTNNB1 and C-MYC were chosen as Wnt 
signalling markers of stemness (Kim, et al., 2017; Yang, et al., 2015a; Jang, et 
al., 2015; Zhao, et al., 2017). SURV was chosen as a marker of apoptosis (Chen, 
et al., 2016), and CCND1 was chosen on the basis of being widely overexpressed 
in breast cancer and due to its role in cell cycle regulation and progression (Roy, 
& Thompson, 2006). In primitive terms, these have been chosen to complement 
the investigation of migration (wound-healing), apoptosis and proliferation 
respectively, however it is acknowledged that these genes are all multifaceted in 
their functions. 
The data from this study indicated that upon ASCL2 silencing, the expression of 
stemness-related genes CD44, CTNNB1 and LGR5 decreased in both MCF7 and 
T47D cells. This not only supported the findings from the wound-healing assay in 
this study, but also supported the idea that ASCL2 may be a key gene involved 
in breast cancer stemness via the Wnt signalling pathway. In T47D cells, the 
expression of C-MYC and CCND1 was also reduced after ASCL2 silencing, 
however the opposite trend was observed in MCF7 cells. Although C-MYC has 
been shown to mediate cancer stem cells via sustained activity in triple-negative 
breast cancers (Yin, et al., 2017), amongst other tumour types, the observation 
of overexpression after ASCL2 silencing may be due to another compensatory 
mechanism, as C-MYC also functions to regulate, for example, cell growth and 
proliferation. As both C-MYC and CCND1 are ubiquitous in their functions, a 
single trait cannot be attributed or measured in these genes. Therefore, in this 
case, the mechanism by which C-MYC and CCND1 functions in stemness may 
be context dependent, or may only be present within a small subpopulation of the 
MCF7 tumour cells (Yin, et al., 2017).  
The expression of the gene SURV was also measured as a means to estimate 
the effect of ASCL2 on apoptosis. This gene is also multifunctional but is 
principally recognised for controlling cell division and the inhibition of apoptosis, 
and is associated with therapy resistance and poor prognosis in breast cancer 
(Chen, et al., 2016). Downregulation of SURV subsequent to ASCL2 silencing 
may add weight to the trend observed in the Caspase-Glo 3/7 assay, signifying 
that ASCL2 may contribute to the evasion of apoptosis in breast cancer cells. 
However, the mechanisms of apoptosis involving SURV in tumourigenesis is 
highly complex, therefore this can only be hypothesised rather than confirmed in 
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this study – to elaborate on this, other apoptosis associated genes such as BCL-
2 could also be measured after ASCL2 knockdown.  
Overall, this data suggested that ASCL2 silencing may have inhibited the action 
of cancer stem cells or may have reduced breast cancer ‘stemness’. Results 
demonstrated that ASCL2 did have an effect on the Wnt target genes in breast 
cancer, and therefore may work within this pathway to drive tumourigenesis. To 
strengthen this part of the study, more stemness markers such as Oct4, Sox2 
and CD133 could be added for investigation (Zhu, et al., 2012) 
To summarise the findings of this chapter, as demonstrated, sufficient gene 
knockdown was achieved using anti-ASCL2 siRNAs in all cell lines. In vitro 
functional assays suggested that reducing the expression of this gene had the 
potential to lessen cellular migration within MCF7/T47D Luminal A subtypes, and 
may contribute to the evasion of apoptosis in these breast cancer cells (however, 
this requires additional confirmation). Conversely, it appeared that ASCL2 gene 
knockdown did not impact cell proliferation in the same way. The data described 
also demonstrated that ASCL2 silencing resulted in reduced expression of Wnt 
signalling associated genes; the effect of silencing on CTNNB1 (the gene 
encoding the b-catenin protein, a key player in Wnt signalling), highlighted that 
ASCL2 was likely to exercise its effect on breast tumourignesis, as confirmed in 
colon cancer via the action of the canonical Wnt pathway. In particular, 
knockdown of ASCL2 resulted in the greatest reduction of the stemness marker 
genes CD44 and LGR5, as well as the apoptosis gene SURV, thus confirming 
the trends seen in functional assays and echoing evidence published in colon 
cancer studies (Zhu, et al., 2012). Ultimately, this data provides a sufficient body 
of evidence that ASCL2 is involved in breast tumourigenesis, and although 
mechanisms have not yet been fully elucidated, provides a basis for which further 
hypotheses and research can be conducted.  
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Chapter	V	
 
Assessment	of	molecular	features	and	survival	
outcomes	associated	with	ASCL2	in	patient	breast	
tumours,	to	evaluate	potential	as	a	clinical	or	
prognostic	marker	
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5.1	Introduction	
In recent years, considerable efforts have been made to explore the gene 
expression profiles underlying the distinctive breast cancer subtypes, as well as 
possible markers associated with poorer survival, therapeutic sensitivity and 
clinical outcomes (Dai, et al., 2015; Prat, & Perou, 2011; Reaz, et al., 2018). The 
utility of such genetic markers has been demonstrated in the clinic for some time, 
for example, the expression of the proliferative gene, Ki67, has been used as a 
determinant of chemotherapy response and as an indicator of prognosis 
(Yerushalmi, et al., 2010). Additionally, the identification of novel molecular 
markers for predicting aggressive phenotypes could provide new opportunities 
for future therapy development, or the personalised management of tumours 
across patients (Reaz, et al., 2018).  
However, as knowledge and understanding of the genetic diversity of breast 
cancer advances, the current intrinsic subtype classification has come under 
scrutiny (Russnes, et al., 2017). In light of this, a more extensive and integrated 
classification system was proposed termed the integrative clusters. These 10 
clusters were each linked with likely molecular markers, variable causal biology, 
and thus discrete clinical outcomes in which personalised management and 
treatment approaches could be tailored towards (Dawson, et al., 2013). Still, 
inter- and intra-tumour heterogeneity presents important challenges to 
researchers due to the resultant variations in molecular and clinical 
characteristics (Bedard, et al., 2013). In this respect, the pursuit of a variety of 
functional oncogenic markers to develop biological understanding, improve 
cancer risk models, and enhance marker-based therapies are of significant 
interest within the field of precision medicine for breast cancer (Kalia, 2015).  
The recent application of high-throughput technologies for gene expression 
profiling, and the curation of publically available repositories, means it is now 
possible for large published studies to share clinically relevant datasets. 
Researchers may use these perpetually for candidate gene investigation, to yield 
insights into novel molecular markers and targets, and assist in the clinical 
translatability of oncology research (Cheng, et al., 2015; Y. Yang, et al., 2015b). 
One such resource designed to facilitate gene exploration and discovery is the 
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cBioPortal, an open-access online platform, providing access to large-scale 
datasets from 246 cancer studies (Cerami, et al., 2012; Gao, et al., 2013). 
Within the literature, ASCL2 has been implicated in a number of cancers, alluding 
to the notion that it may be an attractive gene worth exploring as a novel marker 
in breast cancer. Previous studies have reported evidence suggesting the role of 
ASCL2 as a prognostic indicator in tumours; high ASCL2 protein expression was 
associated with advanced tumour stage and poorer differentiation status in lung 
squamous cell carcinoma, and poorer overall and metastasis-free survival in 
osteosarcoma (Hu, et al., 2015; Liu, et al., 2016). However, little is known about 
the role of ASCL2 in breast cancer. One of the few studies exploring the 
relationship between ASCL2 and clinical outcomes in breast cancer was that by 
Xu, et al., (2017); this study used semi-quantitative immunohistochemical 
staining in a small cohort of patients, suggesting that increased ASCL2 protein 
expression was correlated with poorer survival and relapse.  
In the present study, previous analysis of cell line data indicated that ASCL2 
expression was elevated in some breast tumour cells vs non-tumourigenic cells 
(Chapters 3 and 4). To develop these findings, it was hypothesised whether 
elevated ASCL2 expression may be correlated with advanced or aggressive 
breast tumours, as well as poorer patient survival. Further, the association of 
ASCL2 with the distinct intrinsic subtypes or integrative clusters of breast cancer, 
hence its specificity as a potential marker, has not yet been examined. Exploring 
such relationships may be used to identify promising avenues for further 
research, and enable more focussed study of ASCL2.  
The aim of this chapter was therefore to determine the suitability of ASCL2 as a 
clinical or prognostic marker. In order to execute this, the expression levels of 
ASCL2 were analysed among a large cohort of patient breast tumours (n=1904) 
from the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) study (Curtis, et al., 2012), obtained via the cBioportal (Gao, et al., 
2013). In this Chapter, the association of ASCL2 mRNA expression with clinical 
features such as, subtype, receptor status, age of onset, and overall survival was 
examined to assess the prognostic significance of ASCL2 in breast cancer.  
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5.2	Results	
The work presented in Chapter 3 used in silico methods to identify ASCL2 as a 
potential tumourigenic candidate gene in breast cancer, primarily within the 
Luminal A subtype. This was followed using cell lines in vitro (Chapter 4), 
demonstrating a functional role of ASCL2 in cellular migration, hypothetically 
within the Wnt signalling pathway.  
To accompany the work in cell lines, gene expression data from patient samples 
were explored to examine the clinical impact of ASCL2 and association between 
clinicopathologic features. Data obtained from the METABRIC study (Section 
2.2) (Curtis, et al., 2012; Pereira, et al., 2016)  was accessed through the 
cBioPortal web application (Gao et al., 2013). Expression level Z-score data of 
±2 was used as a threshold to classify clinical breast cancer cases into 3 groups 
according to the expression level of ASCL2: upregulated (overexpressed), 
downregulated and unaltered. The METABRIC dataset contained 2509 samples 
from primary tumours, of which, gene expression data for ASCL2 was recorded 
in 1904 patients. Of these, 3.3% (82) of patient samples were shown to 
overexpress ASCL2 with only one case (0.04%) shown to downregulate ASCL2.  
Descriptive statistics for all clinical parameters and corresponding ASCL2 
expression in the METABRIC cohort is presented in Table 5.1 and 5.2, and can 
also be found in Appendix 5.  
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METABRIC		
Study	
	
Total	
Downregulated	
(≤	-2)	
Unaltered	
(-2	to	+2)	
Upregulated	
(≥	+2)	 P	value	
N	(%)	 N	(%)	 N	(%)	
Age	
Mean	(Years)	
Range	
1,904	
1	
75.13	
-	
1821	
61.05	
21.93,	96.29	
82	
61.75	
32.99,	87.18	
0.497	
Survival	
Mean	(Months)	
Range	
1,904	
1	
58.67	
-	
1821	
125.53	
0.00,	355.20	
82	
114.70	
9.60,	297.23	
0.311	
Stage	
0	
1	
2	
3	
4	
	
4	
475	
800	
115	
9	
	
-	
-	
-	
-	
-	
	
4	(0.3)	
460	(34.2)	
766	(57)	
106	(7.9)	
9	(15.5)	
	
-	
15	(25.9)	
34	(58.6)	
9	(15.5)	
-	
0.224	
Grade	
1	
2	
3	
4	
	
165	
740	
927	
0	
	
-	
-	
-	
-	
	
160	(9.1)	
711	(40.6)	
882	(50.3)	
-	
	
5	(6.3)	
29	(36.7)	
45	(57)	
-	
0.45	
PAM	50	Subtype	
Luminal	A	
Luminal	B	
HER2	+	
Basal	
Claudin-Low	
Normal-like	
	
679	
461	
220	
199	
199	
140	
	
1	(100)	
-	
-	
-	
-	
-	
	
660	(36.4)	
434	(23.9)	
193	(10.6)	
192	(10.6)	
199	(11)	
137	(7.5)	
	
18	(22)	
27	(32.9)	
27	(32.9)	
7	(8.5)	
-	
3	(3.7)	
<0.001*	
Integrative	Cluster	
1	
2	
3	
4ER-	
4ER+	
5	
6	
7	
8	
9	
10	
	
132	
72	
282	
244	
74	
184	
84	
182	
288	
142	
219	
	
-	
-	
-	
-	
-	
-	
-	
-	
1	(100)	
-	
-	
	
126	(6.9)	
68	(3.7)	
275	(15.1)	
238	(13.1)	
71	(3.9)	
163	(9)	
81	(4.4)	
176	(9.7)	
279	(15.3)	
132	(7.2)	
212	(11.6)	
	
6	(7.3)	
4	(4.9)	
7	(8.5)	
6	(7.3)	
3	(3.7)	
21	(25.6)	
3	(3.7)	
6	(7.3)	
9	(11)	
10	(12.2)	
7	(8.5)	
0.010*	
ER	Status	
Positive	
Negative	
	
1458	
445	
	
1	(100)	
-	
	
1396	(76.7)	
425	(23.3)	
	
62	(75.6)	
20	(24.4)	
0.838	
PR	Status	
Positive	
Negative	
	
1008	
895	
	
1	(100)	
-	
	
971	(53.3)	
850	(46.7)	
	
37	(45.1)	
45	(54.9)	
0.222	
HER2	Status	
Positive	
Negative	
	
236	
1668	
	
-	
1	(100)	
	
215	(11.8)	
1606	(88.2)	
	
21	(25.6)	
61	(74.4)	
0.001*	
Table 5.1. Population distribution of the METABRIC study, and association 
between ASCL2 expression and clinicopathologic characteristics of breast 
cancers.  
* For each data type the total number of cases may differ due to missing values or 
incomplete data within the METABRIC dataset.   
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ASCL2	
Z-score	
Downregulated		
(≤	-2)	
Unaltered		
(-2	to	+2)	
Upregulated		
(≥+2)	
N	 Mean	 N	 Mean	 95%	CI	 N	 Mean	 95%	CI	
Stage	 	 	 	 	 	 	 	 	
0	 -	 -	 4	 0.21	 -2.57,	2.99	 -	 -	 -	
1	 -	 -	 460	 -0.2	 -0.28,	-0.13	 15	 2.43	 2.25,	2.60	
2	 -	 -	 766	 -0.04	 -0.10,	0.03	 34	 2.40	 2.29,	2.51	
3	 -	 -	 106	 0.18	 0.02,	0.34	 9	 2.43	 2.22,	2.65	
4	 -	 -	 9	 -0.29	 -1.04,	0.45	 -	 -	 -	
Grade	 	 	 	 	 	 	 	 	
1	 -	 -	 160	 -0.28	 -0.41,	-0.15	 5	 2.64	 2.27,	3.00	
2	 -	 -	 711	 -0.24	 -0.30,	-0.18	 29	 2.45	 2.32,	2.57	
3	 -	 -	 882	 0.07	 0.01,0.13	 45	 2.37	 2.28,	2.46	
4	 -	 -	 -	 -	 -	 -	 -	 -	
PAM	50		
Subtype	 	 	 	 	 	 	 	 	
Luminal	A	 1	 -2.08	 660	 -0.19	 -0.25,	-0.13	 18	 2.35	 2.24,	2.45	
Luminal	B	 -	 -	 434	 -0.34	 -0.42,	-0.26	 27	 2.49	 2.35,	2.62	
HER2	+	 -	 -	 193	 0.53	 0.41,	0.65	 27	 2.38	 2.25,	2.50	
Basal	 -	 -	 192	 0.00	 -0.12,	0,12	 7	 2.35	 2.07,	2.63	
Claudin-Low	 -	 -	 199	 0.04	 -0.06,	0.13	 -	 -	 -	
Normal-like	 -	 -	 137	 -0.03	 -0.17,	0.11	 3	 2.49	 1.17,	3.80	
Cluster	 	 	 	 	 	 	 	 	
1	 -	 -	 126	 -0.28	 -0.43,	0.13	 6	 2.45	 2.13,	2.77	
2	 -	 -	 68	 -0.38	 -0.56,	-0.20	 4	 2.30	 1.87,	2.74	
3	 -	 -	 275	 -0.12	 -0.22,	-0.03	 7	 2.23	 2.11,	2.36	
4ER-	 -	 -	 238	 -0.13	 -0.24,	-0.03	 6	 2.28	 2.08,	2.47	
4ER+	 -	 -	 71	 0.34	 0.13,	0.55	 3	 2.10	 1.91,	2.29	
5	 -	 -	 163	 0.47	 0.33,	0.60	 21	 2.42	 2.26,	2.58	
6	 -	 -	 81	 -0.30	 -0.49,	-0.11	 3	 2.38	 1.32,	3.44	
7	 -	 -	 176	 -0.26	 -0.38,	-0.14	 6	 2.36	 2.15,	2.58	
8	 1	 -2.08	 279	 -0.29	 -0.39,	-0.20	 9	 2.56	 2.32,	2.79	
9	 -	 -	 132	 0.17	 0.01,	0.34	 10	 2.65	 2.39,	2.91	
10	 -	 -	 212	 -0.05	 -0.15,	0.05	 7	 2.35	 2.10,	2.60	
ER	Status	 	 	 	 	 	 	 	 	
Positive	 1	 -2.08	 1394	 -0.19	 -0.24,	-0.15	 62	 2.43	 2.35,	2.51	
Negative	 -	 -	 425	 0.24	 0.16,	0.32	 20	 2.33	 2.19,	2.47	
PR	Status	 	 	 	 	 	 	 	 	
Positive	 1	 -2.08	 971	 -0.23	 -0.28,	-0.18	 37	 2.42	 2.31,	2.52	
Negative	 -	 -	 850	 0.07	 0.01,	0.13	 45	 2.40	 2.31,	2.50	
HER2	Status	 	 	 	 	 	 	 	 	
Positive	 -	 -	 215	 0.40	 0.28,	0.52	 21	 2.43	 2.27,	2.59	
Negative	 1	 -2.08	 1606	 -0.16	 -0.20,	-0.12	 61	 2.40	 2.32,	2.48	
Table 5.2. Association between ASCL2 expression (Z-score) and clinicopathologic 
characteristics of breast cancers in the METABRIC dataset. 
* For each data type the total number of cases may differ due to missing values or 
incomplete data within the METABRIC dataset.   
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5.2.1	Distribution	of	clinicopathological	features	based	on	ASCL2	expression	
The average age of breast cancer onset between tumours with overexpressed, 
unaltered and downregulated ASCL2 was first analysed, as patients presenting 
at a younger age (before 40 years) are known to have more aggressive tumours 
and a reduced overall survival compared to older women (Anders, et al., 2009). 
However, the mean age of onset was approximately 61 years for all ASCL2 
expression groups - a one-way ANOVA (with Tukey post hoc multiple 
comparisons test) showed no significant difference in age of breast cancer onset 
between the upregulated, downregulated and unaltered expression groups of 
ASCL2 (p=0.497, F=0.699).  
Stage and grade were other clinical parameters used to assess the invasive 
capacity and aggression of tumours in patients. Likewise, no difference was 
observed, other than a slight tendency for ASCL2 overexpressing tumours to be 
associated with a higher grade and a more advanced stage (stage 3 and 4 more 
frequently observed where ASCL2 is upregulated (16%) compared with unaltered 
ASCL2 expression (8%)). Analysis of stage and histological grade of tumours 
across ASCL2 expression groups did not show statistical significance (Pearson 
Chi-Square, χ2, p=0.224 and p=0.45 respectively). Overall, breast cancer was 
most frequently diagnosed as Stage 2 across ASCL2 unaltered and upregulated 
tumours. 
As breast cancer is a clinically and biologically heterogeneous disease, 
highlighting the possible genes involved and the underlying gene expression 
patterns of each subtype can provide a clearer portrait to guide clinical 
management. Therefore, the association of ASCL2 expression with intrinsic 
subtype and integrative cluster (10-subtype classification by Curtis, et al., (2012)) 
distribution was investigated.  
The greatest frequency of tumours with overexpressed ASCL2 were found to be 
classified as Luminal B or HER2 Positive (32.9% for each). Luminal A tumours 
represented 22% of samples with increased expression in ASCL2 mRNA, whilst 
the lowest frequency of tumours overexpressing ASCL2 (8.5%) was observed 
within the triple negative subtype (basal and claudin low) (Figure 5.1). The 
highest mean ASCL2 expression was seen in HER2 positive tumours (Figure 
5.1). Despite the large spread of data within each subtype (Figure 5.1 A), the 
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distribution of breast cancer subtypes appeared to be statistically different 
(p<0.001, χ2) between the three ASCL2 expression groups. 
 
  
 
 	
	147	
	
 
 
 
 
 
 
Figure 5.1. A. Boxplots showing the distribution of ASCL2 gene expression across the intrinsic subtypes. HER2+ cancers appear to exhibit 
the highest expression of ASCL2. B. A histogram showing the frequency of tumours at various expression levels. The majority of HER2+ 
samples were shifted to the right of the histogram, compared to the other subtypes exhibiting a skew towards the left of the histogram.  
N=679	
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Although the current diagnostic standard of classification is based on the PAM50 
intrinsic subtypes, Curtis, et al., (2012) previously proposed a new and more 
refined integrated classification of breast cancer, based on the combined analysis 
of genomic and transcriptomic information. This defined 10 distinct integrative 
clusters, with different genetic profiles and clinical courses.  
Figure 5.2 illustrates the distribution of ASCL2 gene expression across the 10 
integrative clusters, where it can be seen that cluster 5 exhibited the highest 
mean expression of ASCL2, as well as the greatest percentage of ASCL2 
overexpressing tumours compared to all other clusters (25.6%). Cluster 5 
represented tumours that were HER2 positive (can be ER-/+) with a poor 
prognosis, presenting early and of a higher grade according to (Dawson, et al., 
2013); this was also concordant with subtype data presented in Figure 5.1. 
Among tumours with an unaltered ASCL2 expression, cluster 8 was more 
common, representing 15.3% of cases; cluster 8 was characterised by a 1q gain, 
16q loss, the presence of hormone receptors, and were more likely to be low 
grade Luminal A tumours with a good prognosis. Consistent across all data was 
that the triple negative/basal phenotype was the least associated with ASCL2 
overexpression. The varying distributions of the integrative cluster classifications 
were shown to be statistically significant between expression groups (p=0.01, χ2). 
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Figure 5.2. Boxplots showing the distribution of ASCL2 gene expression across the 
integrative clusters. Clusters have been mapped to the most dominant PAM50 
intrinsic subtype.  n Luminal A  l Luminal B  u HER2 +  p TNBC/Basal  ª Mix 
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Analysis of receptor status highlighted that tumours overexpressing ASCL2 were 
more likely to be ER positive, HER2 negative, and PR negative (based on 
percentage distribution, Appendix 5). However, those that were HER2+ were 
more likely to be correlated with a higher gene expression of ASCL2, which is 
illustrated in Figure 5.3, by the upward shift of ASCL2 expression in the 
distribution of HER2+ tumours. Statistical analysis using a Pearson Chi-Square 
(χ2) test revealed that ER and PR receptor status did not show a significant 
difference between expression groups (p=0.838 and 0.222 respectively). In 
addition, logistic regression analysis was performed to model the relationship 
between ASCL2 expression and HER2 status. Results of this model indicated 
that ASCL2 expression was less associated with negative HER2 status (Odds 
Ratio [OR] = 0.546; 95% confidence interval [CI] = 0.5, to 0.6; p<0.001), indicating 
that ASCL2 expression is approximately 80% more likely to be associated with 
HER2+ tumours.  
  
Figure 5.3. Boxplots showing the distribution of ASCL2 gene expression between 
ER/HER2 positive and negative tumours. There is evidence to show that ASCL2 may 
correlate with HER2 positivity in breast tumours. 
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5.2.2	Analysis	of	ASCL2	as	an	indicator	of	survival	in	patients	
The impact of ASCL2 overexpression on overall patient survival within the entire 
METABRIC cohort was evaluated. Within the whole patient population in this 
study, there was one patient exhibiting a downregulated expression of ASCL2. 
This patient survived for approximately 59 months, which was roughly half the 
time of the rest the cohort (with unaltered or overexpressed ASCL2, Table 5.1). 
However, as this was an isolated case (n=1), it could not be considered as a true 
representation of survival linked to downregulated ASCL2 expression, and was 
therefore excluded from the majority of analyses.  
When evaluated alone, patients with tumours overexpressing ASCL2 had a lower 
mean survival (114.7 months) compared to tumours with unaltered ASCL2 
expression (125.5 months) (Appendix 5). Yet, no statistical significance was 
found to suggest that ASCL2 overexpression in tumours was associated with 
poorer overall survival in breast cancer, in comparison to tumours with unaltered 
ASCL2 expression (Hazard ratio [HR] = 1.12; 95% confidence interval [CI] = 0.9, 
to 1.4; p>0.05). The Kaplan-Meier plot in Figure 5.4 illustrates no significant 
difference in overall survival between tumours with unaltered and upregulated 
ASCL2 gene expression, determined by a log-rank test.  A one-way ANOVA (with 
Tukey post hoc multiple comparisons test) also indicated no significant difference 
(p=0.311, F=1.167) in overall survival between the 3 expression groups. 
However, there is a possibility that these findings could have been attributed to 
large differences between the size of each group (82 tumours overexpressing 
ASCL2 vs 1821 with unaltered expression).   
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Figure 5.4. Kaplan–Meier overall survival analysis comparing breast tumours with no 
alterations or overexpression in ASCL2 within the complete METABRIC cohort. No 
statistically significant difference was observed for overall survival based on ASCL2 
expression, calculated based on the Mantel-Cox log-rank test, and cox regression 
analysis (HR = 1.12; 95% CI = 0.9, to 1.4; p>0.05). Overall survival was defined as 
the time of diagnosis to the time of death.  
 
P=0.230  
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Next, the relationship between subtype (PAM50 intrinsic subtyping vs integrative 
clustering) and patient survival was explored. Firstly, it was determined whether 
ASCL2 overexpression affected overall survival, and therefore patient outcome, 
based on intrinsic subtype classification. Figure 5.5 illustrates the differences 
between overall survival trends in each subtype. Overall, the results revealed that 
there was no statistically significant impact of unaltered or increased ASCL2 
expression on survival across the subtypes, therefore no additional prognostic 
value was provided when subtype was considered (Table 5.3). However, among 
all subtypes, tumours with ASCL2 overexpression did appear to exhibit a 
decreased survival time.  
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Figure 5.5. Kaplan–Meier curves for 
overall survival comparing breast 
tumours with no alterations or 
overexpression in ASCL2 within the 
intrinsic subtypes A. Luminal A, B. 
Luminal B, C. HER2+, D. Basal. 
Overall survival for the claudin low 
subtype is not presented as none of 
these tumours exhibited an increased 
expression of ASCL2. No significant 
differences were observed for overall 
survival depending on ASCL2 
expression between the intrinsic 
subtypes. P values were calculated 
based on the Mantel-Cox log rank test.  
 
N=660 
N=18 
N=434 
N=27 
N=193 
N=27 
N=192 
N=7 
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With regards to the integrative clusters, although Kaplan-Meier curves illustrate 
that overexpression of ASCL2 was associated with overall survival in cases 
classified as cluster 4ER- (Figure 5.6A, p<0.05) and cluster 6 (Figure 5.6C, 
p<0.05), no significant association was exhibited using cox regression analysis 
(Table 5.3). Cluster 4ER- represents tumours which are ER negative and a 
mixture of the intrinsic subtypes, with low level of genomic instability and a 
favourable outcome. By contrast, cluster 6 tumours are considered aggressive 
ER positive/HER2 negative, Luminal A or B tumours with high genetic instability 
and an intermediate prognosis (Dawson, et al., 2013). However, in these two 
clusters, it was observed that the frequency of tumours with ASCL2 
overexpression were much smaller than the number of unaltered cases (cluster 
4ER -, no alteration, n=238 vs overexpressed, n=6; cluster 6, no alteration, n=81 
vs overexpressed, n=3). As the number of tumours overexpressing ASCL2 were 
so low, this is likely to be influencing the estimation of significance compared to 
the other clusters, and therefore calls into question the reliability of the Mantal-
Cox log rank test statistics here.   
Despite cluster 5 tumours presenting the majority of cases overexpressing 
ASCL2 and the highest mean ASCL2 expression, no significant association 
between ASCL2 and overall survival was found (Figure 5.6 B, Table 5.3). As 
previously mentioned, within tumours with an unaltered ASCL2 expression, the 
greatest frequency was classed as cluster 8. However, in this survival analysis, 
cluster 8 tumours with an increased ASCL2 expression appeared to exhibit an 
improved overall survival in this cluster (Figure 5.6 D), contrary to the other 
clusters; nonetheless, this estimation is statistically insignificant, and therefore, 
no significant association between ASCL2 and overall survival was found in 
cluster 8.
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Figure 5.6. Kaplan–Meier curves for 
overall survival comparing breast 
tumours with no alterations or 
overexpression in ASCL2 within the 
integrative clusters. A. Cluster 4ER-, B. 
Cluster 5, C. Cluster 6, D. Cluster 8. 
Overall survival for all intrinsic 
subtypes are not presented, however 
were analysed. No significant 
differences were observed for overall 
survival depending on ASCL2 
expression in cluster 5 despite being 
highlighted as the cluster most 
associated with ASCL2 
overexpression. P values were 
calculated based on the Mantel-Cox 
log rank test.  
N=238 
N=6 
N=163 
N=21 
N=81 
N=3 
N=279 
N=9 
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Finally, to evaluate the association of ASCL2 on overall survival, as a single factor 
in the context of clinicopathologic factors, or adjusted for clinicopathologic factors, 
cox regression analysis was used. This showed that when evaluated alone 
ASCL2 expression was not significantly associated with overall survival in breast 
cancer patients (univariate, HR = 1.04, 95% CI = 0.99, to 1.09; p>0.05), similarly 
to when adjusted for other clinical factors (multivariate, HR = 1.00, 95% CI = 0.94, 
to 1.08; p>0.05) (Table 5.3).   
Overall, these results show that there was no statistically significant relationship 
between ASCL2 expression and overall survival, and therefore no additional 
prognostic value is provided when considering ASCL2 expression in patients 
(Table 5.3).   
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	 Univariate	 Multivariate	
Factor	 HR,	95%	CI	 P	value	 HR,	95%	CI	 P	value	
ASCL2	Expression	 1.04	(0.99	–	1.09)	 0.11	 1.00	(0.94	-	1.08)	 0.878	
ASCL2	Expression	Group		
Unaltered	vs		
Upregulated	
1.12	(0.90	–	1.40)	 0.30	 0.97	(0.70	–	1.34)	 0.840	
Age	
≥60	vs	
	<	60	
	
1.09	(1.02	–	1.17)	
1.01	(0.95	–	1.07)	
	
0.02*	
0.80	
1.36	(1.21	–	1.52)	 0.001*	
ER	Status	
positive	vs		
negative	
	
1.05	(0.99	–	1.10)	
0.95	(0.86	–	1.06)	
	
0.11	
0.36	
0.78	(0.62	–	0.99)	 0.038*	
PR	Status	
positive	vs		
negative	
	
1.00	(0.93	–	1.07)	
1.04	(0.98	–	1.11)	
	
0.99	
0.23	
0.94	(0.81	–	1.08)	 0.342	
HER2	Status	
positive	vs		
negative	
	
1.04	(0.92	–	1.17)	
1.01	(0.96	–	1.07)	
	
0.57	
0.61	
1.13	(0.85	–	1.50)	 0.410	
PAM	50	Subtype	
Luminal	A	
Luminal	B	
HER2	+	
Basal	
Claudin-Low	
Normal-like	
	
1.04	(0.95	–	1.13)	
1.05	(0.97	–	1.14)	
1.04	(0.91	–	1.18)	
0.91	(0.78	–	1.07)	
0.94	(0.77	–	1.16)	
1.05	(0.88	–	1.27)	
	
0.41	
0.26	
0.56	
0.25	
0.59	
0.57	
	
1.00	
1.05	(0.89	–	1.23)	
0.80	(0.62	–	1.04)	
1.00	(0.74	–	1.33)	
1.01	(0.79	–	1.29)	
1.22	(0.96	–	1.54)	
0.16	
-	
0.58	
0.10	
0.97	
0.94	
0.10	
Integrative	Cluster	
1	
2	
3	
4ER-	
4ER+	
5	
6	
7	
8	
9	
10	
	
1.07	(0.91	–	1.26)	
0.89	(0.69	–	1.15)	
1.11	(0.96	–	1.28)	
0.99	(0.77	–	1.27)	
1.09	(0.94	–	1.25)	
1.07	(0.94	–	1.22)	
1.28	(1.01	–	1.63)	
0.97	(0.82	–	1.15)	
0.89	(0.79	–	1.00)	
1.05	(0.90	–	1.21)	
0.86	(0.73	–	1.02)	
	
0.40	
0.36	
0.17	
0.93	
0.26	
0.32	
0.04*	
0.75	
0.06	
0.56	
0.08	
	
1.00	
1.09	(0.78	-.	1.52)	
0.91	(0.70	–	1.20)	
0.91	(0.69	–	1.20)	
0.87	(0.59	–	1.29)	
1.34	(0.93	–	1.93)	
0.95	(0.69	–	1.33)	
0.92	(0.69	–	1.23)	
0.91	(0.69	–	1.19)	
1.08	(0.80	–	1.46)	
0.75	(0.55	–	1.02)	
0.25	
-	
0.63	
0.52	
0.51	
0.49	
0.11	
0.78	
0.59	
0.48	
0.61	
0.07	
Grade	
1	
2	
3	
4	
	
0.96	(0.82	–	1.14)	
1.05	(0.97	–	1.13)	
1.03	(0/96	–	1.10)	
-	
	
0.65	
0.28	
0.42	
-	
	
1.00	
0.98	(0.80	–	1.21)	
0.97	(0.77	–	1.21)	
-	
0.94	
-	
0.88	
0.75	
-	
Stage	
0	
1	
2	
3	
4	
	
0.75	(0.32	–	1.76)	
1.06	(0.96	–	1.17)	
0.97	(0.91	–	1.05)	
1.05	(0.89	–	1.24)	
2.0	(0.78	–	5.01)	
	
0.51	
0.26	
0.48	
0.59	
0.15	
	
1.00	
0.88	(0.12	–	6.37)	
1.27	(0.17	–	9.22)	
1.97	(0.27	–	14.5)	
3.22	(0.40	–	26.1)		
-	
-	
0.90	
0.82	
0.51	
0.27	
Table 5.3. Hazard ratio univariate and multivariate cox regression analysis of the 
relationship between ASCL2 expression and overall survival in patients of the 
METABRIC study. Statistical significance was calculated using the Cox proportional 
hazards regression test.  
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5.3	Discussion	
The results in this chapter suggest that when analysed as a single entity in patient 
tumour samples, higher ASCL2 expression was most associated with HER2+ 
tumours in breast cancer. However, no statistically significant findings suggested 
that ASCL2 overexpression was associated with poorer patient survival in breast 
cancer, when analysed in the whole study population or in the context of other 
clinical features. Therefore, this gene cannot be considered a prognostic marker. 
Results from primary tumour samples indicated that increased expression of 
ASCL2 had a significant correlation with HER2 receptor expression in breast 
cancer (Figures 5.1, 5.2, 5.3). However, this did not exclude tumours with 
upregulated ASCL2 primarily expressing hormone receptors (ER/PR) or of 
Luminal A or B subtypes. Overall, HER2+ tumours appeared to be more likely to 
aberrantly overexpress ASCL2 compared to other tumour subtypes. In addition 
to this, approximately a quarter of all tumours with upregulated ASCL2 were 
classified into integrative cluster 5 associated with HER2+ tumours (whereas all 
other tumours with increased ASCL2 expression were equally distributed among 
the remaining clusters). Although many drugs have emerged in the last decade 
that target HER2, these have been met with challenges including acquired 
resistance (Vu, & Claret, 2012). Hence, exploring the relationship between 
ASCL2 and HER2+ tumours further may shed light on possible mechanisms that 
lead to resistance, to improve patient response to these drugs. Although this 
remains a tenuous link, it may be an avenue worth pursuing. Tumours with 
unaltered expression were mainly associated with cluster 8 (15%), however 
distribution is more equal among clusters, and conversely do not show a strong 
affinity with one cluster in particular.  
To assess the impact of ASCL2 on patient outcomes and as a possible prognostic 
marker, overall survival was examined. Xu, et al., (2017) investigated the clinical 
relevance of ASCL2 in breast cancer by examining specimens from 191 breast 
cancer cases using immunohistochemical staining. The study concluded that 
higher levels of ASCL2 correlated with poorer overall survival, greater tumour 
recurrence and relapse in patients.  
In the present study, overall, patients with tumours overexpressing ASCL2 
survived for approximately 11 months less, which, in clinical terms, could be 
	160	
	
considered critical. However, statistical analysis indicated otherwise, concluding 
that there was little to no evidence to show that ASCL2 expression was 
associated with patient survival. Though, consistent with the literature, ASCL2 
expression did not affect overall survival based on the breast cancer intrinsic 
subtypes. 
Although the study by Xu, et al., (2017) presented significant survival trends 
relating to ASCL2 expression, their study focussed on protein expression scored 
semi-quantitatively into high and low groups, whereas the present study relied on 
quantitative gene expression data (with an objective, numerical threshold value), 
a larger sample size, and also included an ‘unaltered ASCL2’ group of patients. 
Therefore, it could be assumed that the classification of ASCL2 overexpression 
had a higher and more stringent cut off in the present study. In addition, it could 
be argued that the present study, inclusive of almost 2000 patients, is more 
robust than the study by Xu, et al., (2017) focussing on just under 200 samples. 
However, the findings in this chapter neither support nor reject the work carried 
out by Xu, et al., (2017) due to the differences in study design.  
Nevertheless, with the previous study in mind, to strengthen and expand the 
estimation of the prognostic significance of ASCL2, future work may include 
investigation into tumour recurrence, or disease-specific survival (distinguishing 
patients dying from breast cancer specifically, in comparison to other possible 
causes); this data was not available from the METABRIC dataset. Further 
exploration of this hypothesis could include more datasets such as those from 
The Cancer Genome Atlas (TCGA), available from the cBioPortal, which did 
follow-up on tumour relapse.   
Upon analysing the results obtained from the METABRIC study, there was a 
slight discrepancy in the data mining of primary tumours compared to the data 
mining of cell lines (Chapter 3) and in vitro laboratory work (Chapter 4). Extreme 
variation analysis presented in Chapter 3 pointed to the highest ASCL2 
expression in MCF7 cells. Likewise, RT-qPCR gene expression analysis 
revealed the highest ASCL2 expression in MCF7 and T47D cells (Luminal A), 
and SKBR3 cells (HER2+) respectively, with low expression in BT474 cells 
(Luminal B). Functional analysis also highlighted a potential role of ASCL2 in the 
migration of Luminal A cells, yet no impact was observed in HER2+ cells. 
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Therefore, it was considered that ASCL2 expression was the most associated 
with Luminal A tumours.  
Yet, analysis of clinical cases revealed the strongest correlation (according to 
distribution) with HER2+ tumours and Luminal B tumours. Nevertheless, there 
was evidence supporting the association with Luminal A tumours; ASCL2 was 
overexpressed in 22% of these tumours and approximately three quarters of 
tumours with ASCL2 expression were ER positive. Additionally, analysis of 
receptor status highlighted that tumours overexpressing ASCL2 were more likely 
to be ER positive, HER2 negative, and PR negative (based on percentage 
distribution). From this perspective, data was consistent with the MCF7 cell line 
used for ASCL2 investigation in Chapter 4. However, considering the variability 
in trends observed between cell lines and patient tumour data in this study, it 
remains uncertain whether overexpression of ASCL2 is correlated with HER2 
positivity. Hence, further analysis of the relationship between ASCL2 and HER2 
positivity is required to confirm this. Overall, the possibility that ASCL2 
overexpression may result in susceptibility to a specific breast cancer subtype 
was not entirely confirmed in this study.  
Though the methodology used in this chapter was beneficial within the scope of 
this project, the shortfall with this type of analysis was that it investigated the 
overexpression of ASCL2 as an isolated event in cancer. Cancer is an extremely 
complex and multifaceted process, yet this analysis reduced the complex nature 
of cancer down to a single gene relating to patient survival. The magnitude of the 
impact of ASCL2 overexpression as a single entity is likely to be minute in 
comparison to the expression of the entire genome (Prat, et al., 2014). However, 
it is completely plausible to consider that ASCL2 could be one part of a larger 
puzzle influencing survival; therefore, ASCL2 could be investigated as part of a 
multi gene signature. As of yet, the mechanistic role of this gene in breast cancer 
remains to be discovered, so pinpointing other genes to investigate alongside 
ASCL2 would be the first step to achieving this. It must also be noted that the 
absence of a statistically significant trend between ASCL2 expression and patient 
survival should not be considered as the only marker of clinical outcome. For 
example, ASCL2 may be a contributor to other measures such as therapy 
resistance, or the spread of secondary tumours. Likewise, the predictive potential 
of ASCL2 on these variables could be further explored in the future.  
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Of particular note when analysing the data presented in this chapter was the large 
variation, diversity and spread of data from patient tumours. An explanation for 
this may have been due to the inter-tumour heterogeneity seen between clinical 
breast tumours, compared with in vitro cell culture, which generally consists of a 
uniform cell population (Sun, & Yu, 2015). A further complication of data 
collection and analysis in patients is the genetic and epigenetic heterogeneity 
reported in different parts of the same tumour; oncologists tend to rely on the 
molecular characterisation of a small sample of tumour tissue, which is unlikely 
to represent the true heterogeneity seen within and between patients (Bedard, et 
al., 2013; Zardavas, et al., 2015). This has been observed in many multi-omic 
and single-cell transcriptome profiling studies (Bareche, et al., 2018; Bedard, et 
al., 2013; Chung, et al., 2017).  The heterogeneity observed between the samples 
of this dataset exemplify the challenging nature of gene investigation that 
researchers are attempting to navigate and overcome.  
Despite the use of cell lines being scrutinised over the years, mainly due to their 
questionable representation of tumour biology in situ, and their translatability of 
research findings into the clinic (Choi, et al., 2014), their use in this study was 
warranted. Firstly, because on the whole, laboratory findings have been 
consistent with cell line gene expression data from Array Express and Gene 
Expression Omnibus (GEO) (Chapter 3); additionally, the Human Protein Atlas 
also verified expression of ASCL2 in MCF7, T47D and SKBR3 cells. Secondly, 
the clinical data mining component of this study complements laboratory 
evidence, by taking into account the tumour biology of primary tumours and the 
effect of ASCL2 on clinical parameters in patients. These results can also be used 
to direct the trajectory of further study in the future. Although cell line models are 
not ideal, they are a good pre-clinical model and basis for initial candidate gene 
investigation; ultimately, using cell lines can inform researchers about tumour 
biology prior to investigation using more advanced models (Gillet, et al., 2013; 
Katt, et al., 2016). 
Although clinical investigation added to the breadth of this study, there were 
drawbacks to this analysis which need to be addressed in the future to strengthen 
conclusions. The issue with small sample size is of high priority here. Despite 
2509 patient samples downloaded from the METABRIC study, not all samples 
had full clinical information provided, and therefore not all samples were able to 
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be analysed. This led to missing information that needed to be culled prior to 
statistical analysis. As well as this, owing to the low prevalence of ASCL2 
overexpressing tumours within the METABRIC cohort (3.3%, representing 82 
tumours), a small sample size for such a varied population meant that some 
parameters or ‘events’ could only be measured at very low frequencies. This 
broad spread of data, divided into smaller unbalanced subsets (for example, 
Table 5.1, 18 Luminal A tumours overexpressing ASCL2 vs 660 Luminal A 
tumours with no alteration in ASCL2 expression), complicated statistical analysis 
and may have resulted in a bias towards statistical insignificance (Block, et al., 
2018; Ogden, et al., 2017). Small sample sizes do not have the power to detect 
subtle gene expression changes, and are in essence only applicable when 
expression changes are large (Biau, et al., 2008; van Iterson, et al., 2009). 
Therefore, a greater sample size of tumours overexpressing ASCL2 would lead 
to more reliable conclusions. To target this shortcoming, further data could be 
downloaded from other studies to compile a larger dataset from multiple sources, 
thus integrating ASCL2 gene expression data and clinical information from a 
greater number of primary tumours, rather than from a single dataset (Prat, et al., 
2014). Although caution must be taken to account for differences between study 
designs, this may represent a more relevant approach to investigating the clinical 
impact of ASCL2 in patient tumours.  
Another improvement to further develop this study, could focus on sourcing a 
dataset which includes information on modifiable (age, family history) and non-
modifiable (BMI, childbirths) factors in patients, as well as clinicopathologic 
features of tumours. In the same vein, the results from this dataset may have 
benefitted from the inclusion of factors such as menopausal state, allowing for 
the adjustment of data by other risk factors, potentially improving the estimation 
of ASCL2 as a prognostic indicator. Statistical analysis could also be elaborated 
by the inclusion of power analysis, for the determination of the appropriate 
sample size.  
The cBioPortal web tool was used to access METABRIC data, and was selected 
as it allowed the refined analysis of a single gene (or a select group of genes) 
within a large-scale cancer dataset (Zhang, et al., 2018). This tool was also open-
access, allowing the use of existing public data, as well as being suitable for use 
by researchers at any level, even those with little knowledge in bioinformatics. 
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These factors were in-line with themes discussed in Chapter 3 regarding the 
accessibility and usability of bioinformatics tools to enhance research (Zhang, et 
al., 2018).   
To conclude this chapter, it must be noted that identifying clinically relevant, 
specific and robust markers that translate from the laboratory to the clinic is a 
prominent and pertinent challenge for researchers. Overall, the present study 
was well performed, indicating no statistically significant evidence to support the 
role of ASCL2 as a clinical marker in patient tumours; the hypothesis that higher 
ASCL2 expression may be related to poorer survival in patients was not 
supported by the data presented in this study. However, likely causes influencing 
these findings may be heterogeneity between patient tumours, and the low 
prevalence of elevated ASCL2 expression, therefore further analysis will be 
important for the confirmation of this data. The widespread and varied expression 
of ASCL2 across the subtypes also discounts the possibility of aberrant 
expression being subtype-specific, yet does suggest that this gene may play a 
more fundamental role during tumour development; a view also expressed by Xu, 
et al., (2017). Consistent across all data in this Chapter was that the triple 
negative/basal phenotype was the least associated with ASCL2 overexpression. 
Therefore, even considering the limitations discussed, the work presented in this 
Chapter has contributed to the knowledge of ASCL2 in breast cancer, concluding 
that this gene is not associated with survival.  
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6.1	Overall	Discussion	
Research directed towards improved understanding, identification of novel 
markers and stratification of the complex heterogeneity of breast cancer has led 
to increased patient survival over the past decade; as of 2014, almost 90% of 
patients survived for 5 years or more (National Cancer Institute, 2018). The 
research outlined in this thesis aimed to use an integrated approach to identify a 
novel candidate gene in breast cancer, and investigate its biological function and 
potential as a clinical marker.  
This research provides novel evidence that ASCL2 may be involved in breast 
tumourigenesis by way of influencing cellular migration via the Wnt signalling 
pathway. The evidence gathered in Chapters 3 and 4 employing bioinformatics 
and RT-qPCR, demonstrated the differential expression of ASCL2 across varying 
breast cancer cell lines. Notably ASCL2 expression levels were significantly 
increased in MCF7 cells compared to non-tumourigeneic cells (MCF10A). In 
addition to this, it was proposed that ASCL2 knockdown may have had an anti-
migratory effect in Luminal A cell lines; further supporting this was the enrichment 
of GO terms relating to the regulation of cell migration and motility, wound 
healing, morphogenesis and EMT in breast cancer cell lines (DAVID and GO 
analysis, Chapter 3). Data described also exhibited the reduced expression of 
Wnt signalling associated genes as a result of ASCL2 silencing, in particular, the 
stemness marker genes CD44 and LGR5, and CTNNB1 (β-catenin) suggesting 
that ASCL2 is an upstream regulator of these Wnt pathway genes. This inhibition 
of migration resulting from ASCL2 silencing could be considered as an effect of 
the downregulation of Wnt signalling in breast cancer, however further 
confirmation is needed. Together with previous studies in colon cancer (Tanaka, 
et al., 2019), these findings indicate that the Wnt/ASCL2 pathway may harbour 
key targets for the management of the Wnt pathway in cancer.  
Within a broader context, it could be inferred from this primary analysis that 
ASCL2 may be an oncogene contributing to the migratory and invasive properties 
of certain breast cancer cells and cancer stem cells that push progression 
through the EMT. The EMT is a fundamental biological process within 
embryogenesis, development and wound-healing, yet is also considered a 
malignant driver (Chaffer, et al., 2016). Likewise, ASCL2 has been established 
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as a developmental gene within neurogenesis and embryogenesis (García-
Bellido, & de Celis, 2009; Guillemot, et al., 1994; Oh-McGinnis, et al., 2011). In 
intestinal stem cells it has been shown that ASCL2 correlates directly with LGR5 
expression to regulate stemness (van der Flier, et al., 2009; Yan, et al., 2015). 
Giakountis, et al., 2016 and Schuijers, et al., 2015 also demonstrated that 
alongside TCF4/β-catenin, ASCL2 can activate stem cell gene expression 
programmes in intestinal stem cells through an auto-regulatory positive feedback 
loop involving Wnt signalling in colon cancer. Evidence in colon cancer also 
suggests a role of ASCL2 in EMT (Tian, et al., 2014). Therefore, it could be 
hypothesised that the overexpression of this gene may act in a similar way to 
activate transcriptional programmes in breast cancer, and possibly more 
specifically in breast cancer stem cells (Smith, et al., 2017). Overall, this may 
result in tumour initiation and progression, by over activity of the EMT program, 
modulation of plasticity, increased cell migration, and activation of further 
downstream oncogenic genes within the Wnt pathway (Schuijers, et al., 2015; 
Tian, et al., 2014; Zuo, et al., 2018). Although the relevance of ASCL2 to breast 
cancer stem cells is yet to be established, this study highlights an area requiring 
further attention.  
The work undertaken in Chapter 5 looked to evaluate the expression of ASCL2 
as a potential prognostic indicator and clinical marker. Considering the previously 
observed effects on cellular migration in MCF7 and T47D cells (Chapter 4), one 
might have expected to have seen a correlation between high ASCL2 expression 
and more aggressive tumours in patients (for example, earlier age of onset, 
advanced stage and grade, poorer survival), particularly within Luminal A 
tumours. However, patient data had a largely varied distribution, and no 
significant association between ASCL2 and survival outcomes were identified. 
Thus, the exact impact of ASCL2 on clinicopathologic features remains to be 
elucidated, and this study concluded that ASCL2 cannot be said to be associated 
with patient survival. Though, the variation observed in this clinical data acted to 
highlight the multifaceted complexity and diversity of tumourigenesis within 
patients, as well as the inter-tumour heterogeneity between patients within a 
population (Bedard, et al., 2013).  
Although previous reports have documented ASCL2 as a potential prognostic 
indicator in other cancers (Hu, et al., 2015; Liu, et al., 2016; Xu, et al., 2017), the 
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results from this study suggests that this relationship may be more complex in 
breast cancer. This work suggests that ASCL2 may play more of a core role in 
breast tumourigenesis that encompasses and underpins a variety of tumours, 
rather than a specific role attributed to a single subtype. In this sense, it seems 
unlikely that ASCL2 could be considered as a specific molecular marker, but may 
be investigated as part of a predictive signature or multi-gene test in the future. 
For example, the Oncotype DX Breast Cancer Assay uses RT-qPCR to quantify 
gene expression of a 21-gene panel, for the estimation of overall survival, 
recurrence risk and response to chemotherapy (Cronin, et al., 2007; Harbeck, et 
al., 2014). Moreover, while a minority of breast cancers may be attributed to a 
single specific genetic aberration, most cases are triggered by a combination of 
genetic alterations. Complex diseases like cancer are caused by multiple genes 
that are dysregulated at different points of disease development, resulting in the 
presentation of diverse symptoms and different responses to treatment. 
Across the literature, ASCL2 is involved in a number of developmental processes, 
and has been implicated in some cancers. However its role remains varied and 
occasionally conflicting between tissues, species, and pathologies (Wang, et al., 
2017; Zhongfeng, et al., 2018). This gene has essential roles in trophoblast 
development within the placenta (Bogutz, et al., 2018), epidermal development 
(Moriyama, et al., 2008), maintaining stemness of intestinal stem cells, follicular 
T-helper cell development (Liu, et al., 2014), as an inhibitor of myogenic 
differentiation (Wang, et al., 2017), and as a negative regulator of Schwann cell 
proliferation (Küry, et al., 2002). These examples appear to be reflective of the 
complexity of ASCL2, suggesting both a microenvironment and tissue dependent 
function (Zhongfeng, et al., 2018).  
Within the context of breast cancer, evidence presented in this work and from the 
literature discussed throughout may lead to the future investigation of ASCL2 as 
an ‘accessory driver’, or an epidriver. Currently, no driver mutations have been 
identified in ASCL2, thus it cannot be considered as a driver gene (affirmed by 
the COSMIC database, v87 – www.cancer.sanger.ac.uk). Yet, it is plausible to 
suggest that ASCL2 may have an epistatic effect with varying potency on a 
number of other genes, including driver genes, thus investigation into mutual 
exclusive interactions and genetic co-occurrence could yield significant results. 
An example of an epistatic interaction is the synthetic lethality between BRCA 
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mutations and PARP inhibition. This knowledge is now used in clinical practice 
for breast cancer treatment utilising PARP inhibitors (Gonzalez, et al., 2016; Park, 
& Lehner, 2015). A growing body of evidence suggests that ASCL2 contributes 
to tumourigenesis in a number of cancer types, and has been identified as a 
causative gene in colorectal cancer involved in therapeutic resistance (Tanaka, 
et al., 2019). Although the link between ASCL2 and therapeutic efficacy is yet to 
be examined in breast cancer, this represents an attractive area for further 
research. 
In addition to the research centred on ASCL2, a simple analysis pipeline was 
presented in this thesis that is practical for use on its own, or may be flexibly 
adapted to suit the needs or expertise of the researcher. The advent of rapidly 
evolving omics technologies have given rise to an exponentially growing amount 
of biological data. Studies exploiting these technologies generally use extremely 
convoluted computational workflows, which although lead to the discovery of 
novel and interesting genes, yield little functional knowledge. This pipeline has 
demonstrated that gene inquiry can be kept modest without diminishing 
comprehension. A common value presently held by scientists, is the sharing of 
data and accessibility of tools. Thus, this study prioritised the use of open 
databases for the extraction of freely available transcriptomic cell line and patient 
data for gene investigation.  
The merit of this type of study was the integrated approach consisting of a variety 
of bioinformatics methods for gene identification, laboratory analysis for 
functional investigation, and data mining of patient samples, aiming to bridge the 
gap between laboratory research and clinical application. The study design and 
methods utilised within this project also allowed for the broad investigation of a 
single gene which had been largely overlooked in breast cancer in the past. It is 
anticipated that this study may provoke future research in ASCL2.  
Another strength of this study was the multiple levels of validation. Despite their 
assets, microarray studies are prone to issues relating to reproducibility due to 
the large number of gene probes in comparison to small samples sizes. 
Therefore, combining multiple studies can increase reliability and achieve greater 
precision when estimating differential gene expression (Ramasamy, et al., 2008). 
In this work, microarray data from cell lines were pooled from a number of studies 
to address this. In addition, various pathway tools were compared and combined 
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to allow for comprehensive identification of a candidate gene with oncogenic 
potential. This data was subsequently validated in cell lines and the role of this 
gene was explored in vitro. Finally, a large cohort of patient data was also 
obtained to explore the association of this gene on clinical outcomes in patient 
tumours.  
The in vitro component of this study relied on the growth and maintenance of 
well-established breast cancer cell lines (Lacroix, & Leclercq, 2004). However, it 
is widely acknowledged that cell lines are prone to a number of limitations 
compared to other experimental cancer models, such as primary cell lines, 
patient derived tissue, or animal models. Such limitations include genetic and 
phenotypic drift over passages, the absence of a tumour microenvironment, and 
the lack of biological heterogeneity in comparison to patient tumours (Holliday, & 
Speirs, 2011). Yet, the use of a cell line model was practical for such initial 
investigation, due to their convenience, control over experimental variables, and 
ability to directly compare between experiments and replicates (Burdall, et al., 
2003). This research may be expanded using other tumour models, to uncover a 
greater breadth of knowledge regarding ASCL2 in breast cancer.    
As discussed throughout this thesis, a significant challenge within the area of 
gene investigation and marker identification for the implementation of 
personalised medicine and diagnostics, is tumour heterogeneity. Interpatient 
tumour heterogeneity has been acknowledged for some time, resulting in the 
employment of the intrinsic subtype classification system in the clinic. More 
recently, the issue of intra-tumour heterogeneity has been recognised, meaning 
that the predictive biomarkers present in a tumour may be different depending on 
location, and could be prone to change during progression or metastasis (Bedard, 
et al., 2013). Evidence has also shown that breast cancer cells may exhibit 
subtype plasticity by exhibiting the ability to interconvert between subtypes (Yeo, 
& Guan, 2017). However, despite this challenge, huge strides in progress have 
been made over the last 10 years by fully exploiting omics technologies and 
harnessing the growing amount of biological data already available. This is 
reflected in the growing number of women surviving beyond 5 years (National 
Cancer Institute, 2018).  
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6.2	Recommendations	for	Future	Work	
The work presented in this thesis has identified some interesting, yet somewhat 
overlooked, implications in breast cancer, but also highlights a number of 
opportunities for further research. This work has shed light on ASCL2 as a novel 
gene involved in breast carcinogenesis, however some findings and proposed 
mechanisms in this study require additional confirmation and research which 
could be executed in a number of ways.  
To improve on the work detailed in this thesis, it would first be beneficial to 
optimise the consistency of gene knockdown, by performing permanent 
knockdowns via the use of lentiviral construction to improve ‘loss of function’ 
experiments (Boettcher, & McManus, 2015). This could be done by using stable 
expression of short hairpin RNA (shRNA) or the CRISPR/Cas9 system; the 
effects of shRNA transfection are more prolonged than the use of siRNA, 
whereas CRISPR generally yields a more stable, consistent and robust 
knockdown or knockout demonstrating a stronger effect on phenotypes 
(Boettcher, & McManus, 2015).  Both of these techniques may also yield 
validation of a consistent protein knockdown. In addition to this, the study of 
apoptosis and wound-healing in Chapter 4 could be improved to strengthen 
conclusions; flow cytometry and silicon gap inserts along with automated time-
lapse recording equipment could address these issues respectively. Lastly, data 
from other breast cancer studies could be pooled with METABRIC data to 
increase the sample size of tumours with ASCL2 overexpression. As mentioned 
in the previous section, future work including more biologically relevant tumour 
models, such as in vivo models or 3D cell culture (Chen, et al., 2012), would also 
be essential to combat the limitations associated with cell lines. 
To expand on the work detailed in this thesis, the mechanism that leads to the 
overexpression of ASCL2 in MCF7 cells could be investigated. It has been 
previously reported in other cancers that ASCL2 may be epigenetically regulated 
by DNA methylation, the action of miRNAs and the long non-coding RNA, 
WiNTRLINC1 (Conway, et al., 2014; Giakountis, et al., 2016; Tian, et al., 2014; 
Zhu, et al., 2012). Therefore, it may be interesting to pursue this further and 
explore this prospect in vitro in breast cancer. A small number of studies have 
also shown that ASCL2 is involved in therapeutic resistance in colon cancer and 
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postulated its role as a chemoresistance biomarker (Juarez, et al., 2018; Kwon, 
et al., 2013; Tanaka, et al., 2019). With this in mind, it would be worth studying 
this relationship in breast cancer, potentially by assessing the effects of ASCL2 
expression on common chemotherapeutic agents used in the treatment of breast 
cancer, or even the endocrine therapy, tamoxifen, for treatment of Luminal A 
tumours. This could also be expanded to include the monoclonal antibody, 
trastuzumab, targeting the HER2 receptor, as resistance to this drug remains a 
common challenge (Esteva, et al., 2010; Vu, & Claret, 2012). A final consideration 
would be the eventual use of tissue microarrays to assess ASCL2 protein 
expression changes in correspondence with clinical parameters in a high-
throughput manner. 
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6.3	Conclusions	
Identifying and pursuing critical associations within the complex system that is 
breast cancer remains a considerable challenge for researchers. At the time of 
writing this thesis, a PubMed search of ASCL2 returned 171 published studies 
(March 2019). Searching the keywords “ASCL2 cancer” returned 70 results, while 
“ASCL2 breast cancer” revealed 6 results. By comparison, searching “HER2 
breast cancer” gave 17,354 results. This exemplifies how little is known about the 
ASCL2 gene in relation to breast cancer, and highlights a research niche that 
requires attention.  
This project has succeeded in its intentions, yet has also acknowledged a number 
of technical and field-related challenges throughout. Namely, the variability and 
complexity of bioinformatics analysis, the difficulties associated with gene 
investigation, and the vast heterogeneity observed in breast cancer. Ultimately, 
the work presented in this thesis, being the first comprehensive and integrated 
study to examine ASCL2 in breast cancer, has contributed to the understanding 
of the multifaceted function and role of ASCL2 in breast tumourigenesis. This 
study has brought to the forefront the potential of ASCL2 as a novel gene involved 
in breast cancer development, whilst highlighting a number of avenues for further 
research.  
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Appendix	I	–	Candidate	Gene	Lists	Derived	from	Individual	
Pathway	Analysis	Tools	 	
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Appendix	II	–	Optimisation	of	siRNA	Knockdown	of	ASCL2	
 
Experiment & Action Troubleshooting Conditions Notes 
Used positive control (HPRT) to 
determine best siRNA dosage 
 
Fluorescence (TYE 563) used to 
check efficiency prior to qPCR 
10nM, 1nM, 0.1nM HPRT 
& with corresponding 
Dharmafect (DF) 
 
3x104 cells per well (24 
well plate) 
Fluorescence observed 
 
Highest knockdown was at 10nm, 
however poor efficiency (45%) 
Tested a higher DF 
concentration 
10nM siRNA + 25nM DF 
10nM siRNA + 10nM DF 
 
3x104 cells per well (24 
well) 
Fluorescence observed 
 
Knockdown improved with higher 
concentration of transfection reagent 
(DF), however poor efficiency 
Checked effect of cell density on 
knockdown efficiency  
10nM siRNA/25nM DF  
 
3, 4, & 5 x104 per well (24 
well) 
Fluorescence observed 
 
No knockdown 
New transfection reagent tested 
(Lipofectamine RNAiMAX) 
 
Increased cell density to account 
for high volume of cells dying 
during transfection 
10pmol siRNA  + 1.5µl 
Lipofectamine 
 
Tested against  
10nM siRNA + 10nM DF 
 
2x105 cells per well (24 
well) 
Fluorescence observed 
 
Inconclusive results - RNA 
concentration was too poor.   
 
Cells were aggregating in the centre 
of the well and were not growing or 
adhering evenly. Cells had almost all 
detached 48 hours after transfection. 
Larger wells (6 well plate) to see 
if greater RNA would enhance 
qPCR estimation  
30pmol siRNA + 9µl 
Lipofectamine  
 
 
1x106 cells per well 
 
Fluorescence observed 
 
RNA purity was extremely poor for 
the HPRT transfected sample. This 
housekeeping gene is crucial for cell 
development, and therefore affecting 
ability of cells to stay alive. Therefore, 
ASCL2 will be tested, before 
considering a new kit. 
Checked individual ASCL2 
siRNA oligonucleotides 
10pmol HPRT, ASCL2  + 
1.5 ul Lipofectamine  
 
Fluorescence observed 
 
Inconclusive knockdown 
RNA purity poor – this needed to be 
addressed 
Attempted reverse transfection  
 
10pmol HPRT, ASCL2  + 
1.5 ul Lipofectamine 
 
Fluorescence could not be observed 
as cells had died 
 
Reverse transfection was not 
effective, therefore reverted back to 
original transfection. 
Pooled 3xASCL2 oligos 
Seeded more cells and care 
taken to ensure cells seeded 
equally – 5x104 
 
New RNA Microprp kit was used 
and cells were scraped from 
wells 
10nM HPRT and pooled 
ASCL2 (x3 oligos) + 1.5 ul 
Lipofectamine 
 
Fluorescence observed 
 
Sufficient knockdown was measured. 
~70% 
 
Cells had grown evenly and RNA 
purity was good. The Microprep kit 
was used for the proceeding 
experiments and care was taken to 
seed cells evenly going forward 
Extracted 24hrs post 
transfection (rather than 48hrs) 
to minimise amount of cells 
detaching 
 
10nM HPRT and pooled 
ASCL2 (x3 oligos) + 1.5 ul 
Lipofectamine 
 
Fluorescence observed 
 
Knockdown successful >70% 
 
Transfection time of 24hrs was used 
for proceeding experiments 
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Appendix	III	–	Sanger	Sequencing	of	ASCL2	&	siRNA	sequences	
	
GATC LightRun Sanger Sequencing 
Chromatogram confirming the sequence of primers and PCR products as ASCL2. 
The forward and reverse primers are shown.  
 
 
 
 
 
 
PCR Analysis 
Varied gene expression of ASCL2 across breast cancer cell lines, demonstrated 
by PCR analysis. This was also used to demonstrate sample integrity, using a 
reference gene, RPII as a control. 	  
Forward            
	
	
	
	
Reverse 
M
CF
10
a 
M
CF
7 
BT
47
4 
M
DA
-M
B-
23
1 
SK
BR
3 
T4
7D
 
	 
ASCL2 
	 
	
RPII 
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Gene sequence of ASCL2 with siRNA sequences highlighted 
 
Sequence from Ensembl (www.ensembl.org)  
 
 
CAGACCTCCAGGCCCTCCGGGTTAAGGTGCCGCCCAGAGCCCTCAGGCCGGGGGCGCACGGAAACCACAGGCAG
GGTGCGCGTGGAGGGACGGGGAAAGCGGGGCGGGTTGGGGAAGGCGCCCCGGGAACCTGAACCTCCCACCCCGC
CTCAGTCTCGACCACTCCTTAAGCCCCACCCCGCCCCAGGTAAGGCGCAGTCCACCCCCATTCCCAGTAGATTA
ACGCACAGGTGGGGGCGCGCTCGGGACATAGCTGCGCTAGGGGACAGCGCGCCCAGCCCAGTCGCGGGGGCGAG
GAGCAGGGCGGGGCCCAGCAGGAACCCAGCTTTGTTAGCGATGCTCCCCGTGAGCCACGCGCCACGCGTACGCG
CTTCCTCAATGGGGCCGGGCGTGGAGCCGCGCCCTGCGCGATTGGCCAAACGGGTGGCCCACGATTGGCTGAGA
CCCTGGCCCCCGCCTCCTCGGCCCCAGGAGGGTGGGGCGTGGGTGTGGGCTGCGCGGCGCGTGCTGCCCCCGGG
GATCTTGCGCGCCTCCCGAACAGCCGTGTTGTCGCCAGGGCCGCGCCTTCCCTCCCACAGCGCGCGCTGCGCGT
GCGAAGGT 
 
EXON 1 
CTGGCGGCTCTTGGGACTGGCGGGGCTGCGCGCGGGGTTAGGGTGGGGGTACGGGAAGGCTCAACCCAGGACCT
GCGTACCTTGCTTTGGGGGCGCACTAAGCACCTGCCGGGAGCAGGGGGCGCACCGGGAACTCGCAGATTTCGCC
AGTTGGGCGCACTGGGGATCTGTGGACTGCGTCCGGGGGATGGGCTAGGGGGACATGCGCACGCTTTGGGCCTT
ACAGAATGTGATCGCGCGAGGGGGAGGGCGAAGCGTGGCGGGAGGGCGAGGCGAAGGAAGGAGGGCGTGAGAAA
GGCGACGGCGGCGGCGCGGAGGAGGGTTATCTATACATTTAAAAACCAGCCGCCTGCGCCGCGCCTGCGGAGAC
CTGGGAGAGTCCGGCCGCACGCGCGGGACACGAGCGTCCCACGCTCCCTGGCGCGTACGGCCTGCCACCACTAG
GCCTCCTATCCCCGGGCTCCAGACGACCTAGGACGCGTGCCCTGGGGAGTTGCCTGGCGGCGCCGTGCCAGAAG
CCCCCTTGGGGCGCCACAGTTTTCCCCGTCGCCTCCGGTTCCTCTGCCTGCACCTTCCTGCGGCGCGCCGGGAC
CTGGAGCGGGCGGGTGGATGCAGGCGCGATGGACGGCGGCACACTGCCCAGGTCCGCGCCCCCTGCGCCCCCCG
TCCCTGTCGGCTGCGCTGCCCGGCGGAGACCCGCGTCCCCGGAACTGTTGCGCTGCAGCCGGCGGCGGCGACCG
GCCACCGCAGAGACCGGAGGCGGCGCAGCGGCCGTAGCGCGGCGCAATGAGCGCGAGCGCAACCGCGTGAAGCT
GGTGAACTTGGGCTTCCAGGCGCTGCGGCAGCACGTGCCGCACGGCGGCGCCAGCAAGAAGCTGAGCAAGGTGG
AGACGCTGCGCTCAGCCGTGGAGTACATCCGCGCGCTGCAGCGCCTGCTGGCCGAGCACGACGCCGTGCGCAAC
GCGCTGGCGGGAGGGCTGAGGCCGCAGGCCGTGCGGCCGTCTGCGCCCCGCGGGCCGCCAGGGACCACCCCGGT
CGCCGCCTCGCCCTCCCGCGCTTCTTCGTCCCCGGGCCGCGGGGGCAGCTCGGAGCCCGGCTCCCCGCGTTCCG
CCTACTCGTCGGACGACAGCGGCTGCGAAGGCGCGCTGAGTCCTGCGGAGCGCGAGCTACTCGACTTCTCCAGC
TGGTTAGGGGGCTACTGAGCGCCCTCGACCTATGAG 
 
GTAACAGCCGGGAGGCAGGGAGGAGGGAGGGCCGGGGGCCGGGGTGGAGGGACGGGGTGGGCAGGCCCGGCGGG
TCGCGCCCCCAGGAGCCCGCGGAGCCGAGCGCCAGGCCCGAGCGATGGCTTCGATTTCGCTCACTCTTCATTTC
CCCCAAAGTTTTTCAAGCCCGTGCAAGACCGGCGTTTGTTTGTCCGGGATTGCAAAACTTCCCCTCGCGGCTCA
GCCGCCGACGAGGGAGGGGTAGACGAGGGGAGGGGAGCGGCCGTCGGGCCGTTGAGGTCTCTAGTGCTGGCGGA
TCCTGGGGCAGATTGGGGTGCTGGAGGCGGGGTGACTTTGCATTGCAAATCGCGCTCCCGGGCCGGGGCGGCAG
AAATGAGTCGGCGGGCGCGGAGCCCTGACTCACCGCGGCTCCGAGCGCCCGCCCCGCCCCCGCCGTGTCTCAGA
CCGAGTCGCGGCACCCACGGACTCAAGACTCCAAAACCAACCGAGCAAACGAAACTGCCGACTTCGCTTGGGGG
AGGTGCGGGCAGGGCCGGCCCGGGCGGGGTCTGCCCCGGGCCCGCGCCCGCGTTGACGCGCGTTTGGTTCCCCA
CCTTCCCCCCGCAG 
 
EXON 2 
CCTCAGCCCCGGAAGCCGAGCGAGCGGCCGGCGCGCTCATCGCCGGGGAGCCCGCCAGGTGGACCGGCCCGCGC
TCCGCCCCCAGCGAGCCGGGGACCCACCCACCACCCCCCGCACCGCCGACGCCGCCTCGTTCGTCCGGCCCAGC
CTGACCAATGCCGCGGTGGAAACGGGCTTGGAGCTGGCCCCATAAGGGCTGGCGGCTTCCTCCGACGCCGCCCC
TCCCCACAGCTTCTCGACTGCAGTGGGGCGGGGGGCACCAACACTTGGAGATTTTTCCGGAGGGGAGAGGATTT
TCTAAGGGCACAGAGAATCCATTTTCTACACATTAACTTGAGCTGCTGGAGGGACACTGCTGGCAAACGGAGAC
CTATTTTTGTACAAAGAACCCTTGACCTGGGGCGTAATAAAGATGACCTGGACCCCTGCCCCCACTATCTGGAG
TTTTCCATGCTGGCCAAGATCTGGACACGAGCAGTCCCTGAGGGGCGGGGTCCCTGGCGTGAGGCCCCCGTGAC
AGCCCACCCTGGGGTGGGTTTGTGGGCACTGCTGCTCTGCTAGGGAGAAGCCTGTGTGGGGCACACCTCTTCAA
GGGAGCGTGAACTTTATAAATAAATCAGTTCTGTTTACCA 
 
GTGGCTCCTATCACCTACACTTCCCAGGTGACGGCCAGACTTCCGTGGTCACTACTCCTCAAACCCTGCTGCCT
CCTCCGTAGGGTGGGTCTGGGTGAGATCTGGAGTGCAGCCAGGCCGTTGATAGCGGAGCCATTGGGACACCTTG
TGAGGCTGGGGGCATCCTCCAGGAGGTGGTGGGCTGGTGGGTTGTCCAGACAGGGCTACTCGCTGGCTTGGAAG
CTGCAGGCTGGAGGCTGCTGACCCATCCCGAGGGCTGGGGTAAGTGCTGGGTGTGGGGCTAGGCTGAGGTGGTC
TGACCAGAGAGCACCGGCTGTGGGGCTGAGGGCATGGGCTCCTGCGCAGGCCACCACGCTCAGATCTCCACTAA
CGTGGCAGCTGGGCAGCCCAGGGCAAGTGGGTTAACTTGCAAATGGGTTTGACCAGACCCACCTCAACGGCCTC
TGGGAGGAGTTAGTGAGAGGTGCCTGGAGGCTGCCCTCTCGCTAGCTTTGGGTTTTGCCCGCACTGGGGAGGCC
CTGCAGGTCTCCGCTCACCTGAATTCTAAGAGCGGCTCTTGAAAGGAACAAGGAAGGCTTGGAAGCTTTGCGCC
AGGCTCCC  
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Appendix	IV	–	Experimental	Descriptive	Data	
	
ASCL2 Extreme Variation Analysis Descriptive Statistics 
 
 
ASCL2 RT-qPCR Descriptive Statistics 
 
Cell Line 
∆CT Relative Fold Change 
n=1 n=2 Mean Std. Deviation n=1 n=2 Mean 
Std. 
Deviation 
MCF10A 13.26 14.1 13.68 0.59 1 1 1 0 
MCF7 7.06 6.17 6.615 0.63 73.26 244.72 158.99 121.24 
MDA-MB-231 13.6 14.48 14.04 0.62 0.79 0.77 0.78 0.01 
BT474 12 14.03 13.015 1.44 2.39 1.05 1.72 0.95 
SKBR3 9.70 10.1 9.9 0.28 11.79 16 13.90 2.97 
T47D 8.89 9.25 9.07 0.25 20.61 28.94 24.77 5.89 
 
ASCL2 Knockdown Descriptive Statistics 
 
Relative mRNA expression of ASCL2 in experimental samples (siRNA-ASCL2) 
compared to non-targeting control (siRNA-NC), across cell lines.  
	
 
 
 
 
 
  
Cell Line Sample Mean Log 2 Expression, ASCL2 Std. Deviation P 
MCF10A n=10 2.5 0.16  
BT474 n=7 9.16 0.33 <0.0001 
MCF7 n=9 8.84 0.72 <0.0001 
MDA-MB-231 n=4 2.60 0.28 0.46 
T47D n=7 5.11 0.32 <0.0001 
ZR-75 n=3 5.41 2.51 0.0018 
Cell 
Line Sample n=1 n=2 n=3 n=4 n=5 
Mean 
Fold Change 
Percentage 
Knockdown 
Std. 
Deviation 
MCF7 
n=5 
ASCL2 
NC 
0.32 
1 
0.30 
1 
0.38 
1 
0.47 
1 
0.23 
1 
0.34 
1 
66% 
0 
0.09 
0 
T47D 
n=4 
ASCL2 
NC 
0.19 
1 
0.35 
1 
0.43 
1 
0.21 
1 
- 0.30 
1 
70% 
0 
0.11 
0 
SKBR3 
n=3 
ASCL2 
NC 
0.09 
1 
0.34 
1 
- - - 0.20 
1 
80% 
0 
0.12 
0 
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Wound-Healing Assay Descriptive Statistics 
 
Area of wound (µm)  
 
  siRNA n=1 n=2 n=3 n=4 n=5 n=6 Mean Area  (µm) Std. Deviation 
M
C
F7
 
0h ASCL2 383679 551558 362271 449259 374399 304557 404287 85721 
 NC 378105 448258 409788 426729 398355 241273 383751 73799 
24h ASCL2 211266 378455 359391 398369 234676 228101 301710 85618 
 NC 165160 247292 321914 325117 205800 161382 237778 73390 
48h ASCL2 127900 336536 332646 380924 193438 178806 258375 104130 
 NC 90722 189955 300190 289975 174943 113718 193250 87149 
T4
7D
 
0h ASCL2 444636 391440 - - - - 418038 37615 
 NC 393166 376998 - - - - 385082 11432 
24h ASCL2 404135 349472 - - - - 376804 38653 
 NC 341591 311557 - - - - 326574 21237 
48h ASCL2 394491 320579 - - - - 357535 52263 
 NC 310502 312128 - - - - 311315 1149 
SK
BR
3 
0h ASCL2 378740 383884 442193 - - - 401606 35244 
 NC 409191 478284 393282 - - - 426919 45189 
24h ASCL2 357963 372861 442766 - - - 391197 45277 
 NC 389790 451297 383435 - - - 408174 37480 
48h ASCL2 342535 359288 407798 - - - 369874 33895 
 NC 368388 437729 372131 - - - 392749 38999 
 
 
Percentage closure after 48h 
 
 siRNA n=1 n=2 n=3 n=4 n=5 n=6 Mean % Closure 
MCF7 
ASCL2 66.7 39 8.2 15 48.3 41.3 
13.8 NC 76 57.6 26.7 32 56.1 52.9 
% Closure 9.3 18.6 18.5 17 7.8 11.6 
T47D 
ASCL2 11.3 18.1 - - - - 
9.01 NC 26.6 20.8 - - - - 
% Closure 15.3 2.7 - - - - 
SKBR3 
ASCL2 9.6 6.4 7.8 - - - 
0.028 NC 10 8.5 5.4 - - - 
% Closure 0.4 2.1 -2.4 - - - 
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Appendix	V	–	Data	Mining	Descriptive	Statistics	&	Frequency	
Tables	of	ASCL2	Expression	
 
Age of Onset N Mean Std. Deviation Std. Error 
95% Confidence 
Interval for Mean Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
Downregulated 1 75.1300 - - - - 75.13 75.13 
Unaltered 1821 61.0495 12.98345 0.30425 60.4528 61.6463 21.93 96.29 
Upregulated 82 61.7487 12.92019 1.42680 58.9098 64.5875 32.99 87.18 
 
 
Overall 
Survival N Mean 
Std. 
Deviation Std. Error 
95% Confidence 
Interval for Mean Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
Downregulated 1 58.6667 - - - - 58.67 58.67 
Unaltered 1821 125.5265 76.25047 1.78685 122.0220 129.0310 0.00 355.20 
Upregulated 82 114.7004 78.03784 8.61784 97.5536 131.8472 9.60 297.23 
 
 
 
 
Grade Grade1 Grade 2 Grade 3 Grade 4 
Downregulated Count 0 0 0 0 Row N % 0.0% 0.0% 0.0% 0.0% 
Unaltered Count 160 711 882 0 Row N % 9.1% 40.6% 50.3% 0.0% 
Upregulated Count 5 29 45 0 Row N % 6.3% 36.7% 57.0% 0.0% 
 
 
ASCL2 
Expression 
Subtype 
Luminal A Luminal B HER2 Positive Basal Claudin Low Normal 
Mean -0.12 -0.18 0.76 0.08 0.04 0.02 
Median -0.4 -0.53 0.85 -0.03 -0.05 -0.2 
SD 0.92 1.07 1.01 0.94 0.69 0.89 
 
 
Subtype Luminal A Luminal B HER2 Positive Basal Claudin Low Normal 
Downregulated Count 1 0 0 0 0 0 Row N % 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Unaltered Count 660 434 193 192 199 137 Row N % 36.4% 23.9% 10.6% 10.6% 11.0% 7.5% 
Upregulated Count 18 27 27 7 0 3 Row N % 22.0% 32.9% 32.9% 8.5% 0.0% 3.7% 
 
  
Stage .00 Stage 1 Stage 2 Stage 3 Stage 4 
Downregulated Count 0 0 0 0 0 Row N % 0.0% 0.0% 0.0% 0.0% 0.0% 
Unaltered Count 4 460 766 106 9 Row N % 0.3% 34.2% 57.0% 7.9% 0.7% 
Upregulated Count 0 15 34 9 0 Row N % 0.0% 25.9% 58.6% 15.5% 0.0% 
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Integrative 
Cluster 
Downregulated Unaffected Upregulated 
Count Row N % Count Row N % Count Row N % 
Cluster 1 0 0.0% 126 6.9% 6 7.3% 
Cluster  2 0 0.0% 68 3.7% 4 4.9% 
Cluster 3 0 0.0% 275 15.1% 7 8.5% 
Cluster 4ER+ 0 0.0% 238 13.1% 6 7.3% 
Cluster 4ER- 0 0.0% 71 3.9% 3 3.7% 
Cluster 5 0 0.0% 163 9.0% 21 25.6% 
Cluster 6 0 0.0% 81 4.4% 3 3.7% 
Cluster 7 0 0.0% 176 9.7% 6 7.3% 
Cluster 8 1 100.0% 279 15.3% 9 11.0% 
Cluster 9 0 0.0% 132 7.2% 10 12.2% 
Cluster 10 0 0.0% 212 11.6% 7 8.5% 
 
 
Receptor Status 
ER HER2 PR 
Positive Negative Positive Negative Positive Negative 
Downregulated Count 1 0 0 1 1 0 Row N % 100.0% 0.0% 0.0% 100.0% 100.0% 0.0% 
Unaltered Count 1396 425 215 1606 971 850 Row N % 76.7% 23.3% 11.8% 88.2% 53.3% 46.7% 
Upregulated Count 62 20 21 61 37 45 Row N % 75.6% 24.4% 25.6% 74.4% 45.1% 54.9% 
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